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ABSTRACT 
 
 Antimicrobial resistance is a growing threat to human health both worldwide and 
in the United States.  Most concerning is the emergence of multi-drug resistant (MDR) 
bacterial pathogens, especially the ‘ESKAPE’ pathogens for which treatment options are 
dwindling.  To complicate the problem, approvals of antibiotic drugs are extremely low 
and many research and development efforts in the pharmaceutical industry have ceased, 
leaving little certainty that critical new antibiotics are nearing the clinic.  New antibiotics 
are needed to continue treating these evolving infections.  In addition to antibiotics, 
approaches that aim to inhibit or prevent antimicrobial resistance could be useful.  Also, 
studies that improve our understanding of bacterial pathophysiology could lead to new 
therapies for infectious disease.  Natural products, especially those from the microbial 
world, have been invaluable as resources for new antibacterial compounds and as insights 
into bacterial physiology.  The goal of this dissertation is to find new ways to treat 
resistant bacterial infections and learn more about the pathophysiology of these bacteria.  
Investigations of natural products to find molecules able to be used as new antibiotics or 
to modulate resistance and other parts of bacterial physiology are crucial aspects of the 
included studies.   
 The first included study, which is reported in chapter two, details a chemical 
investigation of a marine Pseudoalteromonas sp.  Purification efforts of the microbial 
metabolites were guided by testing against a resistance nodulation of cell division model 
of efflux pumps expressed in E. coli.  These pumps play an important role in the 
resistance of MDR Gram negative pathogens such as Pseudomonas aeruginosa and 
  
 
 
Enterobacteriaceae.  Through this process, 3,4-dibromopyrrole-2,5-dione was identified 
as a potent inhibitor of the RND efflux pumps and showed synergistic effects against the 
E. coli strain with common antibiotics including fluoroquinolones, beta-lactams, 
tetracyclines, aminoglycosides, and chloramphenicol.  The efflux pump inhibitory 
mechanism was further proved through an accumulation assay with the Hoechst dye 
33342.   
 In chapter three, we report the discovery of a 1,2-benzisoxazole with new 
antibacterial activity against MDR A. baumannii, a pathogen with a critical need of new 
treatments. This compound was produced by bacterial fermentation and synthetic 
preparation and shows minimum inhibitory concentrations as low as 6.25 μg/mL against 
a panel of four clinically relevant A. baumannii strains. Key structure activity 
relationships were demonstrated using synthetic analogs of the lead 1,2-benzisoxazole.  
We advocate for further studies to advance the development of this compound.  
 The third study, describes an in vitro quiescent state of uropathogenic E. coli 
(UPEC) and bacteria-produced signals that can prevent this state.  Quiescence was seen 
in the classic UPEC strain CFT073 only when grown on glucose M9 minimal medium 
agar plates seeded with ≤106 CFU. Interestingly, this quiescent state is seen in ~80% of 
E. coli phylogenetic group B2 multilocus sequence type 73 strains, as well as 22.5% of 
randomly selected UPEC strains isolated from community acquired urinary tract 
infections in Denmark.  Furthermore, it was determined that CFT073 forms a high 
persister cell fraction under these growth conditions.  Both the persistent and quiescent 
states were inhibited significantly by a cocktail of lysine, tyrosine, and methionine at 
concentrations relevant to those in human urine.  The use of CFT073 mini-Tn5 metabolic 
  
 
 
mutants (gnd, gdhA, pykF, sdhA, and zwf) showed that both quiescence and persistence 
require a complete TCA cycle, but that the dormant states differ in that persistence 
requires a non-functional rpoS gene and quiescence does not.  These results suggest that 
interference with these central metabolic pathways may be able to mitigate UPEC 
infections. 
 In the fifth chapter, cranberry oligosaccharides and related compounds were 
determined to be able to reduce the quiescent and persistent phenotypes of UPEC 
CFT073.  This is the first report describing components of cranberry juice with the ability 
to modulate these important physiological aspects of UPEC and further suggests that 
cranberry oligosaccharides may be vital to the effectiveness of cranberry juice products in 
urinary tract infections.   
 
 
 
  
v 
ACKNOWLEDGEMENTS 
 
This dissertation is the culmination of the work I have completed but it is really 
an achievement of many people who I need to acknowledge for their important 
contributions. Every one of you has made a lasting impact on my life and career and your 
knowledge, generosity, and companionship are things that I will always treasure, thank 
you. 
I need to firstly acknowledge my advisor, mentor, and friend, Dr. David C. 
Rowley. Dave, it has been a long but exciting journey growing into a scientist with you. 
It is certainly amazing to think how much I have learned working with you: starting out 
as a media-maker and extract-prepping machine and now designing complex experiments 
and presenting research in China. Your passion for teaching and research is obvious, but 
your passion for mentoring and developing your graduate students might be even 
stronger. I am now realizing just how much of yourself you have given towards my 
development in the form of countless hours spent reading, editing, researching, and 
thinking. You once told me that it is really hard to find people that are really enjoyable to 
work with. I was lucky enough to find one of those people on my first try when I sat in 
the basement of Fogarty and asked if you had any room in your lab for another student. I 
only hope that one day I can make an impact on someone’s career in the way you have 
made on mine. Thanks Dave. 
Dr. Navindra P. Seeram has made an extremely positive impact on my time here 
at URI. While only a committee member in title, your lessons to me have gone far 
  
vi 
beyond that. I thank you for your encouragement, support, and wisdom throughout 
graduate school. You taught me to especially focus on the details and subtleties when 
going about my work and that these little things like committing person’s name to 
memory after one meeting can make a huge impact. I will try my best to build myself into 
a professional with style and recognition that people enjoy being around, something you 
have mastered. Thank you  
Dr. David C. Smith was also part of my graduate committee but has contributed 
much more than that to my development. David, I especially want to thank you for your 
genuine interest in me as a person beyond the classroom and lab. You have taught me to 
always pursue what I love and that the road before me is not paved in stone, but rather 
something that I will build as I go. You have given me confidence that will help me 
pursue my next challenge, thank you. 
I also need to acknowledge Dr. Paul S. Cohen. Paul, your unbridled enthusiasm 
for research permeates everyone around you and I am very lucky to have worked with 
you. Our talks always left me feeling excited and energized to complete the next task and 
I strive to bring that energy and commitment to my future endeavors. Thank you for your 
passion and your thoughtfulness and your strong spirit, I am a better person for having 
worked with you. 
I would be remiss not to thank the other Professors who have been a part of 
committees, collaborations, projects, or other endeavors during my time in graduate 
school. Drs. Cho, Mincer, Whalen, Harvey, Bertin, Li, Trzoss, Leatham-Jensen, 
  
vii 
Meschwitz, LaPlante, Bach, and Wang, thank you kindly for your support, effort, and 
enthusiasm. I sincerely enjoyed my time working with all of you. 
I have my doubts about whether or not I would have pursued a graduate degree in 
the Rowley Lab were it not for the amazing support I received upon my integration into 
the lab as an undergraduate in 2012. This is especially due to the mentorship of Stephanie 
Forschner-Dancause and Chrissy Dao. Both of you taught me the skills I needed to 
become proficient in lab research, and this was vital to my progression into graduate 
school. You both helped me simply because that is the kind of person you each are, and I 
can’t thank you enough.  
My time at URI was made significantly more special thanks to Jiadong Sun’s 
presence in our lab. JD, thank you for all of the conversation, knowledge, and 
companionship. I am truly so thankful to have worked with you for nearly all of my time 
in graduate school, having you there inspired me, taught me things, and enriched my life. 
Your friendship is something I will cherish forever. I will truly miss working with you.  
Additionally, I would like to acknowledge all of the students past and present with 
whom I was able to work with and mentor. For those who taught me, your knowledge has 
made me a better researcher but it was your willingness to help that I am most thankful 
for. For those who I mentored, you have kept me humble and taught me that teaching 
others is the only way to truly master a skill. There are too many names to list here, but 
you all have contributed, thank you. 
Finally, I want to thank my family. To my parents, thank you for always believing 
in and supporting me no matter the endeavor. While I have had to work extremely hard to 
  
viii 
accomplish all that I have, it was your hard work before mine that afforded these amazing 
opportunities for me. Every day I try to represent you in the best way that I can and I 
know that everything I do reflects on you as parents. This dissertation would absolutely 
not be possible without you and I hope you can feel a great sense of accomplishment 
when I finally finish my degree. Thank you so much for enriching my life, and letting me 
follow the path that was right for me.  
 To my wife: Lilli, thank you for your unwavering support, patience, love, and 
faith in me. Every day you inspire me to be better in my career and as a person.  I know 
that my extended tenure in school wasn’t an easy thing, but you never showed any 
impatience.  Thank you for being my best friend. I am so lucky to have had you by my 
side during this journey, and I am so excited for our next one.  
  
  
ix 
PREFACE 
This dissertation has been written in the manuscript format as directed by the 
guidelines set forth by the Graduate School of the University of Rhode Island.  
  
  
x 
TABLE OF CONTENTS 
 
Abstract ............................................................................................................................... ii 
Acknowledgements ..............................................................................................................v 
Preface................................................................................................................................ ix 
Table of Contents .................................................................................................................x 
List of Figures ................................................................................................................... xii 
List of Tables ................................................................................................................... xiv 
 
Chapter 1. Introduction ........................................................................................................1 
References ............................................................................................................................8 
 
Chapter 2. Enhancement of Antibiotic Activity against Multidrug Resistant Bacteria 
by the Efflux Pump Inhibitor, 3,4-Dibromopyrrole-2,5-dione, Isolated 
from a Pseudoalteromonas sp. ...................................................................14 
Abstract ..............................................................................................................................16 
Introduction ........................................................................................................................17 
Results and Discussion ......................................................................................................21 
Experimental Section .........................................................................................................34 
References ..........................................................................................................................46 
 
Chapter 3. A Marine Bacteria-Produced Benzisoxazole with Antibacterial Activity 
Against Multi-Drug Resistant Acinetobacter baumannii ..........................56 
 Abstract ......................................................................................................58 
 Introduction ................................................................................................59 
 Results ........................................................................................................60 
 Discussion ..................................................................................................64 
 Materials and Methods ...............................................................................66 
 References ..................................................................................................76 
 
Chapter 4. Uropathogenic Escherichia coli Metabolite-Dependent Quiescence and 
Persistence May Explain Antibiotic Tolerance during Urinary Tract 
Infection .....................................................................................................80 
 Abstract ......................................................................................................82 
 Introduction ................................................................................................83 
 Materials and Methods ...............................................................................85 
 Results ........................................................................................................91 
 Discussion ................................................................................................105 
 References ................................................................................................112 
  
xi 
 Legends to Figure ....................................................................................127 
 
Chapter 5. Constituents from Cranberry Juice Prevent Quiescence and Persistence in 
Uropathogenic Escherichia coli ...............................................................142 
 Abstract ....................................................................................................144 
 Introduction ..............................................................................................145 
 Results ......................................................................................................147 
 Discussion ................................................................................................150 
 Methods....................................................................................................152 
 References ................................................................................................156 
 
Chapter 6. Perspective ...............................................................................................169 
 
Appendix A. Supplementary Materials for Chapter 3 ...................................................172 
 
Appendix B.  Supplemental Figures for Chapter 5 ........................................................186 
 
 
  
  
xii 
List of Figures 
 
Chapter 2 
Figure 1. Effect of 3,4-dibromopyrrole-2,5-dione on Hoechst 33342 accumulation 
and efflux in wild-type (AG100) and transporter-deficient (AG100A) E. 
coli..............................................................................................................53 
Figure 2. Phylogenetic and exo-metabolomic comparison of Pseudoalteromonas sp. 
in culture collection....................................................................................54 
Figure 3. Heat map displaying relative abundances of inferred compounds produced 
by Pseudoalteromonas isolates from (A) –HRESI and (B) +HRESI mode 
data .............................................................................................................55 
 
Chapter 3 
Scheme 1. Synthesis of 3,6-dihydroxy-benzisoxazole ................................................61 
Figure 1. Panel of compounds tested for MICs against A. baumannii ......................63 
 
Chapter 4 
Figure 1. E. coli CFT073 quiescence on glucose plates ..........................................131 
Figure 2. E. coli CFT073 non-quiescence on glycerol, ribose, and xylose plates ..132 
Figure 3. Prevention of quiescence by human urine and amino acids ....................133 
Figure 4. E. coli CFT073 and E. coli MG1655 persistence ....................................134 
Figure 5. E. coli CFT073 persistence in the presence of amino acids ....................135 
Figure 6. Diagram of E. coli central carbon metabolism ........................................136 
Figure 7. E. coli CFT073 sdhA persistence .............................................................137 
Figure 8. E. coli CFT073 gdhA persistence.............................................................138 
Figure 9. E. coli CFT073 sdhA persistence in the presence of fumarate ................139 
Figure 10. Rescue of E. coli CFT073 sdhA quiescence by fumarate ........................140 
Figure 11. Quiescence of the E. coli CFT073 clinical isolate on glucose plates ........141 
 
Chapter 5 
Figure 1.  Persister cell viability assay with Cranf1b fraction .................................161 
Figure 2. Persister cell viability assay with 10% PGC fraction ..............................162 
Figure 3. Structure and subunit designation of unsaturated methyl galacturonic acid 
oligosaccharide (4-mer) ...........................................................................163 
Figure 4. ESI-TOF MS-MS of unsaturated methyl galacturonic acid oligosaccharide 
(4-mer) .....................................................................................................164 
Figure 5. Inhibition of quiescence using cranberry oligosaccharides .....................165 
Figure 6. Amide-80 HPLC chromatogram of 10% PGC ........................................166 
Figure 7. C18 Reverse-phase HPLC chromatogram of iridoid glycosides 
purification ...............................................................................................167 
  
xiii 
Figure 8. LC/MS analysis of 10% PGC fraction .....................................................168 
 
Appendix A 
Figure S1. Chemical structures of compounds 11 and 12 .........................................181 
Figure S2. LC/MS comparison of isolated 1 to synthetic 1.......................................182 
Figure S3. 
1
H NMR of isolated 1 ..............................................................................183 
Figure S4. 
1
H NMR of synthesized 1 ........................................................................184 
Figure S5. 
13
C NMR of synthesized 1 .......................................................................185 
 
Appendix B 
Figure S1. High resolution ESI-TOF-MS of 4 ..........................................................187 
Figure S2. Structures of Iridoid glycosides 1-3 .........................................................188 
Figure S3. 
1
H NMR spectrum of 10% PGC ..............................................................190 
Figure S4.  HSQC spectrum of 10% PGC ..................................................................191 
Figure S5. 
1
H NMR spectrum of 4 ............................................................................192 
Figure S6. 
13
C NMR spectrum of 4 ...........................................................................193 
Figure S7. COSY spectrum of 4 ................................................................................194 
Figure S8. TOCSY spectrum of 4 .............................................................................195 
Figure S9. HSQC spectrum of 4 ................................................................................196 
Figure S10. HMBC spectrum of 4 ...............................................................................197 
Figure S11. NOESY spectrum of 4 .............................................................................198 
Figure S12. 
1
H NMR spectrum of 1 ............................................................................199 
Figure S13. 
13
C NMR spectrum of 1 ...........................................................................200 
Figure S14. COSY spectrum of 1 ................................................................................201 
Figure S15. TOCSY spectrum of 1 .............................................................................202 
Figure S16. HSQC spectrum of 1 ................................................................................203 
Figure S17. HMBC spectrum of 1 ...............................................................................204 
Figure S18. 
1
H spectrum of 2 ......................................................................................205 
Figure S19. COSY spectrum of 2 ................................................................................206 
Figure S20. TOCSY spectrum of 2 .............................................................................207 
Figure S21. HSQC spectrum of 2 ................................................................................208 
Figure S22. 
1
H spectrum of 3 ......................................................................................209 
Figure S23. COSY spectrum of 3 ................................................................................210 
Figure S24. TOCSY spectrum of 3 .............................................................................211 
Figure S25. HSQC spectrum of 3 ................................................................................212 
Figure S26. HR-MS of 1..............................................................................................213 
Figure S27. HR-MS of 2..............................................................................................214 
Figure S28. HR-MS of 3..............................................................................................215 
 
 
  
  
xiv 
List of Tables 
 
Chapter 2 
Table 1. Minimum inhibitory concentration potentiation of 3,4-dibromopyrrole-
2,5-dione on various classes of antibiotics against E. coli strains 
overexpressing efflux pumps .....................................................................24 
Table 2. Hoechst 33342 accumulation and efflux in the presence of 3,4-
dibromopyrrole-2,5-dione ..........................................................................26 
 
Chapter 3 
Table 1. 
1
H and 
13
C-NMR data comparison of 3,6-dihydroxy-1,2-benzisoxazole to 
synthetic and published data ......................................................................61 
Table 2. Minimum inhibitory concentration values of tested compounds against 
included panel of A. baumannii .................................................................63 
Chapter 4 
Table 1. Bacterial strains ........................................................................................121 
Table 2. PCR primer sequences for amplifying mutant genes containing mini-Tn5 
Km insertions ...........................................................................................124 
Table 3. Free amino acid composition of 50-fold concentrated E. coli MG1655 and 
E. coli CFT073 supernatants and human urine ........................................125 
Table 4. E. coli CFT073 persister cells relative to persister cells for other E. coli 
strains .......................................................................................................126 
 
Appendix A 
Table S1. 
1
H and 
13
C NMR data of 12 and comparison to published data ..............179 
Table S2. A. baumannii strain characteristics and resistance profiles .....................180 
 
Appendix B 
Table S1. 
13
C and 
1
H NMR chemical shifts of 4 ......................................................186 
Table S2. 
13
C and 
1
H NMR chemical shifts of 1, 2 and 3 ........................................189 
 
1 
 
 
CHAPTER 1 
Introduction 
Bacterial infections and the post-antibiotic era 
Infectious disease remains a significant threat to human health in the United 
States and worldwide.  In 2010, 117,716 deaths were attributed to infections of bacterial, 
viral, or parasitic origins in the US.
1
 As a category, this ranks infectious disease as the 
fourth most deadly form of illness behind only cardiovascular disease, cancer, and 
respiratory disease, and ahead of diabetes and Alzheimer’s disease.  Worldwide, 
infectious disease has an even larger impact, accounting for 10 million deaths in 2011.
2
 
This ranks it as the second most lethal disease category behind only cardiovascular 
disease.
2
 A growing concern in the treatment of infectious disease is the drastic increase 
in antimicrobial resistance. This is present in bacteria, viruses, and fungi, and is 
complicating the treatment of infectious disease considerably.  In fact, certain pathogenic 
bacteria now exist that are resistant to nearly all treatment options, forecasting the so-
called ‘post-antibiotic era.’3-6 The problem of antimicrobial resistance is immense with an 
estimated 700,000 deaths worldwide each year, and these numbers are increasing.
4
 It is 
estimated that in 2050 there will be 10 million deaths due to antimicrobial resistance 
globally in a single year.
4, 7
 These deaths would lead to an estimated net loss of 100 
trillion dollars of economic output.
4, 7
  Deaths due to infections are not the only clinical 
consequence of a post-antibiotic era.  Surgery, chemotherapy, and organ transplantation 
rely heavily on antibiotics to facilitate their success.
4, 7
 Continuing on the trend of 
increasing antimicrobial resistance would lead to a catastrophic change in lifestyle both 
economically and medically.  
2 
 
 Among the most threatening problems in antimicrobial resistance are bacterial 
infections involving multi-drug-resistant (MDR) pathogens. These are especially a 
problem in the United States, where 23,000 people die each year due to MDR bacterial 
infections.
3
 This is an especially common problem in the hospital setting where 
antimicrobial resistance is difficult to eradicate and is seen in common nosocomial 
pathogens.
8
 These pathogens that have been identified as high priorities for research are 
referred to as ‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter species).
9
 These organisms are in general difficult to treat and can cause 
significant morbidity and mortality.
9, 10
 With the exclusion of E. faecium and S. aureus, 
the ESKAPE pathogens are Gram-negative bacteria.  This is important because there are 
in general fewer treatment options for Gram-negative bacteria and developing antibiotics 
against these bacteria has been historically less successful.
11
 The World Health 
Organization recently released a ranking of highest priority bacteria for antibiotic 
development, and all three critically important organisms are MDR Gram negative 
bacteria.
12
   
A major reason that the problem of antimicrobial resistance is increasing is the 
dearth of new antibiotics being approved or researched. Since 1998, only four systemic 
antibiotics (linezolid, daptomycin, tigecycline, and telavancin) have been approved that 
have novel mechanisms of action.
10
 To combat this issue, antibiotic stewardship 
programs can help, but long term solutions exist in the drug development arena.  In 2010, 
the Infectious Disease Society of America (IDSA) launched a campaign known as the 
“10 x ’20 Initiative” that called for the development 10 new antibiotics approved by 
3 
 
2020.
10
 Currently we are falling well short of the goal, with only four new antibiotics 
being approved since the initiative and none of these with activity against the important 
Gram-negative bacteria.
13
 Additionally, the current pipeline of antibiotics contains only 
five drugs in phase II or III development with target indications of MDR Gram negative 
infections.
13
 There is a clear void in the future treatment of infectious disease especially 
for MDR bacterial infections, and without changes to the current course, a post-antibiotic 
era is likely.  
 
Bacterial mechanisms of resistance 
 Bacteria have developed mechanisms to avoid the toxic effects of antibiotics, 
causing resistance.  Inhibiting or circumventing these biological functions can restore the 
activity of the antibacterial drug.  Understanding the mechanisms of resistance is crucial 
to developing agents that can restore the potency of antibiotics, especially in ESKAPE 
pathogens and Gram-negative bacteria.  Resistance mechanisms fall into these general 
categories: drug alteration/inactivation, reduced drug intracellular accumulation, binding 
site modification, and biofilm formation.
8
   
Drug altering or inactivating enzymes are well studied and therapies have been 
developed that can inhibit these enzymes. A well-studied example is the β-lactamase type 
enzymes which are capable of inactivating β-lactam antibiotics such as penicillins, 
cephalosporins, monobactams, and carbapenems.
14
  These enzymes have been the targets 
of β-lactamase inhibitor drugs such as clavulanic acid, tazobactam, and sulbactam, all of 
which are used in combination with β-lactam antibiotics to successfully treat bacteria that 
produce β-lactamases.15, 16 While these approaches have been successful, the emergence 
4 
 
of extended spectrum β-lactamases (ESBLs) such as New Delhi β-lactamase (NDM-1) 
and oxacillin hydrolyzing enzymes (OXA) that are resistant to β-lactamase inhibitors and 
confer resistance to most β-lactams is concerning.15, 17, 18   
When bacteria are able to reduce the intracellular concentration of antibiotics, this 
is frequently due to reduced production of channels that transport antibiotics into the cell, 
or the up-regulation of efflux pumps able to eject antibiotics.
8
 Efflux pumps expel 
antibiotics from the bacterial cytoplasm before they can reach their site of action.
19, 20
 
These pumps can expel a broad range of substrates by coupling the efflux with a proton 
or other ion.
21
 Certain efflux pumps, such as the resistance nodulation cell division 
(RND) family pump AcrAB, have been suggested as biomarkers for the MDR phenotype 
since they confer resistance to ≥ 5 antibiotics.22 Efflux pumps also contribute to the 
resistance present in the ESKAPE pathogens.
23, 24
 The ability to inhibit efflux pumps with 
a drug adjuvant to antibacterial therapy could help overcome resistance and treatment 
failures. There has been progress in identifying efflux pump inhibitors (EPIs) of Gram-
positive pathogens such as S. aureus, but there is a sizable knowledge gap for Gram-
negative efflux pumps.
24
 Discovery of EPIs for Gram-negative bacteria is greatly needed 
to help supplement the already bare pipeline of new therapies for these problematic 
pathogens.  
 
Persistence and quiescence of bacterial pathogens 
 The phenomenon of bacterial persistence is a rapidly expanding research area in 
the field of antibiotic development. Similar to resistance, bacterial persistence makes the 
treatment of infections much more difficult. Persistence is characterized by dormant 
5 
 
bacterial cells (persister cells) that are highly tolerant to antibiotics.
25
 When these cells 
are isolated, re-cultured, and tested for antibiotic susceptibility, they show full 
susceptibility, indicating these are not resistant mutants. In contrast, antibiotic resistant 
bacteria will show a decrease in antibiotic susceptibility (require higher concentrations of 
antibiotics to inhibit the growth of the bacteria). Persister cells are implicated as the 
causative phenotype in chronic infections such as recurrent urinary tract infections 
(UTIs), infections in cystic fibrosis, and tuberculosis.
26-28
 In addition to chronic 
infections, persister cells are commonly associated with biofilms, which can allow them 
to evade the immune system as well as exhibit antibiotic tolerance, causing antibiotic 
treatment failures.
25, 26, 28
   
 Uropathogenic E. coli (UPEC) is an ideal organism to study persistence. 85% of 
all UTIs are caused by UPEC and reinfection is common.
29
 Studies have shown that 
UPEC are able to invade bladder and kidney epithelial cells during a UTI.
30, 31
 Following 
invasion, the UPEC can either establish an intracellular bacterial community that evades 
host immune defenses (in acute infection) or a quiescent intracellular reservoir (for 
recurrent infections).
31
 The quiescent intracellular reservoir can remain viable for months 
and cause reinfection following exfoliation of UPEC containing epithelial cells. Drugs 
capable of inhibiting persistence and thereby inhibiting reinfection would be valuable 
tools in the treatment of UTIs caused by UPEC. Additionally, compounds that reduce 
persistence in UPEC could help identify targets and mechanisms necessary for persister 
cell formation in other important bacterial pathogens. This could lead to new drugs and 
improved treatment outcomes in challenging bacterial infections.   
 
6 
 
Natural products as drug leads and antibiotics 
 Natural products represent both a classical source of drug molecules and a 
promising future resource of novel medicines.
32, 33
 From the years of 1981-2014, 1211 
small molecule drugs were approved for use, and of those 791 (64%) were either natural 
products or inspired by natural products.
32
  More importantly, 59% of all drugs approved 
to treat bacterial infections were naturally derived or inspired.
32
 The fraction increases to 
74% when you exclude vaccines and look at only small molecule drugs (e.g., antibiotics), 
indicating that natural products are by far the most significant source of antibiotics 
available.  Of the 12 major classes of antibiotics, nine of these, including β-lactams, 
macrolides, tetracyclines, aminoglycosides, glycopeptides, and lipopeptides, contain a 
natural product derived structure.
34
 
 Microorganisms have also been prolific producers of antibacterial compounds.  It 
is estimated that 16,500 antibiotic secondary metabolites have been discovered from 
microorganisms and roughly 12,000 of those have antibacterial effects.
35
 While this 
seems like a vast amount of compounds, genome sequencing has revealed that many of 
the biosynthetic gene clusters are dormant under laboratory conditions, potentially 
indicating that we have only scratched the surface of antibiotic compounds from 
microorganisms.
35, 36
  An additional resource is the many ‘unculturable’ species.  It is 
estimated that upwards of 90% of all terrestrial microorganisms, and >99% of all aquatic 
microorganisms do not grow under normal laboratory conditions.
35, 37
 The amount of 
species diversity yet unstudied is vast, and we are now developing techniques to culture 
these ‘unculturable’ microorganisms.37, 38  It is clear that the most prolific producers of 
antibiotics, microorganisms, are still largely unstudied and could yield thousands more 
7 
 
antibiotics as yet undiscovered.  With the current shortcomings in the development of 
new anti-infective agents, additional investigations of natural products, especially those 
from microorganisms should be pursued.   
 
Marine microorganisms as sources of bioactive natural products 
There is significant data to suggest the promise of marine organisms as potential 
sources of bioactive compounds, including antibiotics.  In a marine environment, an 
average of 10
6
 bacterial cells and 10
3
 fungal cells exist per milliliter of seawater which 
creates a constant and mobile threat of infection to macroorganisms, as well as 
competition between microorganisms for survival.
34
  Investigations of marine organisms 
have uncovered compounds in diverse classes of secondary metabolites (ribosomal 
peptides, non-ribosomal peptides, polyketides, alkaloids, and terpenes) that possess 
potent bioactivities.
34
  Marine sediments also harbor vast microbial diversity (10
8
 cells in 
a gram of wet sediment) that has been largely unstudied.
34, 39
  Compared to terrestrial 
studies, the search for antibiotics from the marine environment is still in its infancy.
34
  
The marine environment comprises a vital resource of biodiversity that should be further 
explored for new antibiotics.   
Natural products discovered from the marine environment span a large variety of 
organisms, but microorganisms show significant potential.  Because terrestrial 
microorganisms have been such a significant source of antibacterial compounds, it stands 
to reason that marine microorganisms would also be prolific producers of bioactive 
molecules.  491 (42%) of the new compounds isolated from the marine environment in 
2013 were isolated from microorganisms indicating they are already a major source of 
8 
 
marine chemistry.
40
 These compounds exhibit diverse bioactivities including 
antibacterial, anticancer/cytotoxic, anti-quorum sensing, antiviral, anti-inflammatory, 
immunosuppressant, antiprotozoal, and antifungal.
40-42
  Some antibacterials discovered 
from marine microorganisms include non-ribosomal peptides (bogorol A, emericellamide 
A, and thiocoraline), polyketides (abyssomycin C and pestalone), and alkaloids 
(marinopyrrrole A).
34
  Additionally, while the macroorganisms such as sponges, algae, 
and tunicates represent a significant source of chemistry, it is proposed that 
microorganisms acting in symbiotic relationships are responsible for at least a portion of 
the identified novel chemistry.
43, 44
 There are currently 20 drugs (molecules in clinical 
trials or approved by the FDA) either isolated from a marine source or inspired by marine 
chemistry.
45
  It has been proposed that 17 are produced by microorganisms associated 
with the macroorganisms from which those drugs were originally isolated.
45
 Thus, marine 
microorganisms show significant potential as a resource for new antibacterial and other 
bioactivities that might be useful in the future treatment of drug resistant bacterial 
infections.  
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CHAPTER 2 
This manuscript was published in 2015 in Journal of Natural Products, vol. 78, issue 
3, pages 402-412. The formatting follows the guidelines set forth by the journal.  
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ABSTRACT 
Members of the Resistance Nodulation Cell Division (RND) of efflux pumps play 
essential roles in multidrug resistance (MDR) in Gram-negative bacteria. Herein, we 
describe the search for new small molecules from marine microbial extracts to block 
efflux and thus restore antibiotic susceptibility in MDR bacterial strains. We report the 
isolation of 3,4-dibromopyrrole-2,5-dione, an inhibitor of RND transporters from 
Enterobacteriaceae and Pseudomonas aeruginosa, from the marine bacterium, 
Pseudoalteromonas piscicida. 3,4-Dibromopyrrole-2,5-dione decreased the MICs of two 
fluoroquinolones, an aminoglycoside, a macrolide, a beta-lactam, tetracycline, and 
chloramphenicol between 2 and 16-fold in strains overexpressing three archetype RND 
transporters (AcrAB-TolC, MexAB-OprM, and MexXY-OprM). 3,4-Dibromopyrrole-
2,5-dione also increased the intracellular accumulation of Hoechst 33342, in wild-type, 
but not in transporter deficient strains; and prevented H33342 efflux (IC50 = 0.79 µg/mL 
or 3 µM), a hallmark of efflux pump inhibitor (EPI) functionality. A metabolomic survey 
of 36 Pseudoalteromonas isolates mapped the presence of primarily brominated 
metabolites only within the P. piscicida phylogenetic clade where a majority of antibiotic 
activity was also observed, suggesting a link between halogenation and enhanced 
secondary metabolite biosynthetic potential. In sum, 3,4-dibromopyrrole-2,5-dione is a 
potent EPI and deserves further attention as an adjuvant to enhance the effectiveness of 
existing antibiotics. 
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The emergence of multidrug resistant (MDR) Gram-negative pathogens, including 
Enterobacteriaceae and Pseudomonas aeruginosa, has become a substantial threat to 
treating infectious disease. Twenty percent of all deaths globally are the result of bacterial 
infections,
1
 and hospital-acquired infections are the sixth leading cause of mortality in the 
U.S.,
2
 with 23,000 deaths per year due to MDR infections in the U.S. alone.
3
 The rapid 
decline in antibiotic effectiveness has led some clinicians to estimate the future utility of 
available antibiotics to be limited to a few years, in some cases, against MDR strains.
4
 
Developing tools to battle these emerging MDR Gram-negative pathogens deserves 
priority status,
5
 as they now account for nearly 70% of infections in intensive care units 
in the U.S.
2
 Alarmingly, many Gram-negative clinical strains are becoming resistant to 
nearly all antibiotics including aminoglycosides, cephalosporins, fluoroquinolones and 
carbapenems,
3
 leaving few antibiotics in the therapeutic repertoire to treat these 
infections.
6-8
 In the search for new antimicrobials, random screening of libraries of 
synthetic or natural products are estimated to have a primary hit-rate of up to 1,000-fold 
lower against Gram-negative than for Gram-positive bacteria.
9
 Of the antibiotics 
approved by the FDA from 1998 to 2005, including those in clinical trials, and various 
stages of preclinical development, most lack appropriate activity against any Gram-
negative bacteria.
6, 7
 Making incremental improvements to the chemical scaffolds of 
existing antibiotics is at best a short-term strategy for the impelling need for both new 
drugs and novel approaches to combat multidrug resistant pathogens.
10
 Consequently, 
developing compounds targeting the resistance mechanisms themselves is warranted (e.g. 
the clinically proven beta-lactam/beta-lactamase inhibitor cocktail, amoxicillin/clavulanic 
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acid),
4
 thereby i) obviating the emergence of resistance, and ii) regaining antibiotic 
potency. 
The rapid spread of resistance is, in part, a result of constitutive over-expression of 
transmembrane efflux pumps that expel antibiotics before they can reach their 
intracellular target.
11
 Members of the Resistance Nodulation Cell Division (RND) 
superfamily of MDR pumps have been implicated in the high intrinsic resistance of 
Gram-negative species,
12, 13
 whose tripartite RND pumps recognize and expel a broad 
range of substrates (including antibiotics, charged and neutral molecules, organic 
solvents, lipids, bile salts, and quorum signal molecules),
9
 via a coupled exchange with 
protons or ions.
14
 Permanent overexpression of RND pumps leads to multidrug resistance 
in bacteria,
15
 while their deletion restores antibiotic susceptibility
16
 further confirming 
this transporter is an important therapeutic target. Polyspecificity of RND pumps is 
central to the emergence and spreading of efflux-mediated resistance, as these pumps 
subsequently allow for acquisition of additional resistance mechanisms,
9, 17
 and have a 
significant role in bacterial pathogenicity/virulence, invasion, adherence and host 
colonization.
14
 In drug resistant Escherichia coli, Salmonella enterica, Enterobacter 
aerogenes, and Klebsiella pneumoniae, overproduction of AcrAB-TolC pump and its 
homologue MexAB-OprM/MexXY-OprM in Pseudomonas aeruginosa are the main 
RND archetypes reported in clinical isolates.
11, 17, 18
 RND transporters are found in both 
prokaryotes and eukaryotes; however, homology between bacterial and human RND 
proteins is negligibly low (16% identity), suggesting minimal overlap in RND transporter 
substrate specificities. 
7
 In addition, clinical isolates with more resistant MDR phenotypes 
(resistant to ≥5 antibiotics, including 100% fluoroquinolone resistance), are more likely 
19 
 
to overexpress the RND pump, AcrAB, suggesting this RND pump maybe a biomarker of 
MDR,
19
 making these efflux pumps “key” targets for the development of an efflux pump 
inhibitor (EPI) as an adjuvant to existing antibiotics.
20
 
Our search for small molecule EPIs from the microbial realm has been aided by the fact 
that natural products have often been selected precisely for their ability to penetrate both 
outer and inner membranes of Gram-negative bacteria.
21
 A countermeasure by antibiotic-
producing microbes is to co-evolve inhibitors of their competitor’s resistance 
mechanisms to enhance the efficacy of their own antibiotics,
21
 exemplified by the 
Streptomyces spp. producing both beta-lactam antibiotics and the beta-lactamase inhibitor 
clavulanic acid. 
22
 There is substantial evidence that marine bacteria produce cocktails of 
both antibiotics to control surface colonization,
23, 24
 and nontoxic secondary metabolites 
capable of quenching quorum sensing-controlled activities in other species.
25
 However, to 
our knowledge no systematic study has screened for EPIs from marine microbial 
exudates (i.e., compounds excreted into the extracellular medium) against RND pumps. 
Regardless, our approach is validated by previous screening of terrestrially-derived 
microbial fermentations which resulted in two new natural product EPIs targeting 
MexAB-OprM from Streptomyces (EA-371α and EA-371δ) potentiating levofloxacin 
minimum inhibitory concentrations (MICs) 4-fold and 8-fold, respectively.
26
 The 
microbial EPI, MP-601,205 is currently used to treat P. aeruginosa respiratory infections 
in cystic fibrosis patients.
14
 Thus far, a diverse set of natural product chemical scaffolds 
(including polyphenols, flavones, flavonols, flavonolignans, flavonoids, diterpenes, 
triterpenoids, oligosaccharide-glycosides, and pyridines) have been validated as EPIs in 
20 
 
Gram-positive bacteria such as Staphylococcus aureus.
27
 A remaining challenge is the 
discovery of EPIs targeted toward Gram-negative efflux pumps.
27
 
We hypothesized that microorganisms obtained from the marine environment produce 
EPIs as regulators of diverse ecological interactions, and as such present a unique bio-
prospecting opportunity. In the present paper our objectives were: (i) to screen our in-
house chemical library to identify marine microbial isolates capable of reducing 
antibiotic MICs ≥4-fold in three strains overexpressing three archetype RND transporters 
(AcrAB-TolC, MexAB-OprM, and MexXY-OprM) common in Gram-negative 
pathogens, (ii) to isolate and chemically characterize the putative EPI lead, (iii) to 
evaluate the potential of our lead molecule to potentiate the activity of various classes of 
antibiotics, (iv) to quantify the inhibitory activity of this molecule in functional whole 
cell accumulation and efflux assays, and (v) to compare the exo-metabolomic fingerprints 
(i.e., the relative abundances of chemical features with unique m/z values and retention 
times)  of EPI-producing Pseudoalteromonas strains versus other related members of the 
genus, thereby linking metabolite diversity with genetic relatedness. We report herein the 
isolation, identification, and demonstration of EPI functionality of 3,4-dibromopyrrole-
2,5-dione, an inhibitor of RND transporters from Enterobacteriaceae and P. aeruginosa, 
having been isolated from the marine bacterium, Pseudoalteromonas piscicida. Our paper 
also demonstrates that the production of halogenated secondary metabolites is associated 
with those Pseudoalteromonas clades harboring antibiotic compounds and EPIs; further 
highlighting that marine microbial sources, especially marine Gram-negative bacteria, 
represent a tractable source of new chemical scaffolds for EPI development. 
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RESULTS AND DISCUSSION 
Isolation and Identification of 3,4-Dibromopyrrole-2,5-dione. Crude exudate 
extracts from a total of 1308 marine microbial isolates were screened in the p-
Iodonitrotetrazolium chloride (INT) assay to assess MDR reversal potential. This initial 
screening identified 36 marine microbial isolates of diverse phylogenetic affiliation 
(2.8% hit rate) capable of potentiating (i.e., reducing the antibiotic MIC by at least 4-fold) 
the activity of chloramphenicol and/or erythromycin when tested against E. coli MDR 
strains AG102, MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM. Phylogenetic analysis 
of 16S rRNA sequences indicated seven isolates of these 36 were Pseudoalteromonas sp. 
(A197, A198, A256, A746, A754, A757, B126) (Figure S1, Table S1, Supporting 
Information). Isolate B126 could not be revived from frozen culture; therefore it was 
dropped from further analysis. Crude extracts displaying an initial positive hit in one or 
more test E. coli strains in the bacterial susceptibility assay were prioritized for further 
testing. The INT assay was performed in the presence and absence of antibiotic to 
establish the MIC of the crude extract (tested in a serial dilution series) and determine if 
EPI-like activity was present by examining the minimal effective concentration of the 
crude extract required to potentiate the antibiotic MIC at least 4-fold. These experiments 
indicated isolates A197, A198, and A256 produced antibiotics only, while A746, A754, 
and A757 demonstrated EPI potential and antibiotic activity (data not shown).  The 
strongest EPI-like activity was seen for A757, therefore this isolate was chosen for 
further study. Bioassay-guided fractionation of the crude extract generated from 16.5 L of 
A757 exudates resulted in the isolation of 3,4-dibromopyrrole-2,5-dione. The structure of 
3,4-dibromopyrrole-2,5-dione was established on the basis of NMR spectroscopic and 
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LC-MS data in comparison with an authentic standard (Figure S2-6, Supporting 
Information). To our knowledge, this paper represents the first description of 3,4-
dibromopyrrole-2,5-dione from a microbial source, although the original report of its 
isolation from nature was from the marine sponge Axinella brevistyla collected in western 
Japan, where it was reported to exert modest antifungal activity and cytotoxicity against 
murine lymphocytic leukemia cells.
28
 However, since over 50% of a sponge’s biomass 
can be attributed to microorganisms, it is conceivable that the origin of 3,4-
dibromopyrrole-2,5-dione may be from sponge-associated microorganisms.
29
  
Antibiotic Potentiation Activity by 3,4-Dibromopyrrole-2,5-dione. The checker 
board assay was used to determine whether 3,4-dibromopyrrole-2,5-dione potentiates the 
activity of two fluoroquinolones (ciprofloxacin; CIP, and levofloxacin; LEV), an 
aminoglycoside (kanamycin; KAN), a macrolide (erythromycin; ERY), two β-lactams 
(oxacillin; OXA, and piperacillin; PIP), tetracycline (TET) and chloramphenicol (CHL), 
known substrates for RND transporters, 
17, 30-32
 against our test strains of MDR E .coli. 
The checkerboard method is so named due to the pattern of wells formed by dilutions of 
the antibiotic and test compound being examined, at concentrations above, at, and below 
their MICs. Interactions between 3,4-dibromopyrrole-2,5-dione and various antibiotics 
were classified based upon the fractional inhibitory concentration index (FICI), where 
FIC of < 0.5 is synergistic, and indicative of the presence of an EPI; 0.5-1 is indifferent; 
and >1 is antagonistic. The results, shown in Table 1, demonstrate 3,4-dibromopyrrole-
2,5-dione decreases the MICs of various antibiotic classes between 2 and 16-fold, with 
corresponding fractional inhibitory concentration indices (FICI) indicating synergistic 
activity of 3,4-dibromopyrrole-2,5-dione with all antibiotics tested with the exception of 
23 
 
piperacillin. 3,4-Dibromopyrrole-2,5-dione exhibited antibacterial activity at 
concentrations >100 µg/mL for all three E. coli strains overexpressing efflux pumps. The 
greatest decrease in antibiotic MICs was seen for erythromycin, where 3,4-
dibromopyrrole-2,5-dione decreased the antibiotic MICs between 8 and 16-fold. 
24 
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Hoechst 33342 Accumulation and Efflux Inhibition. To verify that inhibition of 
efflux, and not membrane permeabilization, is the mechanism by which 3,4-
dibromopyrrole-2,5-dione potentiates antibacterial activity, we determined whether 3,4-
dibromopyrrole-2,5-dione was capable of causing the accumulation of the fluorescent 
efflux pump substrate (Hoechst 33342) in the wild-type, E. coli AG100 expressing the 
AcrAB-TolC pump; and conversely confirm the E. coli mutant AG100A lacking the 
pump would not be affected. Upon entering the bacterial cell, H33342 becomes 
fluorescent once bound to the DNA minor groove. As shown in Figure 1A, addition of 
3,4-dibromopyrrole-2,5-dione at concentrations ranging from 0.06 – 64 µg/mL, resulted 
in a dose-dependent increase in intracellular H33342 fluorescence, consistent with an EPI 
effect. Concentrations of 3,4-dibromopyrrole-2,5-dione ≥ 1 µg/mL were equal to or more 
effective than the reference inhibitor PAβN (15.6 µg/mL) in causing H33342 
accumulation. We reasoned that antibiotic-sensitive mutant E. coli (AG100A), lacking 
the target RND pump of 3,4-dibromopyrrole-2,5-dione would not be affected by the 
compound. Results displayed in Figure 1B, show there is no effect of 3,4-
dibromopyrrole-2,5-dione on H33342 fluorescence in AG100A, which is consistent with 
the hypothesis that RND pumps are the target of 3,4-dibromopyrrole-2,5-dione and 
indicates MDR reversal is limited to efflux pump expressing E. coli strains. In addition, if 
the mechanism of action of 3,4-dibromopyrrole-2,5-dione was via membrane 
permeabilization, we would have seen a dose-dependent increase in H33342 
accumulation regardless of test bacterial strain, which we did not observe. 
 Demonstration of efflux activity in AG100 requires that accumulation of H33342 has 
taken place. Following H33342 “loading”, monitoring of efflux was initiated in the 
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presence of increasing concentrations of 3,4-dibromopyrrole-2,5-dione (0.06 – 64 
µg/mL) in medium containing glucose at 37
o
C. The near complete inhibition of H33342 
efflux was observed in comparison to control wells (Figure 1C) indicating efflux 
competent bacterial cells were not capable of transporting H33342 in the presence of 3,4-
dibromopyrrole-2,5-dione. Concentrations of 3,4-dibromopyrrole-2,5-dione as dilute as 
0.06 µg/mL showed significant (p < 0.05) H33342 efflux inhibition in comparison to 
solvent controls (Table 2). The IC50 value for 3,4-dibromopyrrole-2,5-dione in the efflux 
assay was calculated to be 0.79 µg/mL or 3 µM. A comparison of bacterial RND pump 
EPIs reveals that compounds, including 3,4-dibromopyrrole-2,5-dione, contain 
hydrophobic ring systems that presumably interact with hydrophobic residues located 
near or in the substrate binding site.
33
  
Table 2. Hoechst 33342 accumulation and efflux of in the presence of 3,4-
dibromopyrrole-2,5-dione 
    Accumulation Efflux   
Compound 
(µg/mL) 
AG100
a
 AG100A
b
 AG100
a
   
DBDP Mean (RFU) S.D. Mean (RFU) S.D. Mean (RFU) S.D.   
  64 1208*** 20 1090 10 -68*** 54   
  16 1165*** 8 1103 14 -34*** 58   
  4 1130*** 11 1175 8 -101*** 34   
  1 1006*** 4 1065 5 -247*** 30   
  0.25 796*** 12 1003 17 -351*** 7   
  0.063 758 9 1016 15 -422* 37   
Hoechst only 746 16 1038 10 -472 13   
                  
aAG100, wild-type E. coli K-12 strain 
bAG100A, ΔacrAB mutant 
Final mean values from last four minutes of the assay, compared using a one-way ANOVA 
with Dunnett's multiple comparison test comparing treatment versus Hoechst H33342 
control. The level of significance is indicated by asterisks (***p<0.0001,*p<0.05, n=8)   
IC50 value calculated from efflux data was 0.79 µg/mL or 3µM (95% confidence interval 
0.69-0.91 µg/mL). 
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3,4-Dibromopyrrole-2,5-dione also is known to react with disulfide linkages in the 
presence of a strong reducing agent such as (tris(2-carboxyethyl)phosphine).
34
 It is 
conceivable, but unlikely, that 3,4-dibromopyrrole-2,5-dione is displacing and 
coordinating certain accessible, reduced disulfide linkages in the RND pumps and 
permanently modifying their conformation by this crosslinking type displacement; 
however, the lack of antibiotic activity and range of pharmacokinetics argue against this 
type of action. Although the subject of another study, experiments employing 
halogenated and non-halogenated maleimides will be informative in terms of mode of 
action. 
Chemophylogenetic Analysis of Extracts from Pseudoalteromonas Isolates. 
Analysis of our untargeted -HRESI metabolomics comparison indicated the presence of 
many halogenated features, the distributions of which differed greatly across 
Pseudoalteromonas clades (Figure 2B and 2C, Figure S7, Table S2, Supporting 
Information). Principle component analysis (PCA) of -HRESI mode data (n = 1112 
chemical features present in Pseudoalteromonas samples at concentrations 10x those in 
the media only blank) revealed that most Pseudoalteromonas clades were chemically 
similar overall with the exception of two clades, IV and VI, which were distinguishable 
from the other clades based on the first two principal components of a four component 
model (capturing > 60% of the total variance) (Figure 2B). Of the two clades 
distinguishable via PCA, Clade IV contained the EPI producing strain A757 and two 
additional strains with EPI activity based on dilution series testing (A746 and A754), 
while Clade VI contained two strains (A197 and A198) with antibacterial activity only 
(Table S1, Supporting Information). In summary, the PCA analysis of -HRESI data 
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revealed those strains with the most disparate chemistry (designated by Clades IV and 
VI), corresponded to the majority of strains with antibiotic activity against MDR E. coli.  
In order to discern which chemical features were unique to Clade IV (and 
subsequently strain A757), we examined chemical feature loadings on the first principal 
component. It is important to note that great care must be taken to avoid the assumption 
that any of these features alone would be significantly differentially produced by 
Pseudoalteromonas strains,
35
 however, examining the loadings is still useful and will 
likely reveal suites of compounds with varying concentrations in different 
Pseudoalteromonas extracts. Of the 1112 features, 221 chemical features had small 
negative loadings (<-0.02) within the first principal component and highly positive 
loadings (>0.02) on the second principal component (Figure S7, Supporting Information), 
and were therefore likely candidates to distinguish Clade IV from the remaining clades 
(Figure 2B). Further analysis of these 221 features indicated that i) several shared 
retention times, and ii) had masses ~2 amu apart, suggesting that many chemical features 
were isotopes of halogenated metabolites. We determined that of these 221 features, 129 
were isotopes of 46 individual brominated metabolites based upon both isotopic 
distribution and shared retention time (Table S2, Figures S8-30, Supporting Information).  
Of the 46 halogenated metabolites found, all were exclusively produced by members of 
Clade IV (Figure 2C), demonstrating that there is a distinct Pseudoalteromonas 
chemotype characterized by halogenation of the exo-metabolome. Moreover, this 
“halogenome” appears to be dominated by brominated metabolites, with only some 
metabolites (<10) that are additionally chlorinated (Table S2, Supporting Information). In 
addition, we observed several other brominated compounds (~30-40) based upon isotopic 
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signatures produced by A757 that were not accounted for in the initial 221 chemical 
features (screened based on their loadings), suggesting that a large percentage of A757 
exo-metabolome may be subject to halogenation (Tables S2 and S3, Supporting 
Information). Relative concentrations of halogenated compounds from Clade IV appeared 
different even within members of the same species (Figure 2C), indicative of intra-
species chemical diversity and further sub-clustering among isolates of the same species 
(A757, A754, A746 and B149) a phenomenon previously described for P. luteoviolacea 
strains.
36
 Taken together, these results indicate that the production of halogenated 
compounds could be a biomarker for marine isolates with enhanced biosynthetic 
potential. Of the four strains in our culture collection designated as belonging to Clade 
IV, A757 and A754 produced all 46 metabolites, whereas strains A746 and B149 
produced only select halogenated metabolites, including 2,3,4,5-tetrabromopyrrole, a 
known weak antibiotic from Pseudoalteromonas spp.,
37
 (Figure 2C). 2,3,4,5-
Tetrabromopyrrole appears to be the most abundant brominated compound we observed 
(retention time 20.8 min, major ion m/z 381.6722, Figure 2C, Table S2, Supporting 
Information) and present in all members of Clade IV. Because of the dominance of 
2,3,4,5-tetrabromopyrrole in our samples and its shared carbon skeleton with 3,4-
dibromopyrrole-2,5-dione, we tested an authentic standard of 2,3,4,5-tetrabromopyrrole 
in EPI functionality assays and determined 2,3,4,5-tetrabromopyrrole is not responsible 
for the EPI activity of strain A757 (data not shown). We also determined the presence of 
2,3,4-tribromopyrrole (retention time 20.1 min, major ion m/z 301.7639, Figure 2C, Table 
S2, Supporting Information) present in A757, A754 and A746, but not in B149). 2,3,4-
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Tribromopyrrole is reported to be produced by P. luteoviolacea,
38
 found within Clade IV, 
and is a known feeding deterrent in marine systems.
39
  
The limit of detection of 3,4-dibromopyrrole-2,5-dione with an authentic standard was 
established to be 11.1 ng/mL. Our yield from 16.5L of A757 culture was on the order of 1 
mg/L of 3,4-dibromopyrrole-2,5-dione. 3,4-Dibromopyrrole-2,5-dione should have been 
detected in our crude that was initially screened for antibiotic activity, however, we did 
not see this ion until culture scale-up and further purification, suggesting ionization 
masking effects from the presence of a complex mixture including 2,3,4,5-
tetrabromopyrrole, which was observed to co-elute with 3,4-dibromopyrrole-2,5-dione 
under these chromatographic conditions. In addition to numerous halogenated 
metabolites, we also were able to observe other unique metabolites produced by members 
of Clade IV (versus other Pseudoalteromonas clades), when using PCA to compare 
metabolomes generated with +HRESI data (n = 1552 chemical features; Figures S31, S32 
and S33, Tables S4, S5 and S7, Supporting Information), although we did not follow up 
with a complete characterization of these chemical features to avoid over-interpretation 
of these data. Strain A746 was distinguished by a group of 177 chemical features 
(Figures S31and S32, Table S4 Supporting Information) whereas other members of Clade 
IV (strains A575, A574, B149) were more easily distinguished by a group of 56 chemical 
features (Figure S31 and S33, Table S5, Supporting Information). Although we did not 
seek to fully annotate chemical features detected in +HRESI, these data also indicate 
(along with –HRESI results) that members of Clade IV do possess a characteristic exo-
metabolome.  
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Screening features detected with our untargeted metabolomics approach (both –HRES 
and +HRES) against an in-house database containing previously reported 
Pseudoalteromonas metabolites indicated isolates in our collection potentially produce 
molecules previously described for Pseudoalteromonas spp. Molecular features 
annotated in +/-HRESI mode data with isotopic distribution patterns and predicted 
formulae matching these dereplicated compounds are shown in Figure 3 and Tables S8 
and S9, Supporting Information. A potential annotation for the antibiotic, 2-n-heptyl-4-
quinolinol,
40
 known to also influence bacterium-phytoplankton interactions,
23
 was 
exclusively found within members of Clade IV in both +HRESI and –HRESI data sets 
(Figure 3). Previous work indicated bacterial production of 2-n-heptyl-4-quinolinol is 
surface-dependent, and bacteria are able to generate localized zones of concentrated 2-n-
heptyl-4-quinolinol on sinking or suspended particles without loss of this antibiotic to the 
surrounding seawater.
23
 It would be interesting to know if 3,4-dibromopyrrole-2,5-dione 
has an overlapping accumulation profile as the putative 2-n-heptyl-4-quinolinol ion in 
isolate A757. Moreover, features matching the predicted molecular ions for the antibiotic 
diketopiperazine, cyclo-(L-phenylalanyl-4R-hydroxyl-L-proline)
37
 and the antifungal, 
isatin (1H-indole-2,3-dione)
41
 were also noted in many isolates in both ionization modes 
(Figure 3A & B). Clade IV may also exclusively produce the antibiotic, 2-n-pentyl-
quinolinol
40
 (Figure 3A). Additional annotations for molecular ion matches from our 
database include: the cryptic metabolite, 3-formyl-L-tyrosine-L-threonine dipeptide,
42
 
three isomers of indole-3-carboxaldehyde,
40
 three isomers of the antibiotic, p-
hydroxybenzaldehyde
40
 and two isomers of antibiotic, p-hydroxybenzoic acid,
43
 all of 
which were expressed by the majority of Pseudoalteromonas isolates in our collection 
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(Figure 3A). Molecular features found only in a single isolate include those matching to 
the ions for the antifungal polyketide, alteramide B
44
 from A757; the 
antistaphyloccoccal/antivibrio compound, indolmycin
45
 and Gram-negative antibiotic, 
korormicin 1b
46
 from A345; and the diketopiperazine, cyclo-(D-pipecolinyl-L-
isoleucine)
47
 from A198 (data not shown). Molecular ions matching the antibiotic 
diketopiperazine cyclo-(L-pipecolinyl-L-phenylalanine)
37
 was found in A474 and A454, 
while features matching the calculated [M+H]+ ions of antibiotic, pseudomonic acid C
48
 
and the cytotoxic carboline alkaloid, norharman (9H-pyrido[3,4-b]indole)
49
 appeared to 
be expressed in the majority of our isolates, with a few exceptions (Figure 3B). Future 
work will be able to discern the true identities of these chemical features, as several 
isomers are possible for each of the detected ions in our analysis. Regardless, 
chemophylogenetic analysis indicated that some compounds were i) characteristic of a 
particular isolate, ii) clade specific (e.g., halogenated species, 2-n-heptyl-4-quinolinol, 
and 2-n-pentyl-quinolinol) or iii) ubiquitous in the majority of isolates. 
Increasingly, non-photosynthetic Gram-negative bacteria (NPGNB) are being 
recognized as the true source of pharmaceutically-relevant molecules from marine 
macroorganisms;
29
 however, the difficulty in culturing marine-derived strains to 
sufficient quantities has likely hampered intense bio-prospecting efforts.
29
 Indeed, the 
majority (86%) of our marine isolates found to have MDR reversal activity in our initial 
screening efforts fall within the NPGNB group, and have been isolated from both abiotic 
and biotic surfaces (Table S1, Supporting Information). The cosmopolitan marine genus 
Pseudoalteromonas (class Gammaproteobacteria), which constitute 0.5-6% of bacterial 
species globally,
50
 has been found in seawater, marine sediments and epiphytically 
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associated with marine eukaryotes, and has been a prolific source of brominated 
compounds,
37, 51, 52
 including pentabromopseudilin,
36
 the first marine microbial natural 
product to be described.
53, 54
 Compounds isolated from this genus function in multiple 
ecological roles including their involvement in chemical protection, settlement, 
germination and metamorphosis of marine invertebrate and algal species, as well as more 
commercial uses as antifoulants, antibacterial, antifungal and cytotoxic agents.
37, 52, 55
 
Recent genome mining work has uncovered the biosynthetic pathways responsible for 
brominated pyrrole/phenol biosynthesis (bmp)
38
 indole derivatives, siderophores, 
polyketides, homoserine lactones, peptides (both ribosomal and non-ribosomal origin) 
and hybrid molecules,
56
 which likely represent just the tip of the iceberg, as the number 
of pathways encoded in Pseudoalteromonas genomes eclipses the fraction of molecules 
identified thus far.
55
   
For marine bacteria, including many antibiotic producing Pseudoaltermonas spp.,
37, 57
 
a viable strategy by these organisms may be to secrete an EPI to enhance their own 
antibiotic effectiveness. Previous research suggests the dominance and enriched 
diversity
51
 of Pseudoalteromonas spp. in biofilms could be attributed to their ability to 
rapidly form microcolonies and produce extracellular antibacterial compounds.
36, 58
 The 
production of EPIs targeting RND pumps and other MDR pumps may effectively disable 
the antibiotic resistance mechanisms of competitors allowing Pseudoalteromonas strains 
to colonize and persist in biofilms. This chemical strategy of using EPIs to enhance 
antibiotic potency is not novel in nature; rather it has been previously described in plants 
mounting an attack against surface-associated Gram-positive bacteria.
59
 A blastp search 
of all 54 Pseudoalteromonas spp. genomes available in the IMG database 
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(https://img.jgi.doe.gov/cgi-bin/w/main.cgi) showed amino acid identities to the inner 
membrane RND transporters as high as 71% for AcrB, 65% for MexB and 52% for 
MexY. Efflux pumps with homology to AcrB and MexB are known to be functional in 
Vibrio parahaemolyticus inhabiting brackish saltwater, for example, where the VmeAB 
efflux pumps have been shown in vitro to exhibit bile salt and antibiotic resistance 
phenotypes.
60
 Although it is unclear what role, if any, the putative RND-type homologues 
present in Pseudoalteromonas spp. may play, it is possible that they could be aiding in 
moderating allelopathic interactions as was found with antibiotic resistance and 
production in Vibrio spp. bacteria.
61
 Considering efflux pump inhibitors as antibiotic 
adjuvants among natural populations could add a new dimension to our understanding of 
competition between microbial populations. Our data show that Pseudoalteromonas 
strains indeed display niche specificity in regards to halogenated metabolite production, 
and further bioprospecting efforts could benefit from a focus on environments - such as 
biofilms, to enhance discovery of new antibiotic and EPI therapeutics. 
EXPERIMENTAL SECTION 
General Experimental Procedures. Nuclear magnetic resonance (NMR) spectra (1D 
1
H and 
13
C) were recorded on a Bruker Avance III 300 MHz spectrometer in DMSO-d6 
with the solvent (δH at 2.54, δC at 39.5) used as an internal standard. Chemical shifts are 
given as δ (ppm). HPLC-MS experiments were accomplished using an Agilent 
Technologies 6230 ToF with Dual Agilent Jet Stream Electrospray Ionization source, 
equipped with an Agilent 1260 Infinity series HPLC with a Phenomenex Kinetex™ 2.6 
µm, C18, 100 Å, LC column (150 x 2.1 mm) as the stationary phase. All HPLC-MS 
experiments used a flow rate of 0.2 mL/min. This instrument was also equipped with 
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Agilent Mass Hunter Workstation version B0.4.00 software. Mass spectra peak picking 
and alignment software MZmine 2.11
62
 was used for processing mass spectra before 
principal component analysis with the PLS Toolbox in Matlab version 8.2.0.7. EPI 
isolation was accomplished using vacuum liquid chromatography (10 x 5 cm) with Silica 
gel, pore size 60 Å, particle size 40-75 µm (Sigma-Aldrich, St. Louis, MO, USA). All 
solvents used throughout the project were OPTIMA grade (Fisher Scientific). Semi-
preparative HPLC was carried out on an Agilent 1200 series equipped with an 
autosampler, diode array detector, quaternary pump, and 96-well plate fraction collector 
with a Phenomenex Luna® 5 µm C18(2), 100 Å, LC column (250 x 10 mm) as the 
stationary phase. All semi-preparative HPLC experiments used a flow rate of 4 mL/min. 
Authentic standards of 2,3,4,5-tetrabromopyrrole (Cat. L165042) and 3,4-
dibromopyrrole-2,5-dione (Cat. 553603) were purchased from Sigma-Aldrich and 
dissolved in dimethyl sulfoxide (DMSO) for use in activity assays.  
Bacteria Culture and Chemical Library Production. Currently the Mincer 
Laboratory maintains over 2000 unique marine microbial isolates for chemical 
exploration. All pure cultures are cryopreserved in 10% sterile DMSO and stored at -
85ºC. A “starter” culture was prepared by inoculating 100 µL of frozen culture in 6 mL 
of TSW media (1 g tryptone in1 L of 75:25 seawater/MilliQ water) and incubated at 
23ºC, 100 rpm for 3 d. In general, 1.5 L of TSY media (1 g tryptone, 1 g yeast extract, 
75% seawater) is inoculated with 1.5 mL of “starter” culture and grown at 100 rpm for 8 
d at 23ºC. Twenty four hours before culture filtration (Day 7), 20 mL of 1:1 mixture of 
sterile, washed Amberlite® XAD-7 and XAD-16 resin was added to the cultures. On the 
eighth day, the resin was filtered from the bacterial culture under vacuum, desalted by 
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rinsing with MilliQ water, and allowed to dry overnight at room temperature. Metabolites 
were eluted from the resin first in 100 mL of (1:1) MeOH:DCM, followed by 100 mL of 
MeOH. This crude organic extract was then dried under vacuum centrifugation 
(ThermoSavant). Dried extracts were subsequently resuspended in DMSO at 100 mg/mL 
and stored at -85ºC until further testing in bacterial susceptibility assays. 
Bacterial Susceptibility Determinations. Whole-cell assays were used to search for 
efflux pump inhibitors for three archetype RND efflux pumps (AcrAB-TolC, MexAB-
OprM, and MexXY-OprM) that are known to contribute to antibiotic resistance in 
Enterobacteriaceae and P. aeruginosa clinical isolates. Escherichia coli strains 
engineered to overexpress RND transporters were generous gifts from Dr. C. Elkins 
(U.S.F.D.A)
30
 and Dr. Y. Matsumoto (Osaka University).
63
 Isolates used for screening 
include AG102 (derived from AG100; E. coli K-12), an isolate that overexpresses 
AcrAB-TolC efflux system due to a mutation in the MarR (marR1) which increases the 
expression of MarA, a global regulator, which in turn results in the overexpression of 
AcrAB-TolC efflux system;
30
 and two E. coli MG1655 deletion mutants (ΔacrB ΔtolC) 
that have been transformed with the plasmid carrying genes mexAB-oprM (MG1655 
ΔBC/pABM) and mexXY-oprM (MG1655 ΔBC/pXYM) from P. aeruginosai.63 E. coli 
strains harboring plasmids were always cultured in a medium containing 100 µg/mL 
ampicillin and 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). 
Minimum inhibitory concentrations (MICs, defined as the lowest concentration that 
will inhibit detectable culture growth) of the antibiotics (chloramphenicol and 
erythromycin, both of which are substrates of RND pumps)
30, 64-67
 were determined using 
a twofold standard microdilution method in Muller-Hinton broth (MHB) in microtiter 
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plates as defined by the National Committee for Clinical Laboratory Standards
68
 for each 
of the three E. coli strains. Bacterial susceptibility of crude extracts were tested in 
duplicate at 1 mg/mL and determined by rapid p-iodonitrotetrazolium chloride (INT) 
colorimetric assay in 96-well microtiter plates in a final volume of 200 µL as described in 
Kuete et al. 2010.
69
 The INT assay evaluates if crude extracts have an MDR reversal 
effect (so called ‘MIC/4’, defined as reducing by at least fourfold the antibiotic MICs) by 
examining the growth of our test E. coli strains in the presence of crude extract and either 
chloramphenicol or erythromycin at concentrations at ¼ their MICs. If the crude extract 
is capable of potentiating the concentration of antibiotic needed to inhibit the  growth of 
one or more test strains of MDR E. coli, these initial “hits” were then prioritized for 
further testing (in a serial dilution series) in the presence and absence of antibiotic via the 
INT assay to establish if EPI-like activity was present.  Wells containing MHB, inoculum 
and DMSO at a final concentration of 1% served as a negative control. Phenylalanyl 
arginyl β-naphthylamide (PAβN, general RND pump inhibitor) was used as a positive 
control at 30 µg/mL in INT assays. 
Culture Production Scale-up, Bioassay Guided Fractionation, and Chemical 
Analysis. Marine isolate A757 (GenBank KM596702), determined to be most closely 
related to P. piscicida by 16S rRNA sequence comparison, was targeted for scaled-up 
regrowth to obtain additional material for chemical identification of the putative EPI 
compound. A starter culture of A757 was used to inoculate eleven, 1.5 L Fernbach flasks 
for a total of 16.5 L of culture medium that was processed as described in “Bacteria 
Culture and Chemical Library Production”, yielding a total of 1729.7 mg of crude 
organic extract. At each subsequent fractionation step an aliquot of material was 
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resuspended in DMSO and assayed in the INT assay against MG1655 ΔBC/pXYM to 
confirm retention of MDR reversal activity. A total of 1.7 g of crude extract was applied 
to a silica gel column and eluted with a step-gradient of 100% isooctane, 4:1 
isooctane/EtOAc, 3:2 isooctane/EtOAc, 2:3 isooctane/EtOAc, 1:4 isooctane/EtOAc, 
100% EtOAc, 1:1 EtOAc/MeOH, and 100% MeOH, yielding eight fractions. Active 
constituents eluted with 3:2 isooctane/EtOAc and 2:3 isooctane/EtOAc, were combined, 
and chromatographed on a semipreparative HPLC using a gradient of ACN (0.1% formic 
acid) and H2O (0.1% formic acid). Chromatography methods were as follows: hold at 5% 
ACN for 5 mins, ramp to 40% ACN over 5 min, hold at 40% ACN for 2 mins, ramp to 
95% ACN over 5 min, hold at 95% ACN for 7 min, ramp down to 5% ACN and hold for 
4 min. Active constituents eluted with 95:5 ACN/H2O at a flow rate of 4 mL/min over 28 
min into a 96 deep-well plate. Two wells on the 96 deep-well plate responsible for the 
activity were combined and subject a second round of semipreparative HPLC (ramp from 
55-75% ACN over 20 min; ramp to 95% ACN; hold at 95% ACN for 6 min; ramp to 
55% ACN and hold for 2 min, 4 mL/min flow rate), with active constituents eluting with 
70:30 ACN/H2O into a 96 deep-well plate resulting in activity spread over three wells 
containing 14.4 mg of material. LC-MS analysis with acidified solvents (0.1% formic 
acid) was performed on the active fraction with a solvent gradient of 6:94 MeOH/H2O 
ramping to 8:92 MeOH/H2O over 25 mins, at a flow rate of 0.2 mL/min, which led to the 
identification of 3,4-dibromopyrrole-2,5-dione, the major component of the fraction. 
NMR spectra of 3,4-dibromopyrrole-2,5-dione from A757 and an authentic standard are 
available in Figures S2-5 in Supporting Information. 
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Checker board Assay. To assess the interaction between different classes of 
antibiotics and 3,4-dibromopyrrole-2,5-dione, we performed standard checkerboard 
assays in which the MICs of antibiotics were determined in the presence of different 
concentrations of 3,4-dibromopyrrole-2,5-dione. Standard checkerboard titration 
microtiter plate assays were performed as described in
65, 70
 to determine the fractional 
inhibitory concentrations (FICs) of 3,4-dibromopyrrole-2,5-dione against various 
antibiotics (chloramphenicol, ciprofloxacin, erythromycin, kanamycin, levofloxacin, 
oxacillin, piperacillin, and tetracycline) for all three E. coli strains.  
Hoechst Accumulation and Efflux Assay. To truly be considered an EPI, the 
compound must increase the level of accumulation and decrease the level of extrusion of 
efflux pump substrates. The fluorescent DNA-binding dye Hoechst 33342 (H33342) is a 
substrate for RND pumps, is easily detected in the cell, can freely permeate the outer 
membrane, and can act as a reporter -- all allowing for quantification of transport across 
living cells.
71
 Efflux competent cells extrude H33342 and accumulate dye at a relatively 
slow rate, resulting in low levels of background fluorescence. Conversely, efflux-
defective cells (e.g., presence of EPI) accumulate intracellular levels of H33342 at a 
higher rate, resulting in fluorescence retention. Wild-type E. coli K-12 strain, AG100, 
and AG100A, the ΔacrAB mutant, were a generous gift from Dr. M. Viveiros 
(Universidad Nova de Lisboa, Portugal) and used in accumulation and efflux assays.
72, 73
 
Experiments were performed in microtiter plate format as described in
74, 75
 using H33342 
as described in
71
 at a concentration that does not affect the growth of E. coli strains. All 
wells were performed in duplicate. Heat-inactivated bacteria were used as a positive 
control to assess maximal dye accumulation (data not shown).  
40 
 
For accumulation assays, in efflux competent cells like AG100, H33342 would be 
extruded resulting in low levels of background fluorescence, while the presence of a 
putative EPI would cause intracellular H33342 accumulation. Moreover, AG100A, 
engineered to lack efflux pumps, was used to confirm that 3,4-dibromopyrrole-2,5-dione 
is indeed targeting efflux pumps, and that MDR reversal is limited to efflux pump over-
expressing test E. coli strains. Specifically, accumulation of H33342 in AG100A cells 
would be unaffected by the presence of 3,4-dibromopyrrole-2,5-dione. Briefly, AG100 
and AG100A were grown in Luria Broth (LB) at 37
o
C and 200rpm until an OD600 of 1.0 
then pelleted at 3000 rpm for 15 min, washed twice with phosphate buffered saline 
(PBS), and diluted in PBS (without glucose) to OD600 0.3. The following conditions were 
used to achieve a minimal accumulation of H33342 in AG100 and AG100A cells: the use 
of 2.5 µM H33342 in the presence of 22 mM glucose at 37
oC. PAβN (15.6 µg/mL) was 
used as a positive control. Fluorescence values for wells containing media and 
compounds only were subtracted from those containing bacteria to control for any 
background fluorescence due to the presence of test compounds. Bacteria in PBS without 
H33342 + glucose + 3,4-dibromopyrrole-2,5-dione were also used as a control (data not 
shown). Bacterial cells were allowed to incubate for ~30 min until H33342 accumulation 
stabilized, after which 3,4-dibromopyrrole-2,5-dione (concentrations ranging from 0.06 – 
64 µg/mL) and PAβN (15.6 µg/mL) were added. Accumulation of H33342 was 
continuously monitored (Ex350nm/Em460nm) for another 60 min using a SpectraMax 
M2.  
For efflux assays, a time-dependent decrease in fluorescence of H33342-loaded AG100 
would be observed only when efflux is active, while the presence of a putative EPI would 
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cause the retention of H33342 over time. Briefly, AG100 cells were grown, pelleted and 
washed as described above, then “loaded” with H33342 (2.5 µM) and either PAβN (15.6 
µg/mL) or 3,4-dibromopyrrole-2,5-dione (concentrations ranging from 1 – 64 µg/mL) 
under conditions that favor maximal accumulation (no glucose, 25
o
C). When maximum 
accumulation was reached (after 60 min), bacteria were pelleted at 3000 rpm for 3 min, 
resuspended in ice-cold PBS, aliquoted into the microtiter plate, and exposed to 
corresponding concentrations of either PAβN or 3,4-dibromopyrrole-2,5-dione, with and 
without glucose at 37
o
C. H33342 efflux was continuously monitored by fluorescence at 
(Ex 350 nm/Em 460 nm) for an additional 30 min. Values from the “no glucose” control 
wells were subtracted from the values obtained from wells containing glucose. To obtain 
a comparative analysis of the efflux, the fluorescence data of the H33342-loaded cells 
were normalized to 1, thereby establishing a maximum fluorescence value.  
Statistical comparisons of H33342 accumulation assay data were performed by 
combining fluorescence measurements from the final four time points (period where 
accumulation/fluorescence has stabilized) and comparing fluorescence among treatments 
using a 1-way ANOVA with a Dunnett’s post-test to determine statistical differences 
between treatments and the Hoechst control (Graphpad Prism 6.05). To calculate the 
H33342 efflux IC50 concentration of 3,4-dibromopyrrole-2,5-dione, final fluorescence 
measurements (from final four data points, as described above), were used to plot efflux 
versus EPI concentration. The line was then fitted to a sigmoidal curve and IC50 was 
calculated in Graphpad. 
Chemical profiling with mass spectrometry. Exuded secondary metabolites produced 
by Pseudoalteromonas spp. extracts (n = 36 individual strain extracts) were diluted to 5 
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mg/mL in DMSO for untargeted metabolomic fingerprint analysis. Standards of 2,3,4,5-
tetrabromopyrrole (in a standard curve spanning two orders of magnitude) were used to 
determine the retention time and limit of detection (calculated as 3xS.D./slope of 
regressed standard curve). Extracts were then profiled (5 µL injections) by reversed-
phase HPLC/MS ToF, using MeOH (0.1% formic acid) and H2O (0.1% formic acid). 
Chromatography methods were as follows: hold at 5% MeOH for 5 min, ramp to 40% 
MeOH over 5 min and hold for 2 min, ramp to 95% MeOH over 5 min and hold for 3 
min. The first 4.5 min of each run was not injected into the mass spectrometer to avoid 
DMSO contamination, and there was an 8 min column equilibrium time between 
injections. Column temperature was held at 35°C with a flow rate of 0.2 mL/min. 
For profiling, spectra were collected in both positive (+HRESI) and negative (-HRESI) 
ionization modes in two separate runs (i.e., no polarity switching). Settings were as 
follows for +HRESI: mass correction ions used were 922.0098 m/z and 121.0509 m/z 
(injected at source); scanning a 20-3000 m/z range with a scan rate of 1.00; gas 
temperature and sheath gas temperature at 350°C. Drying gas flow rate was 8 L/min, 
while sheath gas flow rate was 10 L/min with nebulizer pressure set to 40 psi. Capillary 
voltage and nozzle voltages were 3500 V and 1000 V, respectively. Fragmentor and 
skimmer voltages were 135 V and 65 V, respectively. These settings were held for -
HRESI except for the mass correction ions used, which were 1033.9881 m/z and 
112.9856 m/z in negative mode. 
Metabolomics processing and statistical analysis. For metabolomics analysis, 
individual spectra were exported from Mass Hunter Workstation as .mzData files and 
imported in MZmine
76
 for preprocessing, as performed in.
77, 78
 This included mass 
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detection, chromatogram building, peak convolution, deisotoping, retention time 
normalization, spectral alignment, gap-filling, and duplicate peak filtering. The same 
algorithms and settings were used for both +HRESI and -HRESI data, except that 
minimal peak thresholds were set to 5000 ion counts for -HRESI and 10,000 ion counts 
for +HRESI data. After processing, a list of chemical features (m/z-retention time pairs) 
was filtered to only include those features greater than an order of magnitude more 
concentrated in a Pseudoalteromonas sample than in the media blank. For +HRESI data, 
all features detected between 18.99 – 23.0 min were also removed due to contamination 
from polyethylene glycol during those retention times. Filtered datasets were then 
imported into Matlab and autoscaled
79
 before principal component analysis (PCA) using 
the PLS Toolbox
80
, while +HRESI and -HRESI data were analyzed separately. PCA was 
used to visualize differences among the exuded metabolite profiles of the 
Pseudoalteromonas strains. The loadings for particular principal components were 
examined to determine which suites of chemical features were likely to be differentially 
expressed
35
 in different clades of Pseudoalteromonas, and in particular Clade IV. Mass 
Hunter Workstation (Qualitative Analysis) was used to confirm the presence of particular 
chemical features in raw (unprocessed) mass spectra, and to confirm isotopic 
distributions of any halogenated chemical features that were important in distinguishing 
Pseudoalteromonas Clade IV in the PCA. To screen for the presence of known 
Pseudoalteromonas-specific metabolites in our extracts, a literature search was 
performed and previously described compounds (including their names, monoisotopic 
mass, and molecular formulae) were compiled into our in-house “Pseudoalteromonas 
database.” The feature list generated in MZmine (see above) was then searched against 
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this database (assuming a [M-H]- adduct for -HRESI or [M+H]+ adduct for +HRESI) and 
with a mass error threshold of ≤ 5.0 ppm.   
Phylogenetic Analysis. The evolutionary history was inferred using the Neighbor-
Joining method
81
 and the optimal tree is shown for topology. The percentage of replicate 
trees in which the associated taxa clustered together in the bootstrap test (1000 
replicates)
82
 are shown next to the branches for Neighbor Joining (left) and Maximum 
Likelihood (right). The evolutionary history was inferred by using the Maximum 
Likelihood method based on the Kimura 2-parameter model.
83
 Initial tree(s) for the 
heuristic search of the Maximum Likelihood tree nodes were obtained automatically by 
applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated 
using the Maximum Composite Likelihood (MCL) approach. The tree is drawn to scale, 
with branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. The evolutionary distances were computed using the Jukes-Cantor 
method
84
 and are in the units of the number of base substitutions per site. The analysis 
involved 73 nucleotide sequences. All positions containing gaps and missing data were 
eliminated. There were a total of 399 phylogenetically informative positions in the final 
dataset. Evolutionary analyses were conducted in MEGA6.
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Figure 1. Effect of 3,4-dibromopyrrole-2,5-dione on Hoechst 33342 accumulation and 
efflux in wild-type (AG100) and transporter-deficient (AG100A) E. coli. Hoechst 33342 
accumulation in AG100 (A) or AG100A (B) and efflux in AG100 (C) in the presence of a 
dilution series of 3,4-dibromopyrrole-2,5-dione. PAβN (15.6 µg/mL) was used as a 
positive control.  
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Figure 2. Phylogenetic and exo-metabolomic comparison of Pseudoalteromonas sp. (A) 
Neighbor-Joining dendogram displaying the evolutionary history of the 16S rRNA gene 
sequences of the 36 Pseudoalteromonas spp. featured in this study. Topology of the tree 
was tested by 1000 bootstrap replicates and scores are displayed for Neighbor-Joining 
(top) and Maximum Likelihood (bottom) at each node. Scores under 50% are not shown. 
(B) PCA Scores plot of exo-metabolomes (-HRESI) of, 36 different Pseudoalteromonas 
strains representing seven clades (I-VII). The first principal component (PC1) describes 
20.7% of the variance while the second principal component (PC2) describes 16.2% of 
total variance. Dashed line indicates 95% confidence interval. (C) Heat map displaying 
relative abundances of brominated metabolites produced exclusively by 
Pseudoalteromonas Clade IV (strains A757, A754, A746, and B149). Colored bar rank 
peak areas of the major brominated isotope of each metabolite. Column headings display 
each ion (m/z) with retention time (RT) for each ion in minutes. Peak areas were 
calculated in MZmine. ND = non-detect. 
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Figure 3. Heat map displaying relative abundances of inferred compounds produced by 
Pseudoalteromonas isolates from (A) –HRESI and (B) +HRESI mode data. Colored bars 
indicate peak areas of each ion (m/z) with the corresponding retention time (RT) in 
minutes. Preliminary compound identification is as follows: 2-n-heptyl-4-quinolinol (47), 
2-n-pentyl-quinolinol (48), 3-formyl-L-tyrosine-L-threonine dipeptide (49), cyclo-(L-
phenylalanyl-4R-hydroxyl-L-proline) (50), three isomers of indole-3-carboxaldehyde 
(51), isatin (1H-indole-2,3-dione) (52), three isomers of p-hydroxybenzaldehyde (53), 
two isomers of p-hydroxybenzoic acid (54), cyclo-(L-pipecolinyl-L-phenylalanine) (55), 
pseudomonic acid C (56), 9H-pyrido[3,4-b]indole (57). Asterisks indicate a low 
abundance ion (121.03, RT = 14.49 min) in isolate B149 (peak area = 5129) and isolate 
A453 (peak area = 3589). The presence of two inferred compounds (●) 2-n-heptyl-4-
quinolinol (46) and (▲) cyclo-(L-phenylalanyl-4R-hydroxyl-L-proline) (49) were present 
in both –HRESI (A) and +HRESI(B) heat maps. Peak areas were calculated in MZmine. 
ND = non-detect. 
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CHAPTER 3 
This manuscript is formatted for publication in Marine Drugs. The formatting 
follows the guidelines set forth by the journal.  
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Abstract 
The emergence of multidrug resistant (MDR) pathogenic bacteria represents a serious 
and growing threat to national healthcare systems. Most pressing is an immediate need 
for the development of novel antibacterial agents to treat Gram-negative MDR infections, 
including the opportunistic, hospital-derived pathogen, Acinetobacter baumannii. Herein 
we report a naturally occurring 1,2-benzisoxazole with minimum inhibitory 
concentrations as low as 6.25 μg/mL against clinical strains of MDR A. baumannii. This 
molecule represents a new chemotype for antibacterial agents against A. baumannii and is 
easily accessed in two steps through total synthesis. Structural analogs suggest that the 
natural compound may already be optimized for activity against this pathogen. Further 
studies to advance the development of this 1,2-benzisoxazole as an antibiotic for 
treatment of MDR A. baumannii infections are strongly warranted.  
Keywords: multidrug resistant bacteria, Acinetobacter baumannii, benzisoxazole, 
antibacterial  
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1. Introduction 
Acinetobacter baumannii is a non-fermenting, Gram-negative bacterium 
commonly implicated in nosocomial infections such as wound infections, sepsis, and 
ventilator associated pneumonia.[1] The World Health Organization recognizes antibiotic 
resistance as one of the three greatest threats to human health, and recently classified 
carbapenem-resistant A. baumannii as one of the most urgent threats, calling for a 
renewed investment in antibiotic development.[2] A. baumannii tenacity in hospitals is 
enhanced both by its ability to develop antibiotic resistance and capacity to survive on 
surfaces, including skin, for several days.[3] A. baumannii can also spread via 
aerosolization, promoting this pathogen’s ability to easily colonize new environments.[4-
6] A. baumannii is a member of the ‘ESKAPE’ pathogens [7] and has garnered 
significant attention due to its naturally occurring resistance to the most commonly used 
antibiotics.[8] Alarmingly, intensive care unit patients contracting A. baumannii 
infections have a high mortality rate (>50%), complicated by the fact that new pan-drug 
resistant (PR) strains of A. baumannii with resistance to all treatment options have now 
emerged.[1,8-10] Carbapenems, typically in combination with other antimicrobial agents 
(e.g. colistin) are a commonly utilized treatment option for MDR A. baumannii but it is 
estimated that more than half of MDR strains are now carbapenem-resistant.[1,11,12] 
Currently, the polypeptide antibiotic colistin is the primary method of treatment for 
patients with carbapenem-resistant A. baumannii; however, this therapy has significant 
toxicological and dosing concerns.[1,12] With the lack of new antibiotics in the drug 
discovery pipeline to treat Gram-negative infections, coupled with accelerated evolution 
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of antibiotic resistance, it is imperative that new antibacterial drugs for treating A. 
baumannii infections be developed.[13] 
Most antibacterial drugs are products of microbial biosynthesis and derivatives 
thereof.[14] Herein we report the identification of a 1,2-benzisoxazole antibiotic 
produced by a marine bacterium identified as a Bradyrhizobium denitrificans. A series of 
synthetically prepared analogs define key structural features for the antibacterial effects 
against A. baumannii. This molecule represents a new lead structure for antibacterial drug 
development against clinical isolates of A. baumannii that possess MDR phenotypes.   
2. Results  
Exudate extract from Bradyrhizobium denitrificans (Isolate B158) was initially 
screened in the p-iodonitrotetrazolium chloride (INT) assay to assess MDR reversal 
potential.[15] Phylogenetic analysis by 16S rRNA gene sequence comparison indicated 
that isolate B158 was most closely related to Bradyrhizobium denitrificans.  Bioassay-
guided fractionation of extract generated from B158 microbial culture resulted in the 
isolation of 1 and two other known compounds (lumichrome and (1H-indol-3-yl) 
oxoacetamide; see 11 and 12 in Supplementary Materials) [16,17] with varying degrees 
of bioactivity. 
Compound 1 was isolated as an amorphous white powder.  An [M-H]
-
 ion of 
150.0204 using HRESIMS indicated a molecular formula of C7H5NO3. 
1
H-NMR 
resonances at δH 7.49, 6.75, and 6.67 as well as the molecular formula suggested 1 to be 
3,6-dihydroxy-benzisoxazole.[18]  Because of limited quantity of the natural product, 
3,6-dihydroxy-benzisoxazole was synthesized (Scheme 1) and determined to be identical 
to the natural product by NMR (Table 1) and LC/MS analysis (Figure S2).[18]   
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Scheme 1: Synthesis of 3,6-dihydroxy-benzisoxazole (1). a – H2NOH:HCl/KOH in 
Dioxane/H2O; b – CDI/Et3N/THF reflux.  
 
 
Table 1: Comparison of 
1
H and 
13
C NMR data of 1, synthetic 3,6-dihydroxy-1,2-
benzisoxazole, and published 3,6-dihydroxy-1,2-benzisoxazole.[18] Chemical shifts are 
referenced to residual MeOH in CD3OD at δH 3.31 and δC 49.0. 
 
Synthetic 3,6-
dihydroxy-1,2-
benzisoxazole (1) 
Published 1 Isolated 1 
position δC, type δH, (J in Hz) δC, type δH, (J in Hz) 
3 167.6, C  167.4, C  
3a 108.2, C  108.1, C  
4 123.6, CH 7.50, d (8.6) 123.6, CH 7.49, d (8.6) 
5 114.5, CH 
6.77, dd 
(8.6, 1.9) 
114.5, CH 6.75, d (8.6) 
6 163.2, C  163.1, C  
7 96.2, CH 6.70, d (1.9) 96.2, CH 6.67, s 
7a 166.9, C  166.8, C  
 
 
Compound 1 was previously reported to possess growth inhibitory effects against 
Gram-negative bacteria, but not Gram-positive pathogens.[19] Because this prior testing 
was completed more than 30 years ago, we screened 1 for antibacterial activity against 
contemporary and MDR Gram-negative bacteria (data not shown) including two beta-
lactamase producing E. coli, a carbapenemase producing Klebsiella pneumoniae, and an 
MDR A. baumannii (L1051). Of the strains included, 1 showed promising activity (MIC 
of 8-16 μg/mL) only against the A. baumannii isolate, which merited follow up testing.  
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 A panel of four unique A. baumannii strains was compiled to assess the 
effectiveness of 1 in clinically relevant, antibiotic resistant strains. The panel included 
one strong biofilm forming strains (L1184), one moderate biofilm forming strain 
(L1227), one weak biofilm forming strain (L1222), and one biofilm non-forming strain 
(L1051). Two strains (L1222 and L1051) were classified as multi-drug resistant (MDR) 
organisms by having non-susceptibility to one or more agents in three or more 
antimicrobial categories using previously published guidelines.[20] Minimum inhibitory 
concentrations (MICs) were determined for 1 (Table 2) to be in the range of 6.25 μg/mL 
to 50 μg/mL with the most potent antibacterial effects against the MDR strains L1222 
and L1051 (6.25 and 12.5 μg/mL, respectively). The strong biofilm forming strains 
L1227 and L1184 were not as sensitive to 1 with MICs of 25 and 50 μg/mL, respectively. 
All minimum bactericidal concentrations (MBCs) for 1 were >100 μg/mL.  
 To further understand the structural requirements necessary for the antibacterial 
effects of 1 against A. baumannii, as well as to potentially improve upon the potency of 1, 
we synthesized and purchased analogs to perform a structure activity relationship (SAR) 
study (Figure 1). None of the analogs (2-10) demonstrated increased potency against the 
panel of A. baumannii strains (Table 2). However, structural requirements for optimal 
potency were revealed. Replacement of the hydroxyl substituent at C6 (as in 2-6) 
displayed marked decreases in potency. Based on these data, a hydrogen bond donor 
substituent at C6 appears to be required for antibacterial effects, with hydroxyl (1) as the 
preferred substituent over amino (5). Though the C6 methoxyl group (6) did not 
completely abolish activity, the dramatic decrease in potency concludes that alkyl 
modifications to the hydroxyl group are unlikely to improve potency in this 
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pharmacophore. Because of the preference of the hydroxyl substituent at the C6 position, 
it was also investigated whether an additional hydroxyl group might improve the activity. 
Surprisingly, a second hydroxyl group at C4 (7) abolished the antibacterial activity.  
 
Table 2: MIC values for analog compounds 1-10 against A. baumannii strains. Values in 
bold indicate an inhibition was shown.  
 MIC Values 
(μg/mL) 
A. 
baumannii 
Strain 
Source 1 2 3 4 5 6 7 8 9 10 
L1051* Clinical 12.5 >100 >100 >100 50 >100 >100 >100 >100 >100 
L1222* Blood 6.25 >100 >100 >100 50 100 >100 >100 >100 >100 
L1227 Blood 25 >100 >100 >100 50 100 >100 >100 >100 >100 
L1184** Urine 50 >100 >100 >100 50 >100 >100 >100 >100 >100 
*Multi-drug resistant organism (MDRO) 
**Strong biofilm forming organism 
 
Figure 1: Panel of compounds tested for MICs against A. baumannii in SAR study.  
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 In addition to substituents on the benzene ring, the necessity of the isoxazole ring 
to the pharmacophore was investigated. Methylation of the nitrogen atom (8 and 9) led to 
inactive products; it is noted that this modification leads to loss of conjugation in the 
hydroxyl-isoxazole ring. Similarly, antibacterial activity was also completely absent for 
the oxazolone analog (10).  
 
3. Discussion 
Current therapies for MDR A. baumannii are failing. Resistance to the preferred 
antibiotic class, carbapenems, is rising and many infections are treated with colistin 
which has serious concerns of neurotoxicity and nephrotoxicity.[1]  With a dwindling 
supply of viable treatments, investigation of new chemical scaffolds with antibacterial 
effects against A. baumannii is critical. 1,2-benzisoxazoles, especially the optimized 
structure in 1, represent a new chemotype for the development of therapeutics to treat 
MDR A. baumannii infections.  
From the panel of analogs tested, it appears that the structural features in the 
natural product 1 are necessary components of the pharmacophore. A hydrogen bond 
donor is necessary at C6, and a hydroxyl is preferred over an amino group. Modifications 
to the heteroaromatic ring are detrimental when the isoxazole confirmation is not 
retained. Further optimization of the structure for antibacterial effects against A. 
baumannii would include determining if the 3-position is modifiable, as well as exploring 
other positions on the benzene ring for substitution. 
1,2-benzisoxazoles are bicyclic, heteroaromatic structures found in many 
approved drugs.[21,22] In general, 1,2-benzisoxazoles are able to cross the blood brain 
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barrier (BBB) and have been classified as privileged structures for drug design for CNS 
disorders and other therapeutic areas.[21,22] The heterocyclic ring structure of 1 shares 
similarities to two clinically used antibiotics: cycloserine and linezolid (and other 
oxazolidinone antibiotics). Interestingly, cycloserine was inactive against our panel of A. 
baumannii strains (data not shown). Oxazolidinone antibiotics are only effective against 
Gram-positive pathogens, and match the ring structure of the inactive 10, further 
supporting the highly specific nature of the 1,2-benzisoxazole pharmacophore.  
In the search for antibacterial compounds for MDR pathogens, it has been shown 
that ‘old’ antibiotics that have been excluded from the clinic for decades can be useful as 
alternative treatment options.[23,24]  In addition to older clinical antibiotics, there are 
many antibacterial compounds discovered decades ago that have not been developed, 
including compound 1 that may be useful against modern MDR pathogens.  Compound 1 
was previously reported to possess potent growth inhibition of Gram-negative bacteria 
including E. coli, Proteus spp., Salmonella spp., Klebsiella pneumoniae, Enterobacter 
spp., and Serratia marcescens, as well as low toxicity with an LD50 of over 1500 mg/kg 
in mice.[18,19] No inhibition was observed with the Gram-positive bacteria 
Staphylococcus aureus, Bacillus spp., Micrococcus sp., Corynebacterium sp., or the 
Gram-negative Pseudomonas spp.[18,19]  
Narrow spectrum of antibacterial drugs are becoming more desirable due to 
advances in diagnostic tests and changes to the regulatory environment.[25] Resistance is 
expected to develop more slowly to narrow spectrum antibiotics and collateral damage to 
the gut microbiome, such as with antibiotic-associated colitis, is less likely.[26] We 
suggest that further studies advancing the development of 1,2-benzisoxazoles, including 
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1, as anti- A. baumannii antibiotics are warranted. Investigations into its cellular target, in 
vivo efficacy, and further structure activity relationships are vital next steps to improving 
the outlook for treatment of infections with MDR A. baumannii.  
 
4. Materials and Methods 
4.1 General Experimental Procedures 
NMR experiments were conducted using an Agilent NMRS 500 MHz spectrometer 
with (CD3)2SO (referenced to residual DMSO at δH 2.50 and δC 39.5) or CD3OD 
(referenced to residual MeOH at δH 3.31 and δC 49.0) at 25 °C.  High Resolution 
Electrospray ionization mass spectra (HRESIMS) were acquired using either an AB 
Sciex TripleTOF 4600 spectrometer in the negative ion mode or Agilent Technologies 
6230 ToF with a Dual Jet Stream Electrospray Ionization source, equipped with an 
Agilent 1260 Infinity series HPLC. Flash chromatography was completed with a 
Combiflash Rf200 equipped with a 40 g silica gel RediSepRf High Performance Gold 
column (Teledyne ISCO). HPLC experiments were performed on a Shimadzu 
Prominence-i LC-2030C system equipped with a diode array detector or an Agilent 1200 
series equipped with an autosampler, diode array detector, quaternary pump and 96 well 
plate fraction collector.  Semi-preparative HPLC purifications were accomplished with a 
Waters XBridge Prep C18 5 µm, 10 × 250 mm column at 4.5 mL/min. The exact 
equipment in separation and identification used is specified below. All chemicals and 
solvents were at least reagent grade and purchased commercially (Sigma Aldrich, St. 
Louis, MO). 
4.2 Bacterial Strains  
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We examined four clinically diverse strains of A. baumannii obtained from 
patients at Rhode Island Hospital, American Type Culture Collection (ATCC), and the 
Biodefense and Emerging Infection Research Resources Repository (BEI).  Strains 
depicted various biofilm-forming capabilities (described in Supplementary Materials [27-
31]) (non adherent [n=1]; weak [n=1]; moderate [n=1]; strong [n=1]) and resistance 
patterns, with two multi-drug resistant organisms (MDROs) and two non-MDROs.  
MDRO was defined as organism with non-susceptibility to one agent in three 
antimicrobial classes, according to previously described definitions.[20] These strains are 
available in the investigators’ laboratory and stored frozen at -80 ºC in 20% glycerol. 
4.3 A. baumannii Susceptibility Testing 
Minimum inhibitory concentrations (MICs) of pure compounds against clinical 
isolates of A. baumannii were determined in duplicate by broth microdilution in 
accordance with Clinical Laboratory Standards Institute (CLSI) standards.[32,33] Due to 
antibacterial activity of DMSO at high concentrations,[34] our methods were modified to 
ensure DMSO concentrations do not exceed 2.5%. Plates were subsequently incubated at 
37 C for 24 h. After 24 h, minimum bactericidal concentrations (MBCs) were 
determined in duplicate for each antimicrobial compound in accordance with 
CLSI.[32,33]  
4.4 Cultivation and Extraction of Marine Bacterial Strain B158 
Marine isolate B158 was originally isolated from the oral cavity of the 
ctenophore, Mnemiopsis leidyi from Eel Pond, Woods Hole, MA, U.S.A. in September 
2012. The isolate was streaked to purity on TSW (1 g of tryptone in 1 L of 75:25 natural 
seawater/Milli-Q water) agar plates and cryopreserved in 10% sterile DMSO and stored 
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at -85 °C. Strain B158 was identified as B. denitrificans based on 98% nucleotide 
sequence identity to available B. denitrificans 16S rDNA sequence (Genbank Accession 
Number MF113387). A “starter” culture was prepared by inoculating 100 µL of 
cryopreserved culture in 6 mL of TSW media and incubated at 23 °C, 100 rpm for 3 days. 
A 1.5 L fernbach flask containing TSY media (1 g of tryptone, 1 g of yeast extract in 1 L 
of 75:25 natural seawater/Milli-Q water) was inoculated with 1.5 mL of “starter” culture 
and grown at 100 rpm for 8 d at 23 °C. Twenty-four hours before culture filtration (day 
7), 20 mL of a 1:1 mixture of sterile, washed Amberlite XAD-7 and XAD-16 resin was 
added to the cultures. On the eight day of growth, the resin was filtered from the bacterial 
culture under vacuum, desalted by rinsing with Milli-Q water, and allowed to dry 
overnight at room temperature. Secreted metabolites were eluted from the resin by two 
extractions in 100 mL of (1:1) MeOH/CH2Cl2, followed by 100 mL of MeOH. Both 
extractions were combined and dried under vacuum centrifugation (ThermoSavant). The 
dried extract was resuspended in DMSO at 100 mg/mL and stored at -85 °C until further 
testing in bacterial susceptibility assays against E. coli strains overexpressing RND 
transporters.[15] 
Once isolate B158 was determined to contain active compound(s), a total of 118.5 
L of B158 culture was grown in 1.5 L Fernbach flasks to obtain enough crude material 
for structural elucidation. Briefly, 2 mL of “starter” culture in TSW was used to inoculate 
Fernbach flasks containing 1.5 L of 1 x TSY and allowed to grow for 7 days at 100 rpm 
at 23 °C. On day 7, 20 mL (approximately weight = 7.8 g) of 1:1 mixture of sterile 
Amberlite XAD-7 and XAD-16 resin that had been extensively washed in organic 
solvent, dried, and autoclaved was added to each 1.5 L culture. After 24 h, the resin was 
69 
 
filtered from the bacterial culture through combusted stainless steel mesh under gentle 
vacuum (<5 in Hg), desalted by rinsing with MilliQ water, pooled, and dried overnight at 
room temperature. Each 1.5 L resin equivalent was extracted with 100 mL of (1:1) 
MeOH/CH2Cl2, followed by MeOH. This crude extract was dried under vacuum 
centrifugation and stored at -85 °C until bioassay guided fractionation. 
4.5 Bioassay Guided Fractionation of Exudates from B158 
 Assessment of crude extracts via MDR reversal assays with E. coli MDR strains 
MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM separately overexpressing two 
Resistance Nodulation cell Division (RND) transporters indicated the presence of active 
compound(s) and was completed following previously published methods.[15]  Crude 
extract was applied to a silica gel column (40-60 µm, 60Å) and eluted with a step-
gradient of isooctane, (4:1) isooctane/ EtOAc, (3:2) isooctane/EtOAc, (2:3) 
isooctane/EtOAc, (1:4) isooctane/EtOAc, EtOAc, (1:1) EtOAc/MeOH, and 100% MeOH, 
yielding eight fractions. Bacterial susceptibility testing in the INT assay indicated activity 
to be localized to the following three gradients: (1:4) isooctane/EtOAc, EtOAc, (1:1) 
EtOAc/MeOH. Material from these three fractions were combined and the material was 
further separated by solid-phase extraction (Supelclean ENVI-18) eluting with a step-
gradient of (20:1) water/MeCN, (4:1) water/MeCN, (3:2) water/MeCN, (2:3) 
water/MeCN, (1:20) water/MeCN, and acetone. All solvents, except acetone, were 
acidified with 0.1% formic acid (FA). The active fraction eluted with (4:1) and (3:2) 
water/MeCN gradients. The active fraction totaling (700 mg) was separated further into 
96-deep well plates by semipreparative HPLC using an Agilent 1200 series HPLC and a 
Phenomenex Luna® 5 µm C18 (2) 100 Å, LC column (250 x 10 mm) as the stationary 
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phase, heated to 30 °C and a gradient of water and MeCN with a flow rate of 4 mL/min. 
All solvents were acidified with 0.1% FA. Contents of the 96-deep well plate were 
concentrated in vacuo and tested in the INT assay. Two fractions were found to contain 
the desired activity, wells G6 to H6 (most active) totaling 32.4 mg and H8, A9, B9 
(minor activity) totaling 25.1 mg, which eluted (3:2) water/MeCN and (1:1) 
water/MeCN, respectively. The fraction containing wells G6 to H6 was further separated 
by analytical HPLC using an Agilent 1260 series LC-MS and a Phenomenex Kinetex 2.6 
µm C18 100Å, LC column (150 x 2.1 mm) as the stationary phase, heated to 30 °C and a 
gradient of water and MeOH with a flow rate of 0.2 mL/min. All solvents were acidified 
with 0.1% FA. Compound 1 eluted at 13.2 min corresponding to (7:3) water/MeOH and 
yielded a total of 1 mg of white powder. 
4.6 Compound Data 
3,6-dihydroxy-1,2-benzisoxazole (1): Synthesis of 3,6-dihydroxy-1,2-benzisoxazole was 
performed as previously reported.[35] Hydroxylamine hydrochloride (2.50 g, 36.0 mmol) 
was added to a stirring solution of KOH (2.69 g, 47.9 mmol) in water (30 mL) at room 
temperature. Methyl 2,4-dihydroxy-benzoate (1.01 g, 6.0 mmol) dissolved in 1,4 dioxane 
(5 mL) was added dropwise to the hydroxylamine solution and stirred for 24 h at room 
temperature. After removing the 1,4 dioxane in vacuo, the pH was adjusted to 1 using 3N 
HCl and extracted with EtOAc (3 x 50 mL). The organic layers were combined and dried 
over Na2SO4, filtered and concentrated in vacuo.  The resulting residue was purified by 
silica gel flash chromatography using a gradient of 20-100% EtOAc/hexanes to afford 
2,4-dihydroxy-benzohydroxamic acid (765.7 mg, 76% yield).  
71 
 
 2,4-dihydroxy-benzohydroxamic acid (161.4 mg, 0.96 mmol) was dissolved in 
anhydrous tetrahydrofuran (10 mL) under N2. Dry 1,1′-carbonyldiimidazole (CDI) (489.2 
mg, 3.0 mmol) was added to the mixture and heated at reflux conditions for 30 min. Et3N 
(210 μL, 1.5 mmol) was then added and the reaction proceeded at reflux for 18 h. The 
THF was removed in vacuo and the resulting residue was reconstituted in 1N HCl and 
extracted with EtOAc (3 x 50 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated. The resulting residue was purified by silica gel flash 
chromatography using a gradient of 30-50% EtOAc with 0.1% FA/hexanes to afford 3,6-
dihydroxy-1,2-benzisoxazole (107.7 mg, 74% yield, overall yield 56%). Prior to 
bioassay, this product was further purified by HPLC with an isocratic method of 20% 
MeOH in H2O with 0.1% FA to afford pure 1 (white powder). 
1
H-NMR (500 MHz, 
CD3OD), 
13
C-NMR (125 MHz, CD3OD) see Table 1. HRMS calcd for C7H4NO3: 
150.0191. Found [M-H] 150.0206. 
3-hydroxy-1,2-benzisoxazole (2): Compound 2 was prepared from commercially 
available methyl salicylate (methyl 2-hydroxy-benzoate) according to the scheme used to 
prepare 1. 2 was further purified by semi-preparative HPLC using an isocratic method of 
50% MeOH in H2O with 0.1% FA to afford pure 2 (white powder). 
1
H-NMR (500 MHz, 
(CD3)2SO) δ 7.31 (1H, t, J = 7.0), 7.54 (1H, d, J = 8.2), 7.59 (1H, t, J = 7.9), 7.75 (1H, d, 
J = 8.0), 12.45 (1H, br s). 
13
C-NMR (125 MHz, (CD3)2SO) δ 110.0, 114.6, 121.4, 122.9, 
130.5, 163.0, 165.4. HRMS calcd for C7H4NO2: 134.0242. Found [M-H] 134.0251. 
3-hydroxy-6-fluoro-1,2-benzisoxazole (3): Compound 3 was prepared from 
commercially available methyl 2-hydroxy-4-fluoro-benzoate according to the scheme 
used to prepare 1. 3 was further purified by semi-preparative HPLC using the method: 12 
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min gradient from 55-100% MeOH in H2O with 0.1% FA to yield pure 3 (white powder). 
1
H-NMR (500 MHz, CD3OD) δ 7.09 (1H, td, J = 1.5, 9.1), 7.22 (1H, dd, J = 1.5, 9.1), 
7.70 (1H, dd, J = 5.2, 8.9). 
13
C-NMR (125 MHz, CD3OD) δ 98.3 (d, J = 27.7), 112.8, 
113.0 (d, J = 25.7), 123.9 (d, J = 11.5), 165.7 (d, J = 14.4), 166.3 (d, J = 249.0), 167.0. 
HRMS calcd for C7H3FNO2: 152.0148. Found [M-H]: 152.0271.  
3-hydroxy-6-(benzyloxy)-1,2-benzisoxazole (4): Commercially available methyl 2,4-
dihydroxy-benzoate (1.0 g, 5.92 mmol)  was dissolved in 10 mL acetone and treated with 
K2CO3 (1.0 g, 7.24 mmol) and NaI (0.25 g, 1.67 mmol). The resulting suspension was 
stirred for 10 min under N2 and then benzyl bromide (700 μL, 5.85 mmol) was added 
dropwise. The reaction mixture was stirred for 24 h at ambient temperature. After 
removing the acetone in vacuo, the resulting residue was resuspended in H2O and 
extracted with EtOAc (4 x 40 mL). The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo. The residue (1.8 g) was purified by silica gel flash 
chromatography using a gradient of 10-100% EtOAc in hexanes to afford methyl 2-
hydroxy-4-benzyloxy-benzoate (687.4 mg, 45.5% yield) as white crystals. Methyl 2-
hydroxy-4-benzyloxy-benzoate was then further elaborated per Scheme 1 to afford 
analog 4, which was further purified by semi-preparative HPLC using an isocratic 
method of 50% MeOH in H2O with 0.1% FA (white powder). 
1
H-NMR (500 MHz, 
(CD3)2SO) δ 5.17 (2H, s), 6.94 (1H, d, J = 8.7), 7.15 (1H, s), 7.34 (1H, t, J = 7.4), 7.40 
(2H, t, J = 7.4), 7.46 (2H, d, J = 7.4), 7.60 (1H, d, J = 8.6). 
13
C-NMR (125 MHz, 
(CD3)2SO) δ 69.9, 94.5, 108.3, 113.4, 122.0, 127.9 (2C), 128.1, 128.5 (2C), 136.5, 161.1, 
164.9, 165.7. HRMS calcd for C14H10NO3: 240.0661. Found [M-H] 240.0564.  
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3-hydroxy-6-amino-1,2-benzisoxazole (5): Compound 5 was prepared from 
commercially available methyl 2-hydroxy-4-amino-benzoate (AK Scientific, Union City, 
CA) according to the scheme used to prepare 1 with minor modification. The ring closing 
step was accomplished with CDI/MeCN instead of CDI/THF/Et3N. The resulting mixture 
was purified using semi-preparative HPLC with a gradient method from 10-55% MeOH 
in H2O with 0.1% FA (white powder). 
1
H-NMR (500 MHz, (CD3)2SO) δ 5.80 (2H, s), 
6.39 (1H, d, J = 1.4), 6.50, (1H, dd, J = 1.5, 8.4), 7.30 (1H, d, J = 8.4). 
13
C-NMR (125 
MHz, (CD3)2SO) δ 91.2, 103.6, 111.8, 121.8, 152.3, 165.6, 165.9. HRMS calcd for 
C7H5N2O2: 149.0351. Found [M-H] 149.0323.  
3-hydroxy-6-methoxy-1,2-benzisoxazole (6): Compound 6 was purchased commercially 
(Sigma Aldrich, St. Louis, MO). 
3,4,6-trihydroxy-1,2-benzisoxazole (7): Compound 7 was prepared from commercially 
available methyl 2,4,6-trihydroxy-benzoate (abcr GmbH, Karlsruhe, Germany) according 
to the scheme used to prepare 1. 7 was further purified from a mixture by semi-
preparative HPLC with a gradient method of 25-100% MeOH in H2O with 0.1% FA 
(white powder). 
1
H-NMR (500 MHz, (CD3)2SO) δ 6.08 (1H, d, J = 1.3), 6.14 (1H, d, J = 
1.3), 10.22 (3H, br s). 
13
C-NMR (125 MHz, (CD3)2SO) δ 86.8, 96.6, 97.3, 153.8, 161.9, 
165.2, 166.6. HRMS calcd for C7H4NO4: 166.0140. Found [M-H] 166.0151. 
N-methyl-6-hydroxy-1,2-benzisoxazol-3(2H)-one (8) and N-methyl-6-methoxy-1,2-
benzisoxazol-3(2H)-one (9): Compounds 8 and 9 were prepared from 1 in a one-step 
synthesis and purification. 1 (46 mg, 0.33 mmol) was dissolved in dry MeCN (4 mL) and 
K2CO3 (91 mg, 0.66 mmol) was suspended in the solution. Suspension was stirred rapidly 
under N2 and excess CH3I (260 μL, 4.2 mmol) was added dropwise and stirred for 18 h at 
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room temperature. The reaction was quenched by removing MeCN in vacuo and the 
resulting residue was dissolved in 1N HCl. This solution was extracted with EtOAc (3 x 
30 mL) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated in vacuo.  The resulting products were purified by semi-preparative HPLC 
using a 12 min gradient from 35-80% MeOH in H2O with 0.1% FA to afford 8 (12.1 mg, 
white powder) and 9 (8.5 mg, white powder).  
Compound 8: 
1
H-NMR (500 MHz, (CD3)2SO) δ 3.46 (3H, s), 6.68 (1H, d, J = 
1.6), 6.57 (1H, dd, J  = 1.6, 8.4), 7.55 (1H, d, J = 8.4), 10.73 (1H, br s). 
13
C-NMR (125 
MHz, (CD3)2SO) δ 33.3, 95.3, 106.8, 113.4, 124.7, 162.3, 163.4, 164.2.  HRMS calcd for 
C8H8NO3: 166.0504. Found [M+H]: 166.0216. 
Compound 9: 
1
H-NMR (500 MHz, (CD3)2SO) δ 3.51 (3H, s), 3.86 (3H, s), 6.89 
(1H, dd, J = 2.1, 8.6), 7.05 (1H, d, J = 2.0), 7.64 (1H, d, J = 8.6). 
13
C-NMR (125 MHz, 
(CD3)2SO) δ 33.2, 56.1, 93.8, 108.1, 113.2, 124.5, 162.2, 163.7, 164.5.  HRMS calcd for 
C9H10NO3: 180.0661. Found [M+H]: 180.0341.   
6-hydroxy-2-benzoxazolinone (10): Compound 10 was purchased commercially (abcr 
GmbH, Karlsruhe, Germany). 
  
Supplementary Materials: The following are available online at…. Purification and 
dereplication details of compounds 11 and 12 and pertinent NMR and MS data are 
included.  
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CHAPTER 4 
This manuscript was published in 2016 in mSphere, vol. 1, issue 1. The formatting 
follows the guidelines set forth by the journal.  
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Abstract 
In the present study it is shown that although E. coli CFT073, a human uropathogenic 
(UPEC) strain, grows in liquid glucose M9 minimal medium, it fails to grow on glucose 
M9 minimal medium agar plates seeded with ≤ 106 CFU.  The cells on glucose plates 
appear to be in a “quiescent” state that can be prevented by various combinations of 
lysine, methionine, and tyrosine.  Moreover the quiescent state is characteristic of ~ 80% 
of E. coli phylogenetic group B2 multilocus sequence type 73 strains as well as 22.5% of 
randomly selected UPEC strains isolated from community acquired urinary tract 
infections in Denmark.  In addition, E. coli CFT073 quiescence is not limited to glucose, 
but occurs on agar plates containing a number of other sugars and acetate as sole carbon 
sources.  It is also shown that a number of E. coli CFT073 mini-Tn5 metabolic mutants 
(gnd, gdhA, pykF, sdhA, and zwf) are non-quiescent on glucose M9 minimal agar plates 
and that quiescence requires a complete oxidative TCA cycle.  In addition, evidence is 
presented that although E. coli CFT073 quiescence and persistence in the presence of 
ampicillin are alike in that both require a complete oxidative TCA cycle and that each can 
be prevented by amino acids, E. coli CFT073 quiescence occurs in the presence or 
absence of a functional rpoS gene, whereas maximal persistence requires a non-
functional rpoS.  Our results suggest that interventions targeting specific central 
metabolic pathways may mitigate UPEC infections by interfering with quiescence and 
persistence.  
 
 
84 
 
Importance 
Recurrent urinary tract infections (UTIs) affect 10 to 40% of women. In up to 77% of 
those cases the recurrent infections are caused by the same uropathogenic E. coli (UPEC) 
strain that caused the initial infection.  Upon infection of urothelial transitional cells in 
the bladder, UPEC appear to enter a non-growing quiescent intracellular state that is 
thought to serve as a reservoir responsible for recurrent UTIs. Here we report that many 
UPEC strains enter a quiescent state when ≤ 106 CFU are seeded on glucose M9 minimal 
medium agar plates and show that mutations in several genes involved in central carbon 
metabolism prevent quiescence as well as persistence, possibly identifying metabolic 
pathways involved in UPEC quiescence and persistence in vivo.  
Introduction 
Uncomplicated urinary tract infections (UTIs) affect about 25% of women in their 
lifetime and at least 80% of those infections are caused by uropathogenic E. coli (UPEC) 
(1).  Recurrent UTIs affect between 10% and 40% of women (2) and in up to 77% of 
those cases the recurrent infections are caused by the same UPEC strain that caused the 
initial infection (3, 4).  UPEC infections generate annual costs in excess of two billion 
dollars in the United States alone, placing a significant burden on the health care system 
(5). Although the causes of recurrent UTI are complex (6), it appears that UPEC can bind 
to, enter, and replicate within superficial facet cells in the human and mouse bladder 
epithelium, resulting in biofilm-like intracellular communities (IBCs) (6, 7).  IBCs escape 
from infected superficial facet cells within hours of development (6).  The superficial 
facet cells then exfoliate, exposing underlying transitional epithelial cells, which can be 
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infected with IBC-derived UPEC progeny (6, 8).  Upon infection of urothelial transitional 
cells, UPEC appear to enter a non-growing quiescent intracellular state (6, 8). These 
quiescent UPEC cells have been called QIRs (Quiescent Intracellular Reservoirs) (6) and 
it is thought that QIRs are a major cause of recurrent UTIs (6, 8).  QIRs also help to 
explain why antibiotics have failed to eradicate UPEC reservoirs in the bladders of mice, 
since quiescent UPEC may not be readily affected by antibiotics (6, 8).   
The quiescence of QIRs and their insensitivity to antibiotics is reminiscent of the 
persister state (8, 9, 10, 11).   Persister cells are dormant cells formed in normal microbial 
populations as small subpopulations that are highly tolerant to antibiotics, but upon 
regrowth in the absence of antibiotics regain full sensitivity (11).  Persisters appear to 
play a major role in the ability of chronic infections to withstand antibiotic treatment 
(11).  In the present study, we report that when ≤ 106 CFU of E. coli CFT073, the 
prototypic UPEC strain, as well as ~ 80% of phylogenetic group B2 multilocus sequence 
type 73 (ST73) strains, of which E. coli CFT073 is a member, are plated on M9 minimal 
agar plates containing glucose as sole carbon and energy source, they appear to enter a 
“quiescent” state and that mutations in specific metabolic genes appear to prevent that 
state.  In addition, we show that E. coli CFT073 quiescence also occurs in the presence of 
a number of other sugars and acetate as sole carbon sources and that a complete TCA 
cycle is required for both generation of E. coli CFT073 quiescent cells on glucose plates 
and for formation of persister cells generated in liquid glucose minimal medium in the 
presence of ampicillin.  
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Materials and Methods 
Bacterial strains. The E. coli CFT073, MG1655, and Nissle 1917 strains used in this 
study are listed in Table 1. The original E. coli K-12 strain was obtained from a stool 
sample from a convalescing diphtheria patient in Palo Alto, CA, in 1922 (12). The 
sequenced E. coli MG1655 strain (CGSC 7740) was derived from the original K-12 
strain, having only been cured of the temperate bacteriophage lambda and the F plasmid 
by means of UV light and acridine orange treatment (12).  E. coli Nissle 1917 was 
originally isolated during World War I from a soldier who escaped a severe outbreak of 
diarrhea (13). It has a beneficial effect on several types of intestinal disorders, is well 
tolerated by humans, and has been marketed as a probiotic remedy against intestinal 
disorders in several European countries since the 1920s (13).  E. coli strains tested for 
quiescence in the Testing additional E. coli strains for quiescence on glucose plates and 
the Testing additional ST73 strains for quiescence on glucose plates sections in Results 
are from the E. V. Sokurenko collection and the E. coli strains used in the Testing 40 
UPEC strains isolated from community acquired UTIs in Denmark for quiescence on 
glucose plates  section in Results are from the N. Frimodt-Møller/ K.L. Nielsen 
collection.  
Media.  LB broth (Lennox) (Difco Laboratories) and LB agar (Lennox) (Difco 
Laboratories) were used for routine cultivation. SOC medium was prepared as described 
by Datsenko and Wanner (14).  Liquid M9 minimal medium (15) and M9 minimal 
medium agar plates were supplemented with reagent grade (Sigma-Aldrich, Inc.) L-
arabinose (0.2%, w/v), N-acetyl-D-glucosamine (0.2%, w/v), L-fucose (0.2%, w/v), D-
fructose (0.2%, w/v), D-glucose (0.2%, w/v), D-galactose (0.2%, w/v), D-gluconate 
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(0.2%, w/v), glycerol (0.2%, v/v), D-mannose (0.2%, w/v), maltose (0.2%, w/v),  D-
ribose (0.2%, w/v), D-xylose (0.2%, w/v), potassium acetate (0.4%, w/v), sodium 
succinate (0.4%, w/v), and various amino acids, as indicated.  Since Difco Bacto agar 
contains impurities, M9 minimal medium agar plates were made with 1.6% Difco Agar 
Noble (Difco).  
Lawn assay for quiescence.   All E. coli strains were streaked from -80
o
C stored LB 
broth grown cultures diluted 1:1 with 50% (v/v) glycerol to LB agar plates which were 
incubated overnight at 37°C. A loopful of cells from each streak plate was then grown 
overnight in 10 ml of 0.4% glucose M9 minimal medium at 37°C with shaking in 125 ml 
tissue culture bottles.  Routinely, 10
5
 CFU from an overnight culture was added to a tube 
containing 3 ml of liquid overlay medium (0.2% glucose M9 minimal medium, 0.7% 
Difco Agar Noble at 45°C).  Each tube containing inoculated overlay medium was 
immediately poured on a pre-warmed (37°C) 0.2% glucose M9 minimal medium agar 
plate.  Inoculated overlays were allowed to solidify (with lids slightly ajar) for 1 h at 
room temperature. In addition, as indicated, solidified inoculated overlays were stabbed 
with colonies of E. coli MG1655 grown on 0.4% glucose M9 minimal medium agar 
plates using sterile toothpicks or were spotted with 5 µl to 20 µl of filtered E. coli 
MG1655 culture supernatant, human urine, or defined amino acid solutions.  Spots were 
allowed to dry prior to incubation of plates.  Plates were incubated for 24 h or 48 h at 
37°C, as indicated.  Strains that grew as lawns on 0.2% glucose M9 minimal medium 
agar plates were considered to be non-quiescent and strains that grew in liquid 0.2% 
glucose M9 minimal medium, failed to grow on 0.2% glucose M9 minimal medium agar 
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plates, but were stimulated to grow around E. coli MG1655 stabs were considered to be 
quiescent (see Results).   
Insertional mutagenesis. Mini-Tn5 Km (kanamycin) mutants were constructed by 
insertional mutagenesis as described previously (16). Briefly, the donor E. coli ATM161 
(17) carrying the suicide vector pUT, which contains the mini-Tn5 Km transposon, was 
conjugated with the recipient E. coli CFT073 Str
R
 (Table 1) in the following manner. The 
donor and recipient strains were grown overnight, with shaking, in LB broth at 30°C.  
Aliquots of 100 µl of each culture were mixed together in 5 ml of 10 mM MgSO4 and 
filtered through a 0.45 μm pore size membrane filter (EMD Millipore). The filter was 
placed on the surface of an LB agar plate and incubated for 5 h at 37°C. Following 
incubation, the bacteria on the filter were suspended in 5 ml of 10 mM MgSO4, and 100 
µl aliquots of the suspension were plated on LB agar containing streptomycin sulfate 
(100 µg/ml) and kanamycin sulfate (80 µg/ml) and plates were incubated for 18 h at 
37°C.  Individual mini-Tn5 Km mutant colonies were toothpicked to 2 LB agar plates, 
one lacking and one containing ampicillin sodium salt (100 µg/ml, Sigma-Aldrich, Inc.).  
Colonies that were ampicillin sensitive, signifying loss of the pUT suicide plasmid, were 
toothpicked to sterile 16 mm diameter culture tubes containing 250 µl of 0.2% glucose 
M9 minimal medium.  Culture tubes were incubated overnight at 37°C with shaking, 5 
ml of M9 minimal medium lacking a carbon source was then added to each tube, and 3 µl 
from each tube was spotted on a 0.2% glucose M9 minimal medium agar plate.  Spots 
were allowed to dry (with lids slightly ajar) and plates were incubated overnight at 37°C.  
Each spotted mini-Tn5 Km mutant that grew was retested by seeding 10
5
 CFU of an 
overnight 10 ml liquid 0.4% glucose M9 minimal medium culture on a 0.2% glucose M9 
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minimal medium agar plate and incubating at 37°C for 24 hours.  The gene inactivated in 
each of the mini-Tn5 Km mutants that grew as a lawn was determined by arbitrary PCR 
(18), as described below.  In addition, to be sure that the mini-Tn5 Km insertion was the 
cause of the ability of the individual mutants to grow on glucose plates, the insertion in 
each mutant was transferred into a fresh E. coli CFT073 Str
R
 background by the method 
of Wanner and Datsenko (14).  Each mutant thus obtained was confirmed for the ability 
to grow as a lawn on glucose plates and for the position of the insertion within the E. coli 
CFT073 chromosome by both PCR and sequencing (see Table 2 for primers).  Five 
confirmed mutants were isolated from approximately 2000 mini-Tn5 Km mutants tested.                                                                                    
Arbitrary PCR.  Arbitrary PCR was performed as described previously (18).  Genomic 
DNA was isolated from E. coli CFT073 mini-Tn5 Km mutants using the Wizard® 
Genomic DNA Purification Kit (Promega).  The first round of PCR was performed in 25 
µl reactions (1X Standard Taq Reaction Buffer (New England Biolabs, Inc.), 2 mM 
dNTPs, 100 µM arbitrary primer 1 (5′-
GGCCACGCGTCGACTAGTACNNNNNNNNNNNNGATAT-3′), 10 µM Tn5-specific 
primer (5′-TCTGGATTTCGATCACGGCAC G T-3′),  Taq DNA Polymerase (2 units, 
New England Biolabs, Inc.) and DNA from 1.25 µl of an overnight LB broth culture. The 
first round cycling conditions were: (i) 4 min at 95°C; (ii) 6 x (30s at 95°C, 30s at 30
o
C, 
1.5 min at 72°C 1.5); (iii) 30 x (30s at 95°C, 30s at 45°C, 2 min at 72°C); (iv) 4 min at 
72°C. The second round of PCR used standard conditions and cycling as follows: (i) 4 
min at 95°C; 35 x (30s at 95°C, 30s at 55°C, 2 min at 72°C), (iii) 4 min at 72°C with 0.5 
µl of the first round PCR product as template and 10 µM  arbitrary primer 2 (5′-
GGCCACGCGTCG ACTAGTAC-3′) and 10 µM of a second Tn5-specific primer (5′-
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TTACCGAGAGCTTGGTAC CCAGTC-3′).  The second round of PCR reactions were 
column purified with a QIAquick PCR Purification Kit (Qiagen) and sequenced using a 
third Tn5-specific primer (5′-GTACCCAGTCTGTGTGAGCAGG-3′). DNA sequencing 
was done at the URI Genomics and Sequencing Center, University of Rhode Island, 
Kingston, RI using an Applied Biosystems 3130xl genetic analyzer (Applied Biosystems, 
Foster City, CA). A BigDye Terminator cycle sequencing kit (version 3.1; Applied 
Biosystems) was used for the sequencing reactions.  Sequences were compared with the 
GenBank DNA sequence database using the BLASTX program. 
Identification and quantitation of amino acids in E. coli MG1655 and E. coli 
CFT073 50-fold concentrated culture supernatants.  E. coli MG1655 was grown 
overnight in five 10 ml cultures in liquid 0.4% glucose M9 minimal medium with 
shaking  at 37°C in 125 ml tissue culture bottles. The cultures were pooled and cells were 
centrifuged for 10 min at 8000 x g and resuspended in 1 ml of 0.2% glucose M9 minimal 
medium.  The 50-fold concentrated cultures were incubated standing overnight at 37°C in 
1.5 ml centrifuge tubes (CELLTREAT Scientific Products).  Cells were then centrifuged 
at 16,000 x g for 3 min and the supernatant was removed and filtered free of bacteria 
using a 0.22 µm MCE syringe filter (Fisherbrand).  E. coli CFT073 concentrated culture 
supernatants were prepared identically.  
Amino acids in 50-fold concentrated culture supernatants were identified and 
quantified using a slightly modified version of a method described by Yuan et al. (19).  
The method uses the AccQ Tag Amino Acid analysis method (Waters Corp., Milford, 
MA, USA) with a pre-column derivatization kit 
(http://www.waters.com/webassets/cms/support/docs/wat0052881.pdf).  Acid hydrolysis 
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was not included in the derivatization step to assure that only free amino acids were 
quantified.  The method uses HPLC to separate the derivatized amino acids and a 
fluorescence detector to identify and quantify them.  The chromatographic method using 
AccQ Tag Eluent A (solvent A) and 60% acetonitrile in water (solvent B) is as follows: 
consecutive linear gradients of 0-2% B over 0.5 min; 2-7% B over 14.5 min; 7-10% B 
over 4 min; 10-20% B over 11 min; 20-36% B over 10 min; and 36-100% B over 5 min.  
The method totals 45 min of gradients and an additional 11 min washout phase.  The flow 
rate was constant at 0.7 ml/min using a Waters AccQ Tag column (150 x 3.9 mm) held at 
a 40°C and injecting 5 µl aliquots.  The fluorescence detector was set to an excitation 
wavelength of 250 ηm and emission wavelength of 395 ηm per manufacturer’s 
instructions.  Amino acids were identified by comparison to derivatized amino acid 
reference standards in the following order: tryptophan, 6-aminoquinoline (AMQ, a 
product of the derivatization process), aspartic acid, serine, glutamic acid, glycine, 
histidine, ammonium ion, arginine, threonine, alanine, proline, cysteine, tyrosine, valine, 
methionine, lysine, isoleucine, leucine, phenylalanine.  A calibration curve was generated 
to quantify each amino acid present.   
Persister assay.  Overnight cultures in liquid 0.4% glucose M9 minimal medium were 
grown as described in the Lawn assay for quiescence section, above.  Cultures were then 
diluted 20-fold into 10 ml of fresh 0.2% glucose M9 minimal medium (A600 = 0.1, ~10
8
 
CFU/ml) in both the presence and absence of ampicillin sodium salt (100 µg/ml, Sigma-
Aldrich, Inc.).  The cultures were incubated with shaking at 37°C and viable counts on 
LB agar plates were determined at 2, 4, 6, and 24 h. To determine whether cells surviving 
at 24 h in the presence of ampicillin were persister cells or ampicillin resistant mutants, 5 
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ml were washed free of ampicillin by centrifuging at 16,000 x g for 3 min, washing twice 
in 5 ml of fresh 0.2% glucose M9 minimal medium, and resuspending in 5ml of LB 
broth.  Each 5 ml culture was then grown for 2.25 h at 37°C with shaking in a 125 ml 
tissue culture bottle at which time a sample was taken for viable counts.  Ampicillin 
sodium salt (100 µg/ml) was then added to each culture and 4 h later a sample was again 
taken for viable counts on LB agar plates.  Plates were incubated at 37°C for 18 h prior to 
counting. 
Photography.  Images of agar plates were made using a BIO-RAD Molecular Imager® 
Gel Doc™ XR+ System with Image Lab™ Software. 
Statistics.    Means and standard deviations of data presented in Table 4 and in Figures 4, 
5, 7, 8, and 9 were compared by a two-tailed Student t test.  P values of ≤ 0.05 were 
interpreted as indicating a significant difference.     
Results 
E. coli CFT073, a UPEC strain, and E. coli Nissle 1917, a closely related probiotic 
strain, grow in liquid glucose M9 minimal medium, but fail to grow on glucose M9 
minimal medium agar plates. We were attempting to determine which colicins and 
microcins are active on the sequenced E. coli CFT073, a phylogenetic group B2 
multilocus sequence type 73 (ST73) UPEC strain (20, 21), and the closely related ST73 
probiotic strain, E. coli Nissle 1917 (22).  As expected, we found that after overnight 
incubation at 37°C, both strains formed lawns of growth on 0.2% glucose M9 minimal 
medium agar plates (hereafter called glucose plates) when either 10
7
 or 10
8
 CFU were 
plated from an overnight 0.4 % glucose M9 minimal medium liquid culture.  
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Unexpectedly, however, when 10
6
 CFU or fewer were plated on glucose plates they 
failed to form lawns or colonies after 24 h and 48 h of incubation at 37°C.  This result 
was unusual in that a number of human commensal E. coli strains, including MG1655, 
HS, F-18, EFC1, and EFC2 (Table 1), and the O157:H7 strain E. coli EDL933 (Table 1) 
tested at 10
5
 CFU grew as lawns on the glucose plates after 24 hours at 37°C and viable 
counts could be determined for each strain on glucose plates (not shown).  That all the E. 
coli strains tested for growth on glucose plates are spontaneous streptomycin resistant 
mutants (Table 1), but only E. coli CFT073 and E. coli Nissle 1917 failed to form lawns 
on glucose plates seeded with ≤ 106 CFU, makes it highly unlikely that point mutations in 
ribosomal proteins play a role in the observed lack of growth.  
Toothpicking a colony of E. coli MG1655 grown on glucose plates onto glucose 
plates seeded with 10
5
 or 10
6
 CFU of E. coli CFT073 or E. coli Nissle 1917 resulted in E. 
coli CFT073 and E. coli Nissle 1917 growth around the toothpicked colonies after 
incubation for 24 h at 37°C, but not anywhere else on the plates (Fig. 1A) (toothpicking 
colonies in this manner is a normal procedure used in colicin and microcin testing).  No 
growth was observed around toothpicked E. coli MG1655 colonies grown on glucose 
plates that had not been seeded with E. coli CFT073 or E. coli Nissle 1917 (not shown).  
These results suggested that toothpicked E. coli MG1655 was secreting a molecule(s) 
(hereafter called the MG1655 stimulus ) as it grew on glucose plates that was either 
preventing E. coli CFT073 and E. coli Nissle 1917 death or was preventing them from 
entering a “quiescent” state.  Incubating the plates that had been seeded with 105 CFU of 
E. coli CFT073 or E. coli Nissle 1917 for 48 h at 37°C resulted in a much larger region of 
growth around the toothpicked E. coli MG1655 than at 24 h (Fig. 1B), suggesting that 
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cells could be stimulated to grow after 24 hours of incubation, thereby favoring the 
quiescence hypothesis and suggesting either that the  MG1655  stimulus was diffusible 
and active at a very low concentration or that growing E. coli CFT073 and E. coli Nissle 
1917 also secreted the stimulus .  Also, when glucose plates seeded with 10
5
 or 10
6
 CFU 
of E. coli CFT073 or E. coli Nissle 1917 were incubated for 24 h at 37°C prior to 
toothpicking E. coli MG1655 to those plates, E. coli CFT073 and E. coli Nissle 1917 
growth was observed surrounding the toothpicked E. coli MG1655 colonies after an 
additional 24 h incubation at 37°C (not shown).  Therefore, many of the E. coli CFT073 
and E. coli Nissle 1917 cells were alive, but “quiescent” on glucose plates for at least 24 
hours.  Importantly, quiescence is not observed when Difco Bacto agar is used in glucose 
plates instead of Difco Agar Noble, suggesting impurities in the former allow growth.  It 
should be noted that at the present time we do not know whether it is alive or dead E. coli 
MG1655 cells that are the source of the stimulus as the toothpicked cells grow on the 
glucose plates.  Also, it should be mentioned that E. coli CFT073 and E. coli Nissle 1917 
quiescence is not dependent on using 0.2% glucose M9 minimal medium agar plates, 
identical results were obtained using 0.4% glucose M9 minimal medium agar plates (not 
shown).  
Testing additional E. coli strains for quiescence on glucose plates.  E. coli can be 
separated into four major phylogenetic groups (A, B1, B2 and D) and two additional 
phylogenetic groups that have recently been defined: phylogenetic group AxB1, 
containing strains that derive most of their ancestry from A and B1, and phylogenetic 
group ABD, containing a heterogeneous set of strains with multiple sources of ancestry 
(23). Thirty E. coli strains representing various multilocus sequence types (ST) of the 6 
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phylogenetic groups, i.e. two ST10 and two ST453 strains from phylogenetic group A; 
two ST58, two ST410, and two ST101 strains from phylogenetic group B1; two ST73, 
two ST95, and two ST131 strains from phylogenetic group B2; two ST69, two ST354, 
and two ST648 strains from phylogenetic group D; two ST90 and two ST642 strains from 
phylogenetic group AxB1; two ST62 and two ST117 strains from phylogenetic group 
ABD were grown in liquid glucose M9 minimal medium and the 30 strains were tested 
for the ability to grow on glucose plates seeded with 10
5
 CFU and to respond to the 
MG1655 stimulus.  Of the 30 strains, 2 failed to grow on glucose plates and those strains 
responded to the MG1655 stimulus.  The 2 strains that failed to grow on glucose plates 
were ST73 strains. ST73 is a very common UPEC lineage, accounting for 11% and 
16.6% of UPEC isolated from patients in 2 recent studies (24, 25).  Importantly, E. coli 
CFT073 and E. coli Nissle 1917 are also ST73 strains.  
Testing additional ST73 strains for quiescence on glucose plates.  Since it appeared 
that quiescence on glucose agar plates may be characteristic of the ST73 lineage, 40 
additional ST73 strains were tested for the ability to grow on glucose plates seeded with 
10
5
 CFU and to respond to the MG1655 stimulus .  Two of the strains failed to grow 
overnight in liquid glucose M9 minimal medium, but of the 38 strains that grew, 30 
(78.9%) failed to grow on glucose plates, but responded to the MG1655 stimulus. 
Therefore, the vast majority of ST73 strains, a major UPEC lineage (24, 25), are 
quiescent on glucose plates. 
Testing 40 UPEC strains isolated from community acquired UTIs in Denmark for 
quiescence on glucose plates.  Forty randomly selected UPEC strains isolated from 
community acquired UTIs in Denmark were tested for the ability to grow on glucose 
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plates seeded with 10
5
 CFU and to respond to the MG1655 stimulus.  Of the 40 UPEC 
strains tested, all grew overnight in liquid glucose M9 minimal medium, but 9 failed to 
grow on glucose plates (22.5%) unless stimulated to do so by the MG1655 stimulus.  
Three of the 9 strains that failed to grow on glucose plates were ST73 strains (5 of the 40 
UPEC strains tested [12.5%] were ST73) and 3 of the 9 strains that failed to grow on 
glucose plates were ST141 strains (3 of the 40 UPEC strains tested were ST141 strains 
[7.5%], a group not represented in the original 30 strains tested).  The 3 remaining strains 
that failed to grow on glucose plates (ST104, ST394, and ST998) were not represented in 
the original 30 strains tested and each was represented only once among the 40 UPEC 
strains tested (2.5% each) .  It therefore appears that the inability to grow on glucose 
plates, yet respond to the MG1655 stimulus, is not limited to the ST73 group.   
The inability of E. coli CFT073 to grow on minimal agar plates is not limited to 
glucose as sole carbon source.  E. coli CFT073 was tested for the ability of 10
5
 CFU to 
grow on M9 minimal agar plates containing 0.2% acetate, arabinose, fructose, fucose, 
galactose, gluconate, glycerol, N-acetylglucosamine, maltose, mannose, ribose, and 
xylose as sole carbon sources.  E. coli CFT073 grew overnight in liquid M9 minimal 
medium containing each carbon source, but 10
5
 CFU only grew as a lawn on agar plates 
containing glycerol, ribose, and xylose as sole carbon sources (Fig. 2). On those plates 
that E. coli CFT073 failed to grow, it responded to the MG1655 stimulus.  
Human urine, a cocktail mimicking the amino acid composition of human urine, 
and a cocktail mimicking amino acids present in a concentrated E. coli MG1655 
culture supernatant prevent E. coli CFT073 quiescence on glucose plates.  We 
normally toothpick a colony of E. coli MG1655 to a glucose plate as a source of the 
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MG1655 stimulus, suggesting that the stimulus is secreted on the plate as E. coli 
MG1655 grows.  However, no stimulus activity was found when 5 µl or 20 µl of a cell-
free supernatant derived from an overnight liquid glucose M9 minimal medium culture of 
E. coli MG1655 was placed on a glucose agar plate seeded with 10
5 
CFU of E. coli 
CFT073 or E. coli Nissle 1917.  Stimulus  activity was observed when 5 µl of a cell-free 
supernatant derived from a 50-fold concentrated E. coli MG1655 culture that had been 
incubated overnight at 37°C (see Materials and Methods) was placed on a glucose agar 
plate seeded with 10
5 
CFU of E. coli CFT073 (Fig. 3A).  Analysis of one such E. coli 
MG1655 cell-free supernatant revealed the presence of a number of unknown small 
molecules and 14 amino acids (Table 3).  Importantly, 5 µl of an amino acid cocktail 
identical in composition to the amino acids in the 50-fold concentrated E. coli MG1655 
supernatant displayed similar stimulus activity to 5 µl of the 50-fold concentrated 
supernatant (Fig. 3B).  A cell-free supernatant derived from a 50-fold concentrated E. coli 
CFT073 culture was nearly identical to the E. coli MG1655 supernatant in amino acid 
composition, but in addition contained aspartic acid (Table 3).  As expected, 5 µl of the 
E. coli CFT073 cell-free supernatant also displayed stimulus activity on glucose plates 
seeded with 10
5
 CFU of E. coli CFT073.  Perhaps even more importantly, 5 µl of sterile 
filtered human urine collected from one of us and 5 µl of a cocktail mimicking the amino 
acid composition of human urine ([26] and Table 3) both displayed stimulus  activity on 
glucose plates seeded with 10
5
 CFU of E. coli CFT073 (Fig. 3C and 3D).   
Lysine, methionine, and tyrosine involvement in preventing quiescence.  1.0 mM 
solutions of each of the 20 standard L-amino acids were prepared and 5 µl of each was 
tested on glucose plates seeded with 10
5
 CFU of E. coli CFT073.  None displayed 
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stimulus activity. However, testing 5 µl of single amino acid deletions from the amino 
acid cocktail mimicking the concentrations of amino acids in urine (Table 3) and in the 
50-fold concentrated E. coli MG1655 supernatant (Table 3) revealed that cocktails 
missing lysine, methionine, and tyrosine failed to stimulate.  Furthermore, although 5 µl 
of 1.0 mM lysine alone, 1.0 mM methionine alone, and 1.0 mM tyrosine alone failed to 
stimulate (not shown), 5 µl of mixtures of 1.0 mM each of lysine, methionine, and 
tyrosine (Fig. 3E) were about as stimulatory for growth of E. coli CFT073 on glucose 
plates as either the E. coli MG1655 amino acid cocktail (Fig. 3B) or the amino acid 
cocktail mimicking human urine (Fig. 3D).   5 µl of mixtures of 1.0 mM each of D-
lysine, D-methionine, and D-tyrosine failed to stimulate (not shown), demonstrating the 
importance of the L- forms of the 3 amino acids in preventing quiescence.  Mixtures of 
1.0 mM each of lysine and methionine (Fig. 3F) and 1.0 mM each of lysine and tyrosine 
(Fig. 3G) also stimulated E. coli CFT073 growth on glucose plates, although stimulation 
of E. coli CFT073 growth by the mixture of lysine and tyrosine was minimal (Fig. 3G).  
A mixture of 1.0 mM each of methionine and tyrosine failed to stimulate E. coli CFT073 
growth (Fig. 3H).  In summary, E. coli MG1655 is not required to provide the stimulus 
that prevents E. coli CFT073 quiescence, a mixture of lysine, methionine, and tyrosine, 
found in concentrated 50-fold concentrated E. coli MG1655 supernatants, is just as 
effective.   
E. coli CFT073 and E. coli Nissle 1917, but not E. coli MG1655 generate high levels 
of persister cells in liquid glucose M9 minimal medium.  Persister cells are dormant 
cells formed in normal microbial populations as small subpopulations (10
-3 
to 10
-4
 %) that 
are highly tolerant to antibiotics, but upon regrowth in the absence of antibiotics regain 
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full sensitivity (11).  Persister cells appear to play a role in the ability of bacteria causing 
chronic infections to withstand antibiotic treatment (11).  Because E. coli CFT073 
becomes quiescent on glucose plates and quiescence is reminiscent of persistence, we 
wondered whether E. coli CFT073 generates a high level of persister cells in liquid 
glucose M9 minimal medium.  0.4% Glucose M9 minimal medium grown overnight 
cultures of E. coli CFT073 were diluted 20-fold into fresh 0.2% glucose M9 minimal 
medium (A600=0.1, ~10
8
 CFU/ml) containing or lacking ampicillin (100 µg/ml) and 
viable counts were followed for 24 hours at 37°C (Fig. 4).  During the first 4 h of 
incubation, viable counts in the E. coli CFT073 cultures decreased 10-fold in both the 
presence and absence of ampicillin, i.e. from 10
8
 CFU/ml to 10
7 
CFU/ml.  No further 
death occurred between 4 h and 6 h in the absence of ampicillin, and by 24 h E. coli 
CFT073 had grown to almost 10
9
 CFU/ml (Fig. 4).  In contrast, between 4 h and 6 h in 
the presence of ampicillin, viable counts decreased almost an additional 10-fold to about 
10
6
 CFU/ml in the E. coli CFT073 cultures (Fig. 4).  However, there was little further E. 
coli CFT073 death in the presence of ampicillin between 6 h and 24 h (Fig. 4), suggesting 
the possibility that the survivors (~0.7%) at 24 h might be persisters.  Therefore, at 24 h, 
E. coli CFT073 cultures containing ampicillin were centrifuged, washed free of the 
antibiotic, resuspended in LB broth, and grown at 37°C for 2.25 h to 10
8
 CFU/ml, at 
which time ampicillin was added (100 µg/ml).  Four hours later, viable counts in the E. 
coli CFT073 LB broth cultures had dropped to 10
4
 CFU/ml, suggesting that the vast 
majority of cells that survived ampicillin treatment in liquid glucose M9 minimal medium 
were indeed persister cells, still fully sensitive to ampicillin.  Much like E. coli CFT073, 
E. coli Nissle 1917 generated a high level of persister cells in liquid glucose minimal 
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medium, i.e. about 2.6% at 24 h (Table 4) and the cells were still sensitive to ampicillin 
as described above.   
Unlike E. coli CFT073 and E. coli Nissle 1917, when E. coli MG1655 overnight 
cultures were diluted 20-fold into fresh 0.2% glucose M9 minimal medium, viable counts 
increased immediately in the absence of ampicillin and in the presence of ampicillin 
decreased continuously for 6 h to a level of about 10
3
 CFU/ml (10
-3
 %) and remained at 
that level at 24 h (Fig. 4).  The E. coli MG1655 survivors in cultures containing 
ampicillin were also persister cells, i.e. when regrown in LB broth without ampicillin, 
they regained sensitivity.  Therefore, when grown in liquid glucose M9 minimal medium, 
E. coli CFT073 and E. coli Nissle 1917  cultures generated about 1000-fold more 
persister cells than E. coli MG1655 cultures.   
E. coli CFT073 generates a low level of persister cells in liquid glucose M9 minimal 
medium containing amino acids.  Since amino acids reversed E. coli CFT073 
quiescence on glucose plates, we were interested in determining whether addition of a 
mixture of the 20 standard L-amino acids (100 µg/ml each) to cultures of E. coli CFT073 
grown in glucose M9 minimal medium in the absence of amino acids would generate 
fewer persister cells.  As shown in Fig. 5, in the presence of the amino acid mixture and 
in the absence of ampicillin, E. coli CFT073 viable counts increased immediately, 
reaching stationary phase within 4 h.  Importantly, in the presence of both the amino acid 
mixture and ampicillin, E. coli CFT073 viable counts decreased continuously for 24 h to 
a level of about 5 x 10
3
 CFU/ml (Fig. 5).  That the survivors at 24 were persister cells 
was shown by the fact that when regrown in LB broth without ampicillin, they regained 
sensitivity, as described above.  In the absence of amino acids and in the presence of 
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ampicillin, E. coli CFT073 persister cells were again generated at a level of about 10
6
 
CFU/ml (Fig. 5). Therefore, in the presence of amino acids, about 100-fold fewer E. coli 
CFT073 persister cells were generated than in their absence (Fig. 5).   
Isolation and characterization of E. coli CFT073 mini-Tn5 mutants that grow on 
glucose plates.  Since E. coli CFT073 grows overnight in liquid glucose M9 minimal 
medium, but not on glucose plates, we thought it possible that expression of one or more 
genes on glucose plates, but not in liquid glucose cultures might be responsible.  If so, 
knockout of the responsible gene(s) would result in growth on glucose plates.  Therefore, 
E. coli CFT073 mini-Tn5 Km (kanamycin) mutants were generated by random 
insertional mutagenesis (see Materials and Methods) and any mutant that grew as a lawn 
on glucose plates was confirmed by transferring the insertion into a fresh E. coli CFT073 
background and retesting it for growth on glucose plates (see Materials and Methods). 
Five confirmed non-quiescent mini-Tn5 Km mutants were isolated from 
approximately 2000 mutants tested.  E. coli CFT073 and the mini-Tn5 Km mutants were 
grown overnight in liquid glucose M9 minimal medium and viable counts were made on 
both glucose plates and LB agar plates.  As expected, E. coli CFT073 assayed from the 
overnight cultures failed to grow on the glucose plates when ≤ 106 CFU were plated, but 
when assayed on LB agar viable counts showed that the cultures contained ~10
9
 CFU/ml.  
In contrast, when assayed on either glucose plates or LB agar plates the 5 mini-Tn5 Km 
mutant cultures each contained about ~10
9
 CFU/ml.  It therefore appears that the mini-
Tn5 Km insertion in each of the 5 genes completely prevented quiescence on glucose 
plates.  
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The mini-Tn5 Km insertions that resulted in mutants able to grow on glucose plates 
after transfer into a fresh E. coli CFT073 background were in the following 5 genes (Fig. 
6):  (i) sdhA: encodes the succinate-binding flavoprotein subunit of succinate 
dehydrogenase (27). As a consequence, the E. coli CFT073 sdhA mutant fails to grow on 
succinate as sole carbon source, but grows normally on glucose.  (ii) gnd: encodes 6-
phosphogluconate dehydrogenase which functions in the oxidative branch of the pentose 
phosphate pathway to synthesize ribulose-5-phosphate from 6-phosphogluconate (28, 
29).  Ribulose-5-phosphate is an essential precursor in the synthesis of FAD, nucleotides, 
and LPS. (iii) zwf: encodes glucose-6-phosphate dehydrogenase, which functions in the 
oxidative branch of the pentose phosphate pathway and the Entner-Doudoroff pathway 
when E. coli is grown on glucose (28, 29). (iv) pykF: encodes pyruvate kinase, which 
converts phosphoenolpyruvate to pyruvate in the Embden-Meyerhof-Parnas pathway 
(30). (v) gdhA: encodes glutamate dehydrogenase, which catalyzes the amination of α-
ketoglutarate to glutamate (31).   
It might be argued that the mini- Tn5 Km insertions in the identified genes are not the 
cause of non-quiescence, but that non-quiescence is caused by downstream polarity 
effects.  Indeed, the mini-Tn5 Km transposon used in the present study has strong 
transcription termination sequences flanking both ends of the kanamycin resistance gene 
(17).  However, the intergenic number of nucleotides and nucleotide sequences between  
gnd and the immediate downstream ugd, between pykF and the immediate downstream 
lpp, and between zwf and the immediate downstream edd are identical in E. coli MG1655 
and E. coli CFT073 (GenBank accession numbers U00096.3 and AE014075.1) (21, 32).  
Moreover, in E. coli MG1655 and therefore in E. coli CFT073, there is a strong 
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presumptive promoter between gnd and ugd (33) and in E. coli MG1655 and therefore in 
E. coli CFT073 both lpp and edd have their own experimentally identified promoters 
(33).  It is therefore highly likely that non-quiescence is caused by interrupting gnd, pykF, 
and zwf, and not by downstream polarity effects.  Also, in E. coli CFT073, gdhA is 
immediately upstream of c2163, which is transcribed in the opposite direction to gdhA 
(21), making it highly unlikely that non-quiescence caused by the insertion in gdhA is due 
to downstream polarity.  Finally, although in E. coli MG1655 the number of nucleotides 
between the end of the sdhCDAB operon and the beginning of the immediately 
downstream sucABCD operon is 241 nucleotides less than that in E. coli CFT073 
(GenBank accession numbers U00096.3 and AE014075.1) (31, 32), the experimentally 
identified E. coli MG1655 sucABCD promoter is identical in sequence to the presumptive 
E. coli CFT073 sucABCD promoter and the nucleotide sequence between the 3’ end of 
the promoter and the start of sucA transcription is identical in both strains (21, 32, 33).  It 
is therefore highly unlikely that non-quiescence caused by the insertion in sdhA is due to 
a downstream polarity effect on the sucABCD operon in E. coli CFT073.   
Of the 5 mini-Tn5 Km mutants, only E. coli CFT073 sdhA and gdhA generate low 
levels of persister cells.  Since the 5 E. coli CFT073 mini-Tn5 Km mutants were non-
quiescent on glucose plates, we wondered whether they would generate fewer persister 
cells than E. coli CFT073 in glucose M9 minimal medium.  Indeed, the E. coli CFT073 
sdhA and gdhA mutants, which began growth shortly after dilution of overnight cultures 
into fresh glucose M9 minimal medium, generated only about 5 x 10
2
 persister cells/ml, 
i.e. about 2000-fold fewer persister cells in the presence of ampicillin than wildtype E. 
coli CFT073 (Figs. 7 and 8).  In contrast, the E. coli CFT073 gnd, pykF, and zwf mutants 
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generated about the same level of persister cells as E. coli CFT073 (Table 4), suggesting 
that quiescence and persistence are not identical phenomena.    
E. coli CFT073 persistence and quiescence require a complete TCA cycle.  Succinate 
dehydrogenase converts succinate to fumarate (Fig. 6).  The fact that the E. coli CFT073 
sdhA mutant generated about 2000-fold fewer persister cells than E. coli CFT073 
suggested the possibility that the ability to make fumarate from succinate was required 
for persister cell formation.  To test that possibility, E. coli CFT073 sdhA cultures were 
grown overnight in liquid 0.4% glucose M9 minimal medium in the presence and absence 
of fumarate (200 µg/ml) and persister cell assays were performed in 0.2% glucose M9 
minimal medium in the presence of fumarate for cultures grown with fumarate and in the 
absence of fumarate for cultures grown without fumarate.  In the presence of fumarate 
and ampicillin, E. coli CFT073 sdhA cultures generated between 10
5
 and 10
6
 CFU/ml 
persister cells (Fig. 9), much like E. coli CFT073 (Figs. 4, 5, 7, and 8), whereas in the 
absence of fumarate and the presence of ampicillin, E. coli CFT073 sdhA cultures 
generated only 5 x 10
2
 CFU/ml persister cells (Fig. 9).  Therefore, allowing completion 
of the TCA cycle by supplying E. coli CFT073 sdhA with fumarate rescued its ability to 
generate a high level of persister cells, suggesting that a complete oxidative TCA cycle is 
required for maximal persister cell generation 
Since persister cell generation required a complete TCA cycle, we wondered whether 
the same was true of quiescence.  To that end, E. coli CFT073 sdhA was grown overnight 
in liquid 0.4% glucose M9 minimal medium in the presence and absence of fumarate 
(200 µg/ml).  Glucose plates containing fumarate (200 µg/ml) were seeded with 10
5
 CFU 
of E. coli CFT073 sdhA grown in the presence of fumarate or 10
5
 CFU of E. coli CFT073 
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sdhA grown in the absence of fumarate and were incubated at 37°C for 24 h.  In both 
cases, E. coli CFT073 sdhA failed to grow, but responded to 5 µl of a 1.0 mM mixture of 
lysine, methionine, and tyrosine (Fig. 10A), not only suggesting that the presence of 
fumarate in the glucose plate rescued quiescence, but that quiescence was generated on 
the glucose plate and not in the liquid culture.  As a control, glucose plates without 
fumarate were seeded with 10
5
 CFU of E. coli CFT073 sdhA grown overnight in liquid 
glucose M9 minimal medium in the absence of fumarate and plates were incubated at 
37°C for 24 h.  As expected, a lawn of E. coli CFT073 sdhA growth was observed on the 
glucose plates under these conditions (Fig. 10B).  Therefore, not only does fumarate 
rescue the ability of E. coli CFT073 sdhA to generate a high level of persisters in liquid 
glucose M9 minimal medium in the presence of ampicillin (Fig. 9), it rescues the ability 
of E. coli CFT073 sdhA to enter the quiescent state on glucose plates. As a side note, 
rescue by fumarate, obviating the need for succinate dehydrogenase, further implicates 
the mini-Tn5 Km insertion and not a downstream polarity effect as the cause of non-
quiescence and reduced persistence of the sdhA mutant. 
The E. coli CFT073 original clinical isolate is quiescent on glucose plates, but 
generates very few persister cells in liquid glucose M9 minimal medium.  As we were 
completing this study, we became aware of a paper reporting that the sequenced E. coli 
CFT073 (22), which has long been considered to be the wildtype strain, has a 5 bp 
duplication in rpoS which results in a truncated, non-functional RpoS (34).  RpoS, often 
referred to as the alternative sigma factor σS, directs RNA polymerase to transcribe genes 
involved in the E. coli general stress response, e.g. acid resistance (35).  The E. coli 
CFT073 used in this study does indeed have the 5 bp duplication in rpoS (Leatham-
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Jensen MP, unpublished results).  We therefore obtained and tested the original clinical 
isolate of E. coli CFT073, which has a wildtype rpoS gene (34), for quiescence and 
persister cell formation.  The E. coli CFT073 original clinical isolate is indeed quiescent 
on glucose plates and responds to lysine, methionine, and tyrosine like the rpoS mutant 
used here (Fig. 11), but generates about 2000-fold fewer persister cells in liquid glucose 
M9 minimal medium than the rpoS mutant used in the present study (Table 4).  
Therefore, it appears that the mutant rpoS gene is necessary for the high level of 
persistence observed, but is not necessary for E. coli CFT073 quiescence on glucose 
plates.   
Discussion 
The data presented here show that the uropathogen E. coli CFT073 and the probiotic 
E. coli Nissle 1917, both ST73 strains belonging to phylogenetic group B2, are quiescent 
on glucose plates seeded with ≤ 106 CFU, as are 35/45 (77.8%) additional ST73 strains 
tested.  ST73 is a very common UPEC lineage (24, 25).  In contrast, of 4 phylogenetic 
group A, 6 phylogenetic group B1, 6 phylogenetic group D, 4 phylogenetic group ABD, 
and 4 phylogenetic group AxB1 strains, none (0/24) were quiescent.  However, 9 of 40 
randomly selected UPEC strains isolated from community acquired UTIs in Denmark 
(22.5%) were quiescent on glucose plates (3/5 ST73 strains, 3/3 ST141 strains, 1/1 ST104 
strain, 1/1 ST394 strain, and 1/1 ST998 strain).  Thus quiescence on glucose plates is 
common among UPEC isolates and is not restricted to one ST type. 
The data presented here also show that the E. coli CFT073 original clinical isolate, 
like the E. coli CFT073 strain used here, which has a 5 bp duplication in rpoS that 
inactivates the gene (33), is quiescent on glucose plates (Fig. 11), but unlike the E. coli 
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CFT073 strain used here, generates a low level of persister cells in the presence of 
ampicillin (Table 4).  Therefore, quiescence and persistence, while similar in some 
respects, i.e. both are prevented by amino acids and both require a complete oxidative 
TCA cycle, are not identical.  In addition, quiescence and persistence differ in that of the 
5 E. coli CFT073 mini-Tn5 non-quiescent mutants isolated in the present study (gdhA, 
gnd, pykF, sdhA, and zwf), only 2 (gdhA and sdhA) were deficient in persister cell 
formation (Table 4).   
It has been reported, as reported here for E. coli CFT073, that deleting rpoS in E. coli 
K-12 also dramatically increases formation of persister cells in the presence of ampicillin 
(36).  Why then, does E. coli Nissle 1917, which has a wildtype rpoS gene (Leatham-
Jensen MP, unpublished results and [36]), generate at least as high a level of persister 
cells as E. coli CFT073 (Table 4)?  E. coli Nissle 1917 would be expected to be acid 
resistant since a wildtype rpoS gene is required for acid resistance; however, it has been 
reported to be extremely acid sensitive (37).  This suggests the possibility that the E. coli 
Nissle 1917 rpoS gene may be poorly expressed or that RpoS is rapidly degraded, which 
is consistent with its generating as high a level of persister cells as the E. coli CFT073 
rpoS mutant used here. Many E. coli strains contain wildtype rpoS genes that are 
expressed poorly relative to other strains (38). 
While it is unclear as to why E. coli CFT073 gnd and zwf mutants are non-quiescent 
on glucose plates, the reason E. coli K-12 gnd and zwf mutants grow on glucose as sole 
carbon source is known (29, 30). When E. coli K-12 is grown on glucose as sole carbon 
source, glucose-6-phosphate dehydrogenase, encoded by zwf, and 6-phosphogluconate 
dehydrogenase, encoded by gnd, are used for the synthesis of ribulose-5-phosphate via 
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the oxidative branch of the pentose phosphate pathway (Fig. 6 and [28, 29]).  Ribulose-5-
phosphate is an essential precursor in the synthesis of FAD, nucleotides, and LPS.  
Furthermore, both enzymes generate NADPH for biosynthesis.  It might therefore seem 
surprising that mutations in gnd and zwf allow growth on glucose as sole carbon source 
(Fig. 6).  However, null mutations in gnd and zwf in E. coli K-12 do not significantly 
affect their growth on glucose because the non-oxidative branch of the pentose phosphate 
pathway runs backwards in these mutants, generating ribulose-5-phosphate from 
fructose-6-phosphate and glyceraldehyde-3-phosphate (Fig. 6 and [28, 29]) and the 
necessary NADPH for biosynthesis by increased flux through the TCA cycle (28, 29).  It 
is therefore possible that for unknown mechanistic reasons the oxidative branch of the 
pentose phosphate pathway operates minimally during E. coli CFT073 quiescence, 
generating little ribulose-5-phosphate, but that the gnd and zwf mutations cause the non-
oxidative branch to run backwards and flux through the TCA cycle to increase, 
generating a sufficient level of ribulose-5-phosphate and NADPH to prevent quiescence.  
This scenario is consistent with the observation that ribose and xylose, both of which are 
metabolized in the non-oxidative branch of the pentose phosphate pathway, prevent 
quiescence when used as sole carbon sources (Fig. 2).   
The E. coli CFT073 pykF mutant also grows on glucose as sole carbon source.  The 
pykF gene encodes pyruvate kinase which converts PEP to pyruvate (Fig. 6). There is a 
second pyruvate kinase, encoded by pykA, but during E. coli K-12 growth in glucose 
minimal medium, it contributes little to total pyruvate kinase activity (39).  Moreover, in 
the complete absence of pyruvate kinase, pyruvate can still be generated in E. coli K-12 
both through glucose transport via the phosphotransferase transport system (PTS) (40) 
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and the Entner-Doudoroff pathway (31, 38).  Therefore, it is not surprising that the non-
quiescent E. coli CFT073 pykF mutant can grow on glucose as sole carbon source, but 
why is it non-quiescent?  It has been suggested that pykF mutants contain increased 
intracellular levels of PEP (30).  If PEP, a common precursor in lysine, methionine, and 
tyrosine biosynthesis (Fig. 6), is increased in the E. coli CFT073 pykF mutant growing on 
glucose plates, sufficient intracellular levels of the 3 amino acids might be generated to 
stimulate growth and prevent quiescence.     
The gdhA gene encodes glutamate dehydrogenase, which converts α-ketoglutarate to 
glutamate (Fig. 6).  It is known that E. coli K-12 gdhA mutants grow on glucose as sole 
carbon source in the absence of glutamate dehydrogenase because glutamate can also be 
synthesized via the sequential action of glutamine synthetase and glutamate synthase (31, 
41).  Therefore, it appears that the switch from producing glutamate via glutamate 
dehydrogenase to producing it via glutamine synthetase and glutamate synthase in E. coli 
CFT073 somehow prevents quiescence.  It has been estimated that 88% of assimilated 
nitrogen in E. coli, including the nitrogen in amino acids, originates from glutamate and 
the remaining 12% from glutamine (42).  Perhaps glutamate and glutamine are in higher 
concentrations in gdhA mutants growing on glucose, which could contribute to higher 
intracellular levels of lysine, methionine, and tyrosine and as a consequence, non-
quiescence.    
E. coli K-12 succinate dehydrogenase mutants grow on glucose as sole carbon source 
because it is not necessary for the TCA cycle to function as a complete oxidative cycle to 
achieve growth (43).  In fact, when growing on excess glucose, the E. coli K-12 TCA 
cycle operates in branched mode, i.e. an oxidative branch which runs from citrate to α-
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ketoglutarate and a reductive branch which runs backwards from oxaloacetate to 
succinyl-CoA (Fig. 6 and [43]).  Succinate dehydrogenase is not necessary under these 
conditions and both branches serve biosynthetic functions. As a result, neither branch is 
used for ATP generation (42).  ATP is generated from glycolysis and via the 
phosphotransacetylase (pta)-acetate kinase (ackA) pathway producing acetate in the 
process (Fig. 6 and [43]).  Therefore, it appears likely that forcing the TCA cycle to 
operate in branched mode somehow prevents E. coli CFT073 quiescence.  In branched 
mode, the TCA cycle is unable to regenerate oxaloacetate and therefore gets oxaloacetate 
from PEP via PpC (Fig. 6).  Perhaps under these conditions sufficient oxaloacetate is 
generated via Ppc to increase intracellular levels of lysine and methionine (Fig. 6) and 
consequently, prevent quiescence.  In this vein, addition of fumarate to glucose plates, 
results in return of the E. coli CFT073 sdhA mutant to quiescence, presumably by 
rescuing the ability of the TCA cycle to operate as a complete oxidative cycle.  It should 
also be noted that an E. coli CFT073 succinate dehydrogenase mutant (sdhB) has been 
shown to be severely attenuated in an ascending mouse UTI model (44), indicating a 
possible link between in vitro non-quiescence and reduced pathogenesis in vivo. 
While it is clear why the E. coli CFT073 mini-Tn5 Km non-quiescent mutants are 
capable of growth using glucose as sole carbon source, it is not mechanistically clear as 
to why the mutations prevent quiescence on glucose plates. Possibly, a gene encoding a 
regulator whose synthesis or activity is inhibited by various combinations of lysine, 
methionine, and tyrosine, promotes quiescence.  The regulator would presumably be 
expressed or active in the vast majority of E. coli CFT073 cells on glucose plates, but in 
relatively few cells of the E. coli CFT073 mini-Tn5 Km non-quiescent mutants due to the 
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complex metabolic changes that occur in such mutants (28, 29, 30, 39, 45, 46).  If 
expression and activity of a specific E. coli CFT073 regulator is critical for generation of 
quiescence, much as toxin/antitoxin systems appear to be critical in generating persister 
cells (11, 47), screening more mini-Tn5 Km mutants may lead to its identification.  
Furthermore, it is unclear as to why the E. coli CFT073 gdhA and sdhA mutants generate 
far fewer persister cells than the gnd, zwf, and pykF mutants (Table 4).  Metabolic flux 
analysis (28, 29, 30) and RNA-seq (48) may prove useful in this regard.     
How might the findings reported here be relevant to recurrent UTI infections and how 
might its relevance be tested?  It is known that E. coli CFT073 utilizes amino acids and 
small peptides as carbon sources and a complete oxidative TCA cycle to infect the mouse 
urinary tract (44, 49) and appears to import small peptides to grow in mouse urine in vitro 
(44).  UPEC may also use peptides for growth in vivo in urine during human UTI (50).  It 
is also known that E. coli CFT073 can infect mouse superficial facet cells and form 
biofilm-like intracellular communities (IBCs) (51) and therefore most likely can form 
Quiescent Intracellular Reservoirs (QIRs) in underlying transitional cells. Furthermore, it 
seems reasonable  that QIRs surviving antibiotic treatment serve as a reservoir for 
recurrent UTI infection after withdrawal of antibiotics (8, 10), i.e. as transitional cells 
undergo apoptosis and released QIRs resume growth in urine using peptides and amino 
acids in the process (44, 49, 50).  However, it should be noted that the role of QIRs in 
recurrent UTI is still controversial.  It has recently been shown that UPEC strains isolated 
from the feces and urine of female patients during recurrent episodes are identical, 
consistent with the possibility that recurrent UTI is caused by UPEC strains that colonize 
the intestine, but periodically move to the urinary tract (52).  Nevertheless, if the in vitro 
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quiescence reported here mimics the QIR state and if QIRs are a major source of 
recurrent UTI, the E. coli CFT073 non-quiescent mutants we’ve isolated should be less 
able to establish QIRs in the mouse bladder and therefore be less able to cause recurrent 
UTI.  If so, it is possible that drugs designed to inactivate the enzymes encoded by gdhA, 
gnd, pykF, sdhA, and zwf might be effective in limiting recurrent urinary tract infection.  
On the other hand, if the in vitro persistence state mimics the QIR state in mouse bladder 
cells, only the E. coli CFT073 gdhA and sdhA mutants should be less able to cause 
recurrent UTI and if so, drugs designed to inactivate the enzymes encoded by gdhA and 
sdhA might be effective in limiting recurrent urinary tract infection    A recurrent UTI 
mouse model is available for testing these hypotheses (8).   
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Table 1. Bacterial Strains 
E. coli strain Genotype/phenotype Referred to in text as: Source/Reference 
CFT073 Str
R Spontaneous 
streptomycin resistant 
mutant of  CFT073, 
has 5 bp duplication 
in rpoS 
CFT073 (53) 
CFT073 Str
R
 mini-
Tn5 Km::gdhA 
mini-Tn5 Km 
glutamate 
dehydrogenase mutant 
of CFT073 Str
R
 
CFT073 gdhA This study 
CFT073 Str
R
 mini-
Tn5 Km::gnd 
 
mini-Tn5 Km           
6-phosphogluconate 
dehydrogenase mutant 
of CFT073 Str
R
 
CFT073 gnd This study 
CFT073 Str
R
 mini-
Tn5 Km::pykF 
mini-Tn5 Km 
pyruvate kinase 
mutant of CFT073 
Str
R
 
CFT073 pykF This study 
CFT073 Str
R
 mini-
Tn5 Km::sdhA 
mini-Tn5::Km  
flavoprotein subunit 
of succinate 
dehydrogenase 
CFT073 sdhA This study 
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mutant of CFT073 
Str
R
 
CFT073 Str
R
 mini-
Tn5 Km::zwf 
mini-Tn5::Km 
glucose-6-phosphate 
dehydrogenase 
mutant of  CFT073 
Str
R
 
CFT073 zwf This study 
wildtype CFT073 original clinical 
isolate 
 CFT073 original 
clinical isolate 
(34) 
Nissle 1917 Str
R spontaneous 
streptomycin resistant 
mutant of Nissle 1917 
Nissle 1917 (57) 
MG1655 Str
R
 spontaneous 
streptomycin resistant 
mutant of MG1655 
MG1655 (54) 
HS Str
R spontaneous 
streptomycin resistant 
mutant of HS 
HS (55) 
EFC1 Str
R
 spontaneous 
streptomycin resistant 
mutant of EFC1 
EFC1 (55) 
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EFC2 Str
R spontaneous 
streptomycin resistant 
mutant of EFC2 
EFC2 (55) 
F-18 Str
R
 Nal
R spontaneous 
streptomycin and 
nalidixic acid resistant 
mutant of  F-18 
F-18 (56) 
EDL933 Str
R spontaneous 
streptomycin resistant 
mutant of EDL933 
EDL933 (54) 
ATM161 
 host for pUT, which  
contains the mini-
Tn5 Km transposon, 
resistant to kanamycin 
ATM161 (17) 
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Table 2.  PCR primer sequences for amplifying mutant genes containing mini-Tn5 Km 
insertions. 
gene Primer 1: 5′→3′ Primer 2: 5′→3′ 
gdh
A 
GATGGTCGAGTGGCAGATTAC 
 
CAGAGGCTACTCAATGGCTT
AC 
 
gnd GTTGGTTAAATCAGATTAATCCAGCC 
 
CAACAGATCGGCGTAGTCG 
 
pykF CTGTAGCAATTGAGCGATGAT G 
 
ATCAGGGCGCTTCGATATAC 
 
sdhA CCGTTCCCATACCGTTTCTG 
 
TTTCACCGGATCAACGTGAG 
 
zwf CCGGTAAAATAACCATAAAGGATAA
GC 
 
GAGAATGACATGGCGGTAAC 
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Table 3.  Free amino acid composition of 50-fold concentrated E. coli MG1655 and E. 
coli CFT073 supernatants and human urine (µM). 
Amino Acid
a E. coli MG1655 
Supernatant
b 
E. coli CFT073 
Supernatant
b 
Human Urine
c 
alanine 353 383 3350 
arginine - - 205 
aspartic acid - 22 - 
cysteine - - 1110 
glutamic acid 360 848 - 
glycine 11 86 21200 
histidine - - 9470 
isoleucine 90 170 478 
leucine 56 149 382 
lysine 7472 4059 4480 
methionine 59 37 171 
phenylalanine 99 187 626 
proline 144 116 - 
serine 64 70 4000 
threonine 201 461 2430 
tryptophan 146 312 - 
tyrosine 13 52 1060 
valine 229  748 349 
a
 amino acids not listed are not present in the preparations; 
b
 see Materials and Methods 
for details; 
c
 average of 39 women, reference (26). 
 
  
126 
 
 
 
 
 
 
Table 4.  E. coli CFT073 persister cells relative to persister cells for other E. coli strains. 
E. coli strain # of 
experiments 
% persister 
cells ± SEM
a
 
CFT073 
persister cells 
relative to:
a 
P value 
CFT073 7 0.71 ± 0.19 -  
CFT073 gnd 2 0.34 ± 0.18 1.65  0.44  
CFT073 pykF 2 2.37 ± 0.18 0.23  0.075  
CFT073 zwf 2 0.29 ± 0.29 1.45  0.43 
Nissle 1917 2 2.64 ± 1.22 0.21  0.16  
True wildtype 
CFT073 
2 2.80 x 10
-4
 ± 
1.1 x 10
-4 
1160   0.025* 
a  
% persister cells was calculated by dividing the viable count at 24 h by the viable count 
at time zero times 100. The value for E. coli CFT073 persister cells relative to a specific 
E. coli strain is calculated by dividing the % persister cells at 24 h generated by E. coli 
CFT073 in the experiments listed for the specific strain by the % persister cells at 24 h 
generated by that specific strain in those experiments.  *P < 0.05  using the two-tailed 
Student t test is considered to be statistically significant. 
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Legends to the Figures 
Fig. 1.  E. coli CFT073 quiescence on glucose plates.  A 0.2% glucose plate was seeded 
with 10
5 
CFU of E. coli CFT073 (see Materials and Methods).  (A), 60 min after seeding 
the plate, a colony of E. coli MG1655, grown on a glucose plate, was toothpicked to the 
plate seeded with E. coli CFT073, which was then incubated at 37°C for 24 h; (B), the 
same plate, incubated for 48 h.  Note that E. coli CFT073 only grows around the 
toothpicked E. coli MG1655.  Although not shown, E. coli Nissle 1917 undergoes 
quiescence on glucose plates identically.  
Fig. 2.  E. coli CFT073 non-quiescence on glycerol, ribose, and xylose plates.  0.2% 
glucose, glycerol, ribose, and xylose plates were seeded with 10
5
 CFU of E. coli CFT073 
grown overnight in liquid M9 minimal medium containing their respective sugars (0.4%).  
60 min after seeding the plates, a colony of E. coli MG1655, grown on a glucose plate, 
was toothpicked to the glucose plate.  Plates were incubated at 37°C for 24h. (A), 
glycerol plate; (B), ribose plate; (C), xylose plate; (D), glucose plate. 
Fig. 3.  Prevention of quiescence by human urine and amino acids.  0.2% glucose plates 
were seeded with 10
5
 CFU of E. coli CFT073 and 5 µl of the following mixtures were 
spotted onto the plates. (A), 50-fold concentrated E. coli MG1655 culture supernatant; 
(B), amino acid cocktail mimicking amino acid concentrations in the 50-fold 
concentrated E. coli MG1655 culture supernatant; (C), human urine; (D), amino acid 
cocktail mimicking amino acid concentrations in human urine (Table 3); (E), lysine, 
methionine, tyrosine (1.0 mM each); (F), lysine and methionine (1.0 mM each); (G), 
lysine and tyrosine (1.0 mM each); (H), methionine and tyrosine (1.0 mM each).  Plates 
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were incubated at 37°C for 24h.  Although not shown, results for E. coli Nissle 1917 
were essentially identical.  
 
Fig. 4.  E. coli CFT073 and E. coli MG1655 persistence.  Cultures were grown overnight 
in  
0.4 % glucose M9 minimal medium as described in Material and Methods.  Persister cell 
assays were performed as described in Materials and Methods. (▲), E. coli CFT073; (●), 
E. coli CFT073 plus ampicillin; (♦), E. coli MG1655; (■), E. coli MG1655 plus 
ampicillin.  Bars representing standard errors of the log10 means of CFU per ml for 2 
independent experiments are presented for each time point.  At 24 h the approximate 
1000-fold difference between E. coli CFT073 persisters in the presence of ampicillin and 
E. coli MG1655 persisters in the presence of ampicillin is statistically significant (P = 
0.0052). 
Fig. 5.  E. coli CFT073 persistence in the presence of amino acids.  Cultures were grown 
in 0.4 % glucose M9 minimal medium as described in Material and Methods and diluted 
20-fold into 0.2 % glucose M9 minimal medium either containing or lacking a mixture of 
the 20 standard L-amino acids, each at 100 µg/ml and containing or lacking ampicillin 
(100 µg/ml).  (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E. coli 
CFT073 plus amino acids; (●), E. coli CFT073 plus amino acids plus ampicillin.  Bars 
representing standard errors of the log10 means of CFU per ml for 2 independent 
experiments are presented for each time point.  At 6 h and 24 h the approximate 100-fold 
differences between E. coli CFT073 persisters in the presence of ampicillin and E. coli 
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MG1655 persisters in the presence of ampicillin are statistically significant (P = 0.002 
and P = 0.05 respectively). 
Fig. 6.  Diagram of E. coli central carbon metabolism.  Arrows indicate the 
physiological directions of the reactions. Genes encoding the enzymes for each reaction 
are listed beside each reaction.   Mini-Tn5 Km insertions in E. coli CFT073 genes that 
result in non-quiescence on glucose plates are circled. 
Fig. 7.  E. coli CFT073 sdhA persistence.  Cultures were grown overnight in 0.4 % 
glucose M9 minimal medium and persister cell assays were performed as described in 
Materials and Methods. (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E. 
coli CFT073 sdhA; (●), E. coli CFT073 sdhA plus ampicillin.  Bars representing standard 
errors of the log10 means of CFU per ml for 4 independent experiments are presented for 
each time point.  At 24 h the approximate 2000-fold difference between E. coli CFT073 
persisters in the presence of ampicillin and E. coli CFT073 sdhA persisters in the 
presence of ampicillin is statistically significant (P < 0.001). 
Fig. 8.  E. coli CFT073 gdhA persistence.  Cultures were grown overnight in 0.4 % 
glucose M9 minimal medium and persister cell assays were performed as described in 
Materials and Methods. (♦), E. coli CFT073; (■), E. coli CFT073 plus ampicillin; (▲), E. 
coli CFT073 gdhA; (●), E. coli CFT073 gdhA plus ampicillin.  Bars representing standard 
errors of the log10 means of CFU per ml for 3 independent experiments are presented for 
each time point.  At 24 h the approximate 2000-fold difference between E. coli CFT073 
persisters in the presence of ampicillin and E. coli CFT073 gdhA persisters in the 
presence of ampicillin is statistically significant (P < 0.001). 
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Fig. 9.  E. coli CFT073 sdhA persistence in the presence of fumarate.  Cultures were 
grown overnight in 0.4 % glucose M9 minimal medium containing or lacking disodium 
fumarate (200 µg/ml), diluted 20-fold into 0.2% glucose M9 minimal medium containing 
or lacking fumarate, and persister cell assays were performed as described in Materials 
and Methods.  (▲), E. coli CFT073 sdhA; (●), E. coli CFT073 sdhA plus ampicillin; (♦), 
E. coli CFT073 sdhA plus fumarate; (■), E. coli CFT073 sdhA plus fumarate plus 
ampicillin.  Bars representing standard errors of the log10 means of CFU per ml for 2 
independent experiments are presented for each time point.  At 6 h and 24 h the 
differences between E. coli CFT073 sdhA persisters in the presence and absence of 
fumarate are statistically significant (P = 0.013 and P = 0.046 respectively). 
Fig. 10.  Rescue of E. coli CFT073 sdhA quiescence by fumarate.  E. coli CFT073 sdhA 
was grown overnight in 0.4 % glucose M9 minimal medium and 10
5
 CFU were seeded on 
(A), 0.2% glucose plates containing disodium fumarate (200 µg/ml) or (B), 0.2% glucose 
plates.  One hour later, 5 µl of a mixture of 1.0 mM lysine, 1.0 mM methionine, and 1.0 
mM tyrosine was spotted to each plate.  Plates were incubated at 37°C for 24 h. 
Fig. 11.  Quiescence of the E. coli CFT073 original clinical isolate on glucose plates. 0.2% 
glucose plates were seeded with 10
5
 CFU of the E. coli CFT073 original clinical isolate and 
5 µl of the following mixtures (1.0 mM of each amino acid) were spotted onto the plates.  
(A), lysine, methionine, tyrosine; (B), lysine and methionine; (C), lysine and tyrosine; 
(D), methionine and tyrosine.  Plates were incubated at 37°C for 24h.   
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CHAPTER 5 
This manuscript is formatted for publication in Scientific Reports. The formatting 
follows the guidelines set forth by the journal.  
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Abstract 
Urinary tract infections (UTIs) caused by Escherichia coli create a large burden on 
healthcare and frequently cause recurrent infections.  Contributing to the success of E. 
coli as an uropathogenic bacterium is its ability to form quiescent intracellular reservoirs 
in bladder cells and persistence after antibiotic treatment.  Cranberry juice and related 
products have been used extensively in the treatment and prevention of UTIs with 
varying degrees of benefit reported in the literature.  In this study, cranberry 
oligosaccharides and related compounds were found to both reduce the fraction of 
persister cells formed and inhibit quiescence in the uropathogenic strain, CFT073.  This 
is the first report detailing components of cranberry juice with the ability to modulate 
these important physiological aspects of uropathogenic E. coli, and further studies 
investigating cranberry juice should be keen to include oligosaccharides as part of the 
‘active’ cocktail of chemical compounds.  
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 Bacterial urinary tract infections (UTIs) are among the most common infections 
in the world affecting up to 150 million people each year.
1
 In the US alone, it is estimated 
that the total societal cost burden of UTIs is $3.5 billion each year.
2
 Women are one of 
the most important at risk demographics with a lifetime prevalence of over 50% and an 
estimated recurrence of about 25%.
3
 While UTIs are commonly mild and curable, 
recurrent infections can require continuous antibiotic prophylaxis for prevention which 
can lead to adverse events such as colitis, the development of antibiotic resistant UTIs, or 
the development of complicated UTIs.
2-4
  
 Uropathogenic Escherichia coli (UPEC) is the causative pathogen in the majority 
of UTIs, with estimates ranging anywhere from 65-90% of cases.
2,4-6
 When UPEC is the 
identified pathogen in a recurrent UTI, the original infecting UPEC strain is responsible 
for the recurrence 77% of the time.
7
 While the mechanism of recurrence is not fully 
understood, it is thought that intracellular biofilm-like communities (IBCs) and quiescent 
intracellular reservoirs (QIRs) contribute significantly to recurrent UTIs.
8-10
 During acute 
infection, UPEC are able to adhere to, invade, and replicate inside of superficial bladder 
cells, forming IBCs.
6,10
 As the infection progresses, UPEC infection of the urothelial 
transitional cells can lead to establishment of QIRs which can remain viable for months 
intracellularly.
6,9,11
 Importantly, it is also thought that QIRs may not be affected by 
antibiotics, contributing to treatment failures and recurrence.
8,10
 Upon exfoliation of the 
bladder epithelial cells containing the QIRs, the UPEC would be re-exposed to the urine 
and could cause recurrent infection.
6
 It was also shown in vitro that the amino acid 
content of the urine is able to reverse quiescence in UPEC, and could serve as the 
necessary signal for reinfection.
12
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 A similar physiologic state to quiescence in UPEC is bacterial persistence.
13-16
 
Persister cells are a small subpopulation of bacteria in a dormant, non-dividing state 
characterized by high antibiotic tolerance.
13,14,16
 Persistence differs from antibiotic 
resistance in that upon regrowth of the persister cell fraction after initial antibiotic 
treatment, the bacteria retains sensitivity to the antibiotic and can consistently form the 
same persister cell fraction.
17
 Persister cells are strongly implicated in the pathogenesis of 
chronic infections, including recurrent UTIs where persistence of UPEC has been 
extensively studied.
12,18-21
 While proven to be different metabolically, quiescence and 
persistence both likely contribute to the ability of UPEC to cause recurrent UTI and 
treatment failures.
12
 Therapies aimed at preventing or reversing quiescence and 
persistence could significantly reduce the burden of UPEC recurrent UTI.  
 Cranberry (Vaccinium macrocarpon) products have been extensively researched 
for their role in the treatment and prevention of UTIs especially in UPEC and other 
pathogens.
22-27
 While many studies have shown benefit, especially those completing in 
vitro experiments, the current clinical role of cranberry products in UTIs is 
controversial.
22-26
 Despite numerous completed studies, there is a lack of consistency in 
the type of study, study demographic, and especially the cranberry products and these 
inconsistencies can contribute to the conflicting evidence.
23
 Specifically, current 
literature states that the major ‘active’ components are proanthocyanidins (PACs) with A-
type linkages and fructose, both of which interfere with UPEC adherence to the 
bladder.
23,25,28
 However, in a comprehensive Cochrane review of 24 clinical studies, only 
five of the studies indicated a measurement of the amount of PACs in their tested 
products (juice, concentrate, capsules, or tablets), displaying the shortcomings of much of 
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the chemistry in the clinical trials completed thus far.
23
 With inconsistent standardization 
of the cranberry chemistry, and inconsistent clinical evidence for its use in prevention of 
UTIs, we sought to determine if there were other therapeutic targets that cranberry 
chemistry could exploit to aid in the prevention of UTIs and recurrent UTIs, especially in 
UPEC. With the hypothesized importance of IBCs and QIRs to the infection cycle and 
recurrence of UTIs, as well as published studies detailing natural product compounds that 
are able to sensitize persister cells to antibiotics,
29-31
 we hypothesized that compounds 
from cranberry may be able to reduce persistence and/or quiescence in UPEC. In the 
following study, we identify carbohydrate components from cranberry juice that are able 
to prevent quiescence in UPEC. Additionally, another subset of small molecules from 
cranberry juice significantly reduces the fraction of UPEC persister cells.  
 
Results 
 
Bioassay guided fractionation of active constituents from cranberry juice: A 
pectinase (Klerzyme 150, DSM Food Specialties) degraded cranberry hull extract was 
purified using C18 flash chromatography to afford three fractions: the 100% water 
fraction, 15% MeOH fraction, and the 100% MeOH fraction. From previous work 
completed by our lab, it was known that the 15% MeOH fraction (Cranf1b) was enriched 
in oligosaccharides and was able to reduce biofilm formation in the UPEC CFT073.
32
 
This fraction was further tested in our previously published CFT073 persister cell assay,
12
 
and showed a greater than 3-log reduction in persister cells at 24 h at 1 mg/mL (0.1% 
wt/vol) in the presence of ampicillin (0.1 mg/mL) when compared with ampicillin 
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treatment alone (Figure 1). Using CFT073 persister cell reduction to guide purification, 
we further purified Cranf1b using porous graphitized carbon (PGC) cartridges and 
determined that the second fraction (entitled 10% PGC) was similarly able to reduce the 
CFT073 persister cells more than 3 logs at a final concentration of 0.6 mg/mL (0.06%) 
(Figure 2). The 10% PGC fraction was further purified by semipreparative HPLC and 
analyzed using NMR and LC/MS to determine the chemical components of this fraction.  
Structure elucidation of active constituents from cranberry juice: The 
1
H and HSQC 
spectra of 10% PGC indicated that this fraction was enriched with oligosaccharides with 
methoxy group at 3.70 ppm and an additional correlation at 6.00/112.04 ppm in HSQC 
which together highly suggest the presence of a group of poly-galacturonic acid methyl 
esters with at least one hydroxyl group reduced. Therefore, this fraction was further 
fractionated using an amide column that provides superior separation of this class of 
molecules. The same amide column and program was used for LC-MS analysis and 
preparative purpose. Indeed, LC-MS chromatogram showed that the predominate ions 
presented were poly-galacturonic acid methyl esters of various degrees of 
polymerization. The most abundant ions were with one or two free carboxylic acids and 
with one degree of unsaturation. Surprisingly saturated poly-galacturonic acid methyl 
esters were minor ions in this fraction. Due to the ultra-high complexity of this fraction, 
only two unsaturated poly-galacturonic acid methyl esters were fully purified. The two 
pure unsaturated poly-galacturonic acid methyl esters were of 4-mer and 3-mer with one 
free carboxylic acid (compounds 4 and 5, respectively). Due to the very limited quantity, 
only 4 was fully characterized with NMR and tested in the biological assays. The 
1
H and 
13
C NMR chemical shifts of 4 were listed in Table S1. Five spin systems were found in 
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total and were registered to the four subunits (A, B, C, D, Figure 3) in the oligomer. Key 
HMBC and NOESY correlations across glycosidic bond were shown in Figure 3. In 
addition, HMBC correlation between carbonyl carbon on each unit and methyl group was 
only found for subunit A, B and D, suggesting the free carboxylic acid was located on 
subunit C. The ESI-TOF-MS/MS fragmentation with sequential neutral losses of 190 Da 
in 4 was deduced as shown in (Figure 4) The dehydration at the 4- position on the 
galacturonic acid opposite of the reducing end was very much likely due to the enzymatic 
degradation during cranberry juice manufacturing to break down the insoluble pectic 
polysaccharides. Unlike acid hydrolysis, some pectinase can selectively hydrolyze the 
glycosidic bonds via eliminative cleavage and cause oxygen-aglycone bond breakage. 
This eliminative cleavage generally occurs by the free carboxylate group because of its 
strong electron withdrawing effect.
33-35
 Along with these unsaturated oligosaccharides, 
three previously reported iridoid glucosides were also isolated and identified to be 6,7-
dihydromonotropein (1), deacetylasperulosidic acid (2) and monotropein (3) (Figure 
S2).
36-39
 To the knowledge of the authors, this is the first identification of 2 from V. 
macrocarpon.  
Purified cranberry juice constituents and CFT073 quiescence: Using the compounds 
purified from cranberry juice, we investigated whether or not the inhibition on CFT073 
persister cells could also be demonstrated with quiescent CFT073. 100 μg spots of each 
4, the 10% PGC fraction, mixed methyl galacturonic acid oligosaccharides fraction (Am-
F6),  and 1-3 were tested in the previously published quiescence lawn overlay assay.
12
 
The spot from the 4, the 10% PGC fraction, and the mixed methyl galacturonic acid 
oligosaccharides fraction (Am-F6) all showed regrowth, thus demonstrating inhibition of 
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quiescence (Figure 5). It was notable that the growth with the pure 4 was not as dense as 
with the other active samples. Each of the tested iridoids (1-3) did not show an inhibition 
of quiescence.  
 
Discussion 
 
Despite years of practice, clinical trials, and bench research, the narrative surrounding the 
benefits of cranberry juice in UTIs is not fully understood.  There are many explanations 
attempting to justify its use-from the increased acidity of the juice to the anti-adhesive 
compounds such as PACs-but clinical evidence fails to fully support the scientifically-
derived benefits.
3,23
  The under-studied oligosaccharide components of cranberry juice 
discussed in this manuscript comprise a previously undiscovered benefit, though we have 
seen anti-biofilm effects with cranberry oligosaccharides previously.
32
  Pectic 
oligosaccharides formed in the presence of a juice-making pectinase are able to reduce 
persistence in UPEC.  Over a 1000-fold decrease in persistent UPEC could have a 
tremendous effect on treatment outcomes as there would be less cells ‘avoiding’ the 
antibiotic treatment through persistence.  It is important to consider that any positive 
effects of cranberry oligosaccharides on persister cells could only be appreciated in the 
presence of antibiotics, so this effect could be defined as a ‘treatment’ benefit.  However, 
the inhibition of quiescence in UPEC seen with the cranberry oligosaccharides could 
directly hinder the ability of the UPEC to establish a QIR, thereby reducing the likelihood 
of a recurrent UTI.
6
  Inhibition of quiescence does not require antibiotics and could 
therefore be loosely interpreted as a ‘preventative’ effect on recurrent UTIs.  While the in 
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vitro effects described in this manuscript are distinct from one another, it is important to 
remember that persistence and quiescence are similar biological states.  It is beyond the 
scope of this manuscript to determine if the physiologic change in UPEC associated with 
cranberry oligosaccharides is consistent between the anti-persistence and anti-quiescent 
effects.  Investigations into the biological manifestations of reducing persistence and 
quiescence in UPEC are necessary next experiments to further understand the beneficial 
role of these oligosaccharides. 
While the completed experiments are preliminary, the results strongly suggest that 
cranberry oligosaccharides formed during the juice-making process have the potential to 
benefit sufferers of UTIs caused by E. coli and especially in those suffering from 
recurrent E. coli UTIs.  It is rational to surmise that the full benefit of cranberry juice may 
not be realized with one class of chemical compounds, but multiple.  From our previous 
chemical purification of oligosaccharides, we know that enrichment of the 
oligosaccharides is nearly synonymous with removal of phenolic compounds, including 
the important type A PACs.
32
  One could assume that a phenolic-enriched (or PACs 
enriched) fraction might be similarly depleted of oligosaccharides, including those 
identified in this study.  If the ultimate goal is to understand what the full benefit of 
cranberry juice components are in UTIs, more careful chemistry is needed to assure that 
the preparations tested include the right compounds, in sufficient quantity.  Exhaustive 
reviews of the clinical data show clearly that inconsistencies in the chemical 
standardization are rampant in the literature.
23
 Using the juice as the supplement is the 
obvious answer to including all the components, but there would still need to be clarity 
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on how much of the juice is necessary to drink, especially in the case of the 
oligosaccharide content.   
 There is still much work left to do to determine if cranberry oligosaccharides can 
have a meaningful effect on the treatment or prevention of UPEC UTIs.  
Pharmacokinetic, in vivo modeling, and mechanistic experiments are necessary to 
elucidate the answer.  While these gaps in the research are significant, the current data 
invites a new class of compounds to be considered as part of the ‘active’ component of 
cranberry juice.  We strongly feel that chemical preparations of cranberry meant to yield 
benefits in UTIs should not exclude oligosaccharides or they may be missing a crucial 
component to cranberry’s anti-infective cocktail.  
 
Methods 
 
General experimental procedures: NMR experiments were conducted using an Agilent 
NMRS 500 MHz spectrometer in D2O (99.99%, Sigma-Aldrich) at 25 °C.  LC/MS 
analysis was performed on a Shimadzu Prominence UFLC system coupled to an AB 
Sciex Qtrap 4500 mass spectrometer with electrospray ionization source in the negative 
ion mode. High Resolution Electrospray ionization mass spectra (HR-MS) were acquired 
using an AB Sciex TripleTOF 4600 spectrometer in the negative ion mode. Flash 
chromatography was completed with a Combiflash Rf200 equipped with a 100 g C18 
RediSepRf High Performance Gold column (Teledyne ISCO). HPLC purification 
experiments were performed on a Shimadzu Prominence i-series HPLC.  
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Purification of cranberry compounds: Cranberry hulls were degraded with pectinase 
(Klerzyme 150, DSM Food Specialties) and fractionated as previously described with 
modifications.
32
 Briefly, 2 g of the cranberry pectinase treated powder was dissolved in 
20 ml distilled water and purified using flash chromatography. The column was eluted 
sequentially with 500 ml DI water, 500 ml 15% methanol/water and 500 ml methanol. 
Fractions from each gradient were individually pooled and lyophilized to obtain three 
major fractions, Cranf1W (761 mg, 38.1%) eluted with 100% DI water, Cranf1b (476 
mg, 23.8%) eluted with 15% methanol/water, and Cranf1M (562 mg, 28.1%) eluted with 
100% methanol. The Cranf1b was then subject to purification using a porous graphitized 
carbon (PGC) cartridge (1 g, Thermofisher Scientific). The PGC cartridge was first 
conditioned by eluting with 50% ACN/water and then equilibrated with DI water. For 
each round of PGC purification, 40 mg of Cranf1b was dissolved in 2 mL of DI water, 
loaded onto the PGC cartridge, and eluted sequentially with 18 mL DI water, 12 mL 10% 
ACN/water (+0.1% TFA), and 30% ACN/water (+0.1% TFA). Fractions were 
individually pooled and dried in vacuo to obtain three major fractions: 100% water PGC, 
10% PGC, and 30% PGC. The 10% PGC fraction was then purified using HPLC and a 
TOSOH Tskgel Amide-80 HR (4.6 × 250 mm, 5 μm) (TOSOH Bioscience) at 1 mL/min 
and 35°C. The column was initially eluted with 80% ACN/water (+0.1% formic acid) for 
2 min, followed by a linear gradient to 40% ACN/water (+0.1% formic acid) over 30 min 
and held for 5 min. This afforded six fractions (Figure 3): Am-F1 (2.5-8 min), Am-F2 
(peak at 8.6 min, mixture of 1 and 2), Am-F3 (9 min, 3), Am-F4 (split peak at 12 min), 
Am-F5 (split peak at 14 min, 4), and Am-F6 (15-25 min). The wavelength of UV 
absorbance was set at 235 nm for optimal monitoring of dehydro-poly-galacturonic acids. 
154 
 
Am-F2 was further purified by semipreparative HPLC with a Waters Xbridge C18 
column (4.6 × 250 mm, 5 μm) at 1 mL/min 35°C with isocratic 5% MeOH/water (+0.1% 
Formic acid) for 20 min to afford pure 1 and 2 (Figure 4).  
Structure elucidation of purified compounds: The LC/MS analysis was performed on 
the same Amide-80 column and same HPLC program as in “Purification of cranberry 
compounds.” The mass spectrometer was operated in negative mode and ions from m/z 
200 to m/z 2000 were scanned. Compounds 1-4 were subject to one and two dimensional 
NMR experiments to determine structures. Additionally, molecular weights were 
determined for pure compounds using HRMS. For necessary MS/MS experiments, 
collision energy was set to 70.  
Bacterial strains and cultivation: E. coli CFT073 was obtained from a cryo stock at the 
lab of P.S.C. and stored at -80°C in a 1:1 mixture of LB broth and 50% glycerol by 
volume. LB broth and LB agar were used for routine cultivation. Liquid M9 minimal 
media was prepared as before,
12
 and M9 minimal media agar plates were prepared with 
1.5% noble agar to avoid impurities present in bacteriological agar.  
Persister cell viability assay: The procedure for this assay closely follows a published 
protocol.
12
 In general, CFT073 was streaked from cryo stocks onto LB agar plates and 
incubated overnight at 37°C. A loopful of cells from the plate was added to 10 mL 0.4% 
glucose M9 minimal media in a 125 mL culture flask and incubated overnight at 37°C 
and 200 rpm. Cultures were diluted in fresh 0.2% glucose M9 minimal media to an 
optical density (OD600) of 0.1 (~10
8
 CFU/mL) and grown in the presence of ampicillin 
sodium (0.1 mg/mL) to generate persister fractions. The cultures were incubated shaking 
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(200 rpm) at 37°C and viable counts were measured at 0, 4, and 24 hours by plating on 
LB media.  
Quiescence lawn assay: The procedure for this assay follows closely follows a published 
protocol.
12
 In general, overnight cultures of CFT073 were prepared in 0.4% glucose M9 
minimal media as described in “Persister cell viability assay.” Bacteria from this culture 
were diluted to a final concentration of 10
5
 CFU in 4 mL of liquid overlay media (0.2% 
glucose M9 minimal media with 0.9% noble agar at 45°C). Each 4 mL overlay inoculum 
was poured over a prewarmed (37°C) 0.2% glucose M9 minimal media agar plate 
immediately after inoculation. These plates were allowed to solidify at room temperature 
with lids slightly ajar. Test solutions or bacteria were added to the overlay media and 
allowed to dry before incubating the plate upside down at 37°C for 24 or 48 hours as 
indicated. No growth of E. coli in the overlay was considered to be quiescence if it was 
able to be reversed with the positive control (3 co-spots of 5 μL of each tyrosine, lysine, 
and methionine at 0.1 mg/mL).  
Statistics: Persister assays were completed in triplicate and compared using a two-tailed 
student’s t test. P-values < 0.05 were considered statistically significant.  
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Figure 1: Persister cell viability assay using Cranf1b fraction as the test sample.  **- 
statistically significant, A- ampicillin.  
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Figure 2: Persister cell viability assay using 10% PGC fraction as test sample. **-
statistically significant, A- ampicillin. 
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Figure 3: Subunits of 4. Key HMBC correlations are designated with single-headed 
arrows and key NOESY correlations are designated by double-headed, dotted arrows.  
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Figure 4: ESI-TOF MS-MS of 4. Structure fragments are designated with the 
corresponding fragment ions.  
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Figure 5: Representative quiescence overlay assay plates. Upper image: AA- amino acid 
mixture, positive control; M9- negative control.  Lower image: Am-F5- 4; Am-F6- 
mixture of methylated galacturonic acid oligosaccharides; 10% PGC- fraction described 
in text.  
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Figure 6: Amide-80 HPLC chromatogram of 10% PGC. 
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Figure 7: C18 Reverse-phase HPLC chromatogram of 1 and 2 mixture. 
 
  
168 
 
 
Figure 8: LC-MS analysis of 10% PGC. From top to bottom: Total ion chromatogram; 
Extract ions of m/z 391 and m/z 389; Extract ions for saturated poly-galacturonic acid 
methyl esters (DP 3-8); Extract ions for unsaturated poly-galacturonic acid methyl esters 
(DP 3-8), single free carboxylic acid; Extract ions for unsaturated poly-galacturonic acid 
methyl esters (DP 3-8), double free carboxylic acids. 
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CHAPTER 6 
Perspective 
The current paradigm for treating bacterial infections is about identifying the 
causative pathogen, and choosing an antibiotic that is capable of killing or inhibiting the 
growth of that particular pathogen.  This is the perfect system for developing 
antimicrobial resistance because these antibiotics that kill or inhibit growth are the exact 
types of environmental stressors that a bacterium would need to develop a mechanism for 
circumventing in order to survive.  As such, bacterial resistance to antibiotics is growing 
at an alarming rate and actions are urgently needed to avert this impending pandemic.   
 The identification of new antibacterial molecules and the development of these 
chemical compounds into medicines remains a crucial component in our arms race 
against bacteria.  Declining participation in antibiotic research from the pharmaceutical 
industry does not help this problem.  With fewer resources and time at the disposal of 
researchers, we must choose wisely where we search for these new antibacterial agents 
that we desperately need.  Investigating natural products (especially those from 
microorganisms) has been by far the most successful method for finding molecules that 
become antibiotic drugs, and this remains a viable resource going forward.  Importantly, 
while natural products research is thought of as a ‘classical’ research method, it has been 
decades since the development of natural antibacterial compounds was commonplace in 
industry and there have been thousands of antibacterial compounds isolated and 
published since.  In addition, with new frontiers such as microorganisms from the marine 
environment to explore, the microbial natural resource of antibacterial agents remains 
largely undiscovered.   
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 Continuing to fight fire with fire- that is killing bacteria with antibiotics until they 
develop resistance to them- is a never-ending battle.  In order to fully sustain the 
monumental achievement of antibiotics, we must target the very mechanisms of 
resistance and the characteristics of bacteria that make them pathogenic to find new ways 
to treat infections.  Efflux pumps and the subsequent efflux pump inhibitors are one good 
example of a way to reclaim antibiotics that are losing their potency.  Other molecules 
have shown utility as drugs to re-sensitize resistant pathogens to antibiotics.  
Additionally, targeting mechanisms of pathogenicity such as persistence and quiescence 
in this manuscript, or other characteristics like biofilms and quorum sensing are viable 
avenues towards stopping infections without stimulating resistance.  Also beyond 
antibacterial compounds, we can learn new ways to treat infections from simple things 
like cranberry juice.  Oligosaccharides with no antibacterial effect whatsoever through a 
different biological lens look particularly important to the juice’s effects in UTIs.  We 
must increase our understanding of how and why the pathogens are causing infections in 
order to find the best ways of treating them. 
 I will end this dissertation with a few broadly reaching statements and some 
thought provoking questions from working in this particular area of research:  
Preventing an infection is far better than having to treat it, but bacteria are such a 
huge part of human life, it seems no amount of standardized precautions would stop 
infections from happening all together, that being said, we must have viable ways to treat 
them or we face losing vital aspects of medicine that are taken for granted.  Currently, 
research into developing truly new ways to treat bacterial infections is a bare industrial 
landscape.  Who is going to pay for clinical trials of non-antibiotic agents for infections if 
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the industry will not?  Or better yet, what do we have to change in our health care system 
to incentivize developing antibiotics and similar agents?  Perhaps we as a society are not 
yet ready to make these changes and commit to whatever it takes to preserve our 
antibacterial luxury.  Or maybe the data is not compelling enough to force change in this 
developmental landscape.  What will be the cost of failing to develop new antibiotics for 
5 more years? What about 10 or 20?  I shudder to think about pan-drug resistant 
Acinetobacter baumannii colonizing the majority of our hospitals.  Do we really know 
how long it will take for something like that to happen?  If we only lose 23,000 lives in 
this country to MDR bacteria per year now, how many lives must be lost per year for the 
general public to become aware of this issue?  I sincerely hope that the problem of 
antimicrobial resistance will be solved quietly, but I fear that the noise must become 
louder to draw the attention necessary to prevent the impending post-antibiotic era.   
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APPENDIX A 
A Marine Bacteria-Produced Benzisoxazole with Antibacterial Activity Against Multi-
Drug Resistant Acinetobacter baumannii  
 
Robert W. Deering,
a
 Kristen E. Whalen,
c,d,#
 Ivan Alvarez,
a
 Kathryn Daffinee,
e
 Maya 
Beganovic,
b,e
 Kerry L. LaPlante,
b,e
 Tracy J. Mincer,
d,#
 David C. Rowley
a,# 
 
 
List of Supplementary Material 
1. Additional Results:  
1.1 Bioassay Screening of B. denitrificans B158 Extract 
1.2 Biofilm Formation Assay for Characterization of A. baumannii Strains 
1.3 Isolation and dereplication of additional compounds from B. denitrificans 
B158 
2. Supplementary References 
3. Table S1: 1H and 13C NMR data of 12 and comparison to published data 
4. Table S2: A. baumannii strain characteristics and resistance profiles 
5. Figure S1: Chemical structures of compounds 11 and 12 
6. Figure S2: LC/MS comparison of isolated 1 to synthetic 1 
7. Figure S3: 1H NMR of isolated 1 
8. Figure S4: 1H NMR of synthesized 1 
9. Figure S5: 13C NMR of synthesized 1 
  
173 
 
Additional Results 
1.1 Bioassay Screening of B. denitrificans Extract 
Extract from isolate B158 reduced the MIC of erythromycin >4-fold when tested 
against E. coli MDR strains MG1655 ΔBC/pABM, and MG1655 ΔBC/pXYM according 
to previously published methods.[1]  These strains overexpress two Resistance 
Nodulation cell Division (RND) transporters involved in antibiotic resistance.  Bioassay-
guided fractionation of the B158 extract resulted in the isolation of 1 with an MIC 
between 0.63 – 1.25 μg/mL against E. coli MDR strains MG1655 ΔBC/pABM, and 
MG1655 ΔBC/pXYM.  
1.2 Biofilm Formation Assay for Characterization of A. baumannii Strains 
Quantification of biofilm formation was conducted using a modified microtiter 
plate assay [2-4] previously described by Song et al.[5] Briefly, strains were grown 
overnight on Tryptic Soy Agar (TSA, Becton–Dickinson, Sparks, MD, USA). Tryptic 
Soy Broth (TSB; Becton–Dickinson, Sparks, MD, USA) supplemented with 1% dextrose 
(for total dextrose concentration of 1.25%) was used to optimize biofilm production in 
the biofilm assay.  A 0.5 McFarland standard of overnight growth of test isolates was 
diluted into TSB. The inoculated medium was dispensed into wells of sterile non-tissue 
culture treated flat-bottom 96-well polystyrene plates (Costar no. 3370; Corning Inc., 
Corning, NY, USA). Plates were incubated on a shaker at 37 °C. After 24 h of biofilm 
development, broth was removed and replaced with fresh TSB and incubated at 37 °C for 
an additional 24 h. The solution was then removed and plates were carefully rinsed three 
times with sterile water to remove planktonic bacteria. Adherent bacteria were dried 
overnight and stained for 15 min with 0.1% crystal violet solution. The crystal violet was 
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then resolubilized in 33% glacial acetic acid and the optical density (OD) of stained 
adherent bacterial films was read at 570 nm using a spectrophotometer (ELX800, Biotek, 
Winooski, VT). The OD readings of bacterial films were categorized into non-adherent, 
weak, moderate, and strong based on previously described methods by Stepanovic et 
al.[6] Isolate L1051 was used as a negative control strain. Experiments were carried out 
in quadruplicate. OD readings were averaged, and standard deviations were calculated for 
each isolate.[2,4] 
1.3 Isolation and Dereplication of Additional Compounds from B. denitrificans B158 
Briefly, 1152.4 mg of extract was applied to a silica gel column (40-60 µm, 60Å) 
and eluted with a step-gradient of isooctane, (4:1) isooctane/ethylacetate (EtOAc), (3:2) 
isooctane/EtOAc, (2:3) isooctane/EtOAc, (1:4) isooctane/EtOAc, EtOAc, (1:1) 
EtOAc/MeOH, and 100% MeOH, yielding eight fractions. Bacterial susceptibility testing 
in the INT assay indicated activity to be localized to the EtOAc elution. The active 
fraction totaling was separated further into 96-deep well plates by semipreparative HPLC 
using an Agilent 1200 series HPLC and a Phenomenex Luna® 5 µm C18 (2) 100 Å, LC 
column (250 x 10 mm) as the stationary phase, heated to 30 °C and a gradient of water 
and MeCN with a flow rate of 4 mL/min. All solvents were acidified with 0.1% FA. 
Contents of the 96-deep well plate were dried down and tested in the INT assay, which 
resulted in identifying three wells (E7, F7, and G7) eluting at 35:65 water/MeCN were 
active. Contents of wells E7, F7, and G7 were combined and separated further into a 96-
deep well plate by semipreparative HPLC using an Agilent 1200 series HPLC and a 
Phenomenex Luna® 5 µm C18 (2) 100 Å, LC column (250 x 10 mm) as the stationary 
phase, heated to 30 °C and a gradient of water and MeCN with a flow rate of 4 mL/min. 
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All solvents were acidified with 0.1% FA. The activity was found to be contained in a 
single well (H10) eluting at 22.8 min corresponding to 5:95 water/MeCN visualized by a 
single sharp peak at 276 nm. The contents of well H10 underwent an additional round of 
HPLC purification using the above HPLC column, flow rate, but with starting conditions 
of 1:1 water/MeCN. INT activity testing indicated a well resolved peak with minor 
activity eluting at 4.5 min in 1:1 water/MeCN to contain all of the activity and totaling 
2.6 mg of pure 11 as an amorphous yellow powder.  
Structure elucidation efforts of 11 were pursued.  An [M+H]
+ 
ion of 243.0879 
using HRESIMS indicated a molecular formula of C12H10N4O2.  Examination of the 
1
H 
NMR displayed two singlet methyl groups (δH 2.46, 3H, and δH 2.49, 3H) and two singlet 
aromatic protons (δH 7.70, 1H and δH 7.91, 1H).  These molecular features along with the 
molecular formula strongly suggested the known microbial metabolite, 7,8-
dimethylalloxazine or lumichrome.  This was further confirmed by NMR comparison to 
literature [7] and LC/MS comparison (data not shown) to an authentic standard of 
lumichrome (Cat. 103217, Sigma-Aldrich). A total of 2.6 mg of compound 11 was 
isolated from 1152.4 mg of extract from 9 L of microbial culture.  
Compound 12 was purified from the 96-deep well plate fractions H8, A9, B9, 
totaling 25.1 mg, and had minor activity when tested in the INT assay. The 25.1 mg 
fraction containing wells H8, A9, B9 was further separated by semipreparative HPLC 
(Shimadzu Prominence-i LC-2030C).  Compound 12 eluted at 15.7 min from the 
following method: 0 to 4 min, 30% MeOH in aqueous 0.1% FA; 4 to 24 min, gradient 
from 30% MeOH in aqueous 0.1% FA to 70% MeOH in aqueous 0.1% FA.  This 
afforded 12 as a white amorphous powder. The molecular formula was determined to be 
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C10H8N2O2 using HRESIMS (m/z 187.0531 [M-H]
-
) and NMR. 
1
H-NMR indicated the 
presence of a 1,2 substituted benzene ring based on resonances at δH 7.25 (m, 2H, H-5 
and H-6), 7.53 (dd, 1H, H-7, J = 5.7, 2.2), and 8.22 (dd, 1H, H-4, J = 5.6, 2.5). In 
addition, a singlet at δH 8.68 (1H, H-2) and MS/MS fragmentation experiments showing a 
strong fragment at m/z 116 indicated that the aromatic protons were part of an indole 
subunit (data not included). Using our molecular formula and the indole substructure, 12 
was dereplicated as (1H-indol-3-yl) oxoacetamide by comparison of 
 1
H and 
13
C-NMR to 
published data (Table S1) [8]. A total of 25.1 mg of 12 was isolated from 18.2 g of 
extract representing 118.5 L of microbial culture. Testing in bacterial susceptibility 
assays indicates 12 has antibiotic-like properties against E. coli MDR strains MG1655 
ΔBC/pABM, and MG1655 ΔBC/pXYM resulting in a reduction of 50% growth at 150 
µg/mL. 
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Table S1: Comparison of 
1
H and 
13
C-NMR data of 12 and published (1H-indol-3-yl) 
oxoacetamide. Chemical shifts are referenced to residual DMSO in DMSO-d6 at δH 2.50 
and δC 39.5.  
 
Isolated (1H-Indol-3-
yl) oxoacetamide (12) 
Published (1H-Indol-3-
yl) oxoacetamide[1] 
position δC, type δH, (J in Hz) δC, type δH, (J in Hz) 
1  12.35, br s  12.19, br s 
2 138.2, CH 8.68, s 138.1, CH 8.69, s 
3 112.0, C  112.0, C  
3a 126.1, C  126.1, C  
4 121.2, CH 
8.22, dd 
(5.6, 2.5) 
121.2, CH 8.22, d (6.0) 
5 122.4, CH 7.25, m 122.4, CH 7.25, t (6.0) 
6 123.3, CH 7.25, m 123.3, CH 7.25, t (6.0) 
7 112.5, CH 
7.53, dd 
(5.7, 2.2) 
112.4, CH 7.52, d (6.0) 
7a 136.3, C  136.2, C  
8 182.9, C  182.9, C  
9 166.0, C  165.9, C  
NH2  8.05 br s  8.06 br s 
  7.69 br s  7.69 br s 
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Table S2: A. baumannii strain characteristics and resistance profiles. 
 
 
 
 
 
 
* Multi-drug resistant organisms (MDRO) 
**0-non-adherent, 1-weakly adherent, 2- moderately adherent, 3- strongly adherent 
  
A. 
baumannii 
strain 
Source 
Biofilm 
OD570 
readings 
Biofilm 
Adherence** 
L1051* Clinical 
0.19± 0.03 
 
0 
L1222* Blood 
0.60± 0.12 
 
1 
L1227 Blood 
0.94± 0.27 
 
2 
L1184 Urine 
2.49± 0.17 
 
3 
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Figure S1: Chemical structures of compounds 11 and 12. 
 
 
  
12 11 
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Figure S2:  LC/MS comparison of isolated 1 to synthetic 1.  
 
 
  
Isolated 1 
Synthetic 
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Figure S3: 
1
H NMR of isolated 1 
 
 
  
Formic Acid 
Impurity 
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Figure S4: 
1
H NMR of synthesized 1 
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Figure S5: 
13
C NMR of synthesized 1 
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APPENDIX B 
Supplemental Figures for Chapter 5 
 
 
 A (α-) A (β-) B C D 
Position δ C 
(ppm) 
δ H 
(ppm) 
δ C 
(ppm) 
δ H 
(ppm) 
δ C 
(ppm) 
δ H 
(ppm) 
δ C 
(ppm) 
δ H 
(ppm) 
δ C 
(ppm) 
δ H 
(ppm) 
1 92.3 5.25 96.3 4.55 100.5 4.88 100.0 4.80 99.5 5.04 
2 67.7 3.71 71.2 3.38 67.8 3.62 68.0 3.57 69.8 3.65 
3 68.0 3.93 67.8 3.69 67.8 3.92 68.4 3.83 65.5 4.23 
4 78.8 4.36 78.5 4.31 78.2 4.39 79.0 4.43 111.8 6.00 
5 69.7 4.72 73.1 4.40 70.4 4.99 71.2 4.64 140.6  
6 170.5  169.6  170.7  175.0  164.0  
7 52.8 3.70 52.8 3.70 52.8 3.70   52.8 3.71 
 
Table S1:
 13
C and 
1
H NMR chemical shifts of 4. 
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Figure S1: High resolution ESI-TOF-MS of 4. 
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Figure S2: Structures of Iridoid glycosides 1-3.  
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 1 2 3 
Position δ C (ppm) δ H (ppm) δ C (ppm) δ H (ppm) δ C (ppm) δ H (ppm) 
1 94.8 5.42 97.3 5.04 93.7 5.44 
3 152.0 7.40 148.3 7.08 144.4 7.47 
4 112.0      
5 32.0 2.84 44.8 2.89 38.3 3.43 
6 29.4 1.93/1.57 80.8 4.41 137.9 6.10 
7 34.9 1.70/1.56 128.5 5.75 137.2 5.56 
8 81.8      
9 45.4 2.24 45.9 2.94 44.1 2.56 
10 67.6 3.47 59.8 4.22/4.17 66.6 3.54 
11 191.3      
1’ 98.5 4.71 98.2 4.68 97.9 4.67 
2’ 72.5 3.17 72.6 3.22 72.8 3.18 
3’ 75.6 3.32 75.6 3.40 75.7 3.37 
4’ 69.4 3.31 69.1 3.31 69.5 3.29 
5’ 75.8 3.38 76.1 3.30 75.9 3.30 
6’ 60.5 3.80/3.62 60.4 3.78/3.60 60.6 3.80/3.62 
 
Table S2. 
13
C and 
1
H NMR chemical shifts of 1, 2 and 3. 
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Figure S3: 
1
H NMR spectrum of 10% PGC. 
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Figure S4: HSQC spectrum of 10% PGC. 
192 
 
 
Figure S5:
 1
H NMR spectrum of 4. 
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Figure S6:
 13
C NMR spectrum of 4. 
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Figure S7: COSY spectrum of 4. 
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Figure S8: TOCSY spectrum of 4. 
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Figure S9: HSQC spectrum of 4. 
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Figure S10: HMBC spectrum of 4. 
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Figure S11: NOESY spectrum of 4. 
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Figure S12: 
1
H NMR spectrum of 1. 
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Figure S13: 
13
C NMR spectrum of 1. 
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Figure S14: COSY spectrum of 1. 
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Figure S15: TOCSY spectrum of 1. 
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Figure S16: HSQC spectrum of 1. 
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Figure S17: HMBC spectrum of 1. 
205 
 
 
Figure S18: 
1
H spectrum of 2. 
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Figure S19: COSY spectrum of 2. 
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Figure S20: TOCSY spectrum of 2. 
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Figure S21: HSQC spectrum of 2.
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Figure S22: 
1
H spectrum of 3. 
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Figure S23: COSY spectrum of 3. 
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Figure S24: TCOSY spectrum of 3. 
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Figure S25: HSQC spectrum of 3. 
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Figure S26: HR-MS of 1.  
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Figure S27: HR-MS of 2. 
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Figure S28: HR-MS of 3. 
 
 
